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Dengue virus (DENV) of the Flaviviridae family is the most significant cause of human arboviral 
disease worldwide. While other members of the Flaviviridae family can cause persistent 
infections, there are few reports of persistent DENV infections in mammalian cells. A DENV-
2 mutant that can establish persistent infection in a range of cultured cells was previously 
discovered, and the phenotype was attributed to a single amino acid substitution in the DENV-
2 NS4B protein, T66A. However, prior studies failed to reveal the mechanism conferring the 
persistent phenotype. To further address this question, a comparative RNAseq transcriptomic 
analysis using RNA from HEK293T cells that were infected with DENV-2, persistently-infected, 
or stably expressing a wild-type (RepDV-GP2A) or NS4BT66A mutant replicon (RepDV-GP2A-
NS4BT66A) was performed. Bioinformatic analysis of the transcriptomic dataset revealed that 
the expression of a range of interferon-stimulated genes was increased in the persistently-
infected cells compared to control and DENV-2 infected cells. Immunomicroscopy revealed 
that the distribution of STAT1 was altered between persistently-infected and DENV-2 infected 
cells, indicating an effect of the NS4BT66A mutation on DENV-induced modulation of the host 
interferon response.  Interestingly, genes involved in cholesterol biosynthesis (HMGCR, 
HMGCS1, IDI1, INSIG1, MSMO1, SQLE) were downregulated in the persistently-infected 
cells compared to the control cells, but upregulated during DENV-2 infection. Downregulation 
of target genes was validated by quantitative real-time PCR. The distribution of intracellular 
cholesterol was also examined and found to be altered upon persistent and wild-type DENV-
2 infection. Attempts to pharmacologically clear persistently-infected cells of virus were 
unsuccessful; thus, the persistently-infecting virus genome was sequenced to identify 
mutations that arose and potentially conferred resistance to the anti-DENV drugs. This study 
provides further insight into the mechanism by which persistent infection with the mutated 
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Chapter 1. Introduction 
1.1. Dengue virus: a global burden on public health  
Dengue virus (DENV) is globally considered the most prevalent human arboviral disease, with 
approximately 3.9 billion people at risk of infection worldwide (Brady et al., 2012). Dengue is 
endemic in over 100 countries, and approximately 50-100 million people present with 
symptomatic infections annually (Bhatt et al., 2013; World Health Organisation, 2017).  
1.1.1. Dengue virus epidemiology and transmission 
Dengue is endemic in over 100 countries, including throughout the Americas, Africa, Eastern 
Mediterranean, South-East Asia and Western Pacific (World Health Organisation, 2017), and 
is regarded as ubiquitous throughout the tropics and subtropics. It was estimated that there 
were 96 million dengue infections worldwide that manifested some level of clinical disease in 
2010, with 67 million occurring in Asia, 16 million in Africa, and 13 million in the Americas 
(Bhatt et al., 2013).  However, due to issues such as misdiagnoses, incomplete understanding 
of the full spectrum of disease caused by DENV, and lack of infrastructure to maintain robust 
surveillance programmes, it has been suggested that under-reporting of dengue cases in 
certain countries is between 8- and 28-fold (Sharp et al., 2017).  
DENV is an arthropod-borne virus (arbovirus); its primary vector is the Aedes aegypti mosquito 
which has a vast geographic range, spanning tropical and subtropical areas worldwide 
(Kraemer et al., 2015). Ae. aegypti lives in close proximity to both rural and urban human 
habitats, preferentially feeds on humans, and has a high multiple-feeding rate (Harrington et 
al., 2014; Ndenga et al., 2017; Ponlawat and Harrington, 2005). Ae. albopictus is the 
secondary vector of DENV which has also been shown to preferentially feed on humans 
(Ponlawat and Harrington, 2005). The native range of Ae. albopictus is Eastern Asia and India, 
however this species’ range has expanded rapidly in the last thirty years and this mosquito is 
now an invasive species that is present on all continents (Kraemer et al., 2015; Paupy et al., 
2009). Expansion of the geographic range of both of these vector species is attributed to 
several factors, including urbanisation and population growth, trade and travel, and climate 
change, among many others. These various vector factors – expanding worldwide distribution, 
climate change, and anthropophilic mosquito feeding behaviours – as well as increasing 
human travel, population growth, and urbanisation all contribute to the efficient transmission 
and increasingly extensive global spread of DENV and its associated disease burden.  
1.1.2. Flaviviridae family  
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DENV is a member of the Flaviviridae family of viruses, of the genus Flavivirus. Typically, 
flaviviruses are small and enveloped, with positive-stranded, non-segmented RNA genomes 
of approximately 10.6-10.9 kb (Simmonds et al., 2017). There are around 15 other human 
disease-causing flaviviruses, including Zika (ZIKV), West Nile (WNV), Japanese encephalitis 
(JEV), and yellow fever (YFV) viruses (Burrell et al., 2017).  
Flaviviruses constitute a great number of emerging and resurging diseases worldwide. Many 
flaviviruses are arboviruses (Mackenzie et al., 2004), and as such, their ability to spread and 
become established in new areas where suitable vectors exist is significant. WNV is 
transmitted primarily by Culex spp. mosquitoes, and caused a large outbreak in New York in 
1999 which rapidly spread throughout North America in the following years, and also spread 
to Central and South America via migratory birds and their flyways (Gubler, 2007). JEV is 
endemic and causes epidemic outbreaks throughout temperate and tropical areas of East and 
southern Asia and some northern areas of Oceania, and is also transmitted by mosquitoes in 
the Culex genus (van den Hurk et al., 2009). There are several other flaviviruses, such as 
ZIKV and YFV, that, similarly to DENV, are transmitted by Ae. aegypti and other Aedes 
mosquito species; thus, there is much overlap in geographic range of these diseases, 
particularly between DENV and ZIKV, and another arbovirus, chikungunya virus (CHIKV) from 
the Togaviridae family. These viruses are all distributed and have caused major epidemics 
throughout the tropics and subtropics, particularly in South America, Africa, and Asia (Messina 
et al., 2016; Staples et al., 2009). DENV, ZIKV and CHIKV are known to co-circulate in many 
areas, and as anticipated, co-infections with either two or all three of the viruses have been 
discovered in Central and South America (Pessoa et al., 2016; Waggoner et al., 2016).  
1.1.3. DENV serotypes  
There are four serotypes of dengue, DENV-1-4; these originated approximately 1000 years 
ago, evolved from a common ancestral strain in non-human primates and seemed to transmit 
to humans between 320 and 125 years ago (Holmes and Twiddy, 2003).  
DENV serotypes share between 60-75% amino acid sequence homology, and are 
antigenically distinct (Holmes, 1998). Phylogenetic analysis of DENV serotypes is often based 
on sequencing the envelope (E) gene which encodes the viral envelope protein and is the 
major antigenic determinant of DENV. Phylogenetic analysis has enabled distinction of the 
four DENV serotypes, as well as further characterisation of distinct genotypes within each 
serotype (Chen and Vasilakis, 2011). Viruses within the same serotype share approximately 
6% sequence homology at the nucleotide level, and 3% at the amino acid level (Harris et al., 
2015). Genetic diversity among the various DENV serotypes is increasing; this is attributed to 
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factors such as genetic recombination, high mutation rates during viral replication, natural 
selection and genetic bottlenecks. Increasing viral genetic diversity has many implications for 
potential changes in phenotypic effects, such as increased virulence, epidemic potential, 
transmissibility, or changing host and vector ranges (Harris et al., 2015; Holmes and Burch, 
2000; Holmes and Twiddy, 2003).  
All four DENV serotypes can be found throughout the tropics and subtropics, typically in urban 
and peri-urban environments. Due to the ubiquitous spread of all four DENV serotypes 
throughout the tropics, co-circulation and incidences of co-infection with multiple serotypes is 
increasing in many areas (Shrivastava et al., 2018).  
Recently, there has been debate over the discovery of a putative fifth DENV serotype in 
samples collected during an outbreak in Malaysia in 2007. Genetic sequencing revealed a 
strain that most closely resembled DENV-4 but was phylogenetically distinct from all four 
DENV serotypes and infection of rhesus macaques with the new strain following pre-infection 
with the other four serotypes revealed a distinct antibody response. The putative DENV-5 
strain follows the sylvatic cycle between non-human primates and Aedes spp. mosquitoes; as 
such, it is possible that this human case in Malaysia was a chance event and the infected 
human was an incidental host (Mustafa et al., 2015). However, little follow-up has been carried 
out since the initial report, therefore more data is required to fully characterise this strain and 
determine whether it is truly the first novel DENV serotype to be discovered in over 50 years, 
or whether it is a variant of an existing DENV serotype (Taylor-Robinson, 2016). 
 
1.2. Dengue pathogenesis  
Previous estimates suggest that approximately 96 million cases of dengue infection manifest 
clinically per year (Bhatt et al., 2013), with approximately 500,000 cases of severe dengue 
that require hospitalisation, and a mortality rate of 2.5% (World Health Organisation, 2017).  
1.2.1. Dengue disease  
While most infections with DENV are asymptomatic or subclinical, infection can produce a 
wide spectrum of disease. In 2009, the WHO recommended a revised case classification 
system, classifying clinical dengue infections into dengue fever, dengue with warning signs, 
and severe dengue with the intention of improving dengue clinical treatments and surveillance 
(Barniol et al., 2011).  Most commonly, patients suffer from dengue fever, a relatively severe 
but self-limiting flu-like illness characterised by rapid onset of fever, rash, myalgia, arthralgia, 
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and retro-orbital pain. Dengue with warning signs progresses to include abdominal pain, 
vomiting, clinical fluid accumulation and liver enlargement, which are used as indicators of a 
patient’s potential progression to severe dengue. Severe dengue is characterised by severe 
plasma leakage which can lead to shock, called Dengue Shock Syndrome (DSS), 
haemorrhaging, called Dengue Haemorrhagic Fever (DHF), and organ impairment, including 
effects on the liver, heart, and central nervous system, which can lead to death. Other atypical 
manifestations of dengue disease are also being more frequently reported, such as 
encephalitis and acute respiratory distress syndrome (Barniol et al., 2011; Harris et al., 2015; 
Martina et al., 2009; Whitehorn and Simmons, 2011).  
1.2.2. Immunopathology and risk factors in severe dengue disease 
All four DENV serotypes can cause the full spectrum of dengue disease, however severe 
dengue most commonly occurs upon secondary infection with a different serotype when pre-
existing immunity to the first serotype is already present. Additionally, the peak in symptoms 
is often associated with a rapid reduction in viral load and a cytokine storm, which suggests a 
key role for the host immune response in dengue pathogenesis (Screaton et al., 2015). 
Primary infection with one DENV serotype generates virus-neutralising antibodies that provide 
long-lasting serotype-specific immunity, and E-protein-specific antibodies that are cross-
reactive to different serotypes (Reich et al., 2013). Antibody-mediated protection is transient, 
and over time when antibody levels decline the individual is no longer protected from infection 
with a heterologous serotype. Following primary infection, subsequent infection with the same 
serotype is neutralised and no clinical disease is usually apparent (Whitehorn and Simmons, 
2011). However, upon secondary infection with a heterologous serotype, non-neutralising 
cross-reactive antibodies bind the virus and, rather than offering a protective effect, the 
antibodies bind to Fc receptor-bearing cells and facilitate viral entry (Vaughn et al., 2000). This 
phenomenon is termed antibody-dependent enhancement (ADE). ADE can be readily 
demonstrated in vitro and in animal studies, however, there is still ongoing debate surrounding 
the role of ADE during human infection with DENV and its potential implications for the 
development of a successful dengue vaccine.   
In addition to the B cell-mediated response, cross-reactive DENV-specific T lymphocytes are 
also thought to play a role in immunopathology during both primary and secondary infection, 
with the magnitude of the T cell response correlating with disease severity (Screaton et al., 
2015). CD8+ T cells produce greater levels of proinflammatory cytokines such as tumour 
necrosis factor (TNF) and interferon gamma (IFNγ) during severe dengue disease than during 
mild dengue fever, causing a cytokine storm (Rothman, 2011). This inflammatory response 
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contributes to vascular permeability and plasma leakage, which are important clinical 
manifestations of severe dengue (Whitehorn and Simmons, 2011). Additionally, during 
secondary infection it is thought that the T cell response does not clear infection as effectively 
as during primary infection, and this is partially attributed to the phenomenon of original 
antigenic sin. While some T cells that expand during secondary infection are cross-reactive 
for peptides derived from viruses of both primary and secondary infections, some of the 
expanded T cell population are also cross-reactive but preferentially respond to the primary 
infecting serotype and have lower avidity for the secondary infecting serotype. This may be 
detrimental to the overall response to infection, resulting in delayed and/or weaker viral 
clearance and increased pathogenesis (Mongkolsapaya et al., 2003; Rothman, 2011; 
Screaton et al., 2015). Furthermore, during severe disease caused by secondary DENV 
infection, cross-reactive CD8+ T cells do not degranulate to as high a level as T cells with 
single specificity for the current infecting virus, which potentially also reduces their ability to 
control virus infection (Mongkolsapaya et al., 2006; Rothman, 2011). However, the impact of 
original antigenic sin on dengue disease pathogenesis remains controversial because it has 
yet to be well demonstrated in human DENV infections (Rothman, 2011; Screaton et al., 
2015).  
Sequential infection with a heterologous serotype and the associated immunopathology is 
considered the largest risk factor for severe dengue (Burke et al., 1988; Katzelnick et al., 
2017), however there are many other factors that come together to lead to severe dengue 
disease. Host risk factors for severe dengue disease include host genetic determinants of 
disease susceptibility and pre-existing comorbidities, as well as certain ages, genders and 
nutrition status which are more susceptible to severe disease (Anders et al., 2011; Coffey et 
al., 2009). Viral determinants of disease severity include viral genotype and viremia titre at 
early stages of infection (Vaughn et al., 2000). Viral epidemiology also plays a role; oscillations 
in the prevalence of each serotype in DENV-endemic areas due to the development of herd 
immunity puts more people at risk of sequential infection with a heterologous serotype (Adams 
et al., 2006). DENV serotypes are phylogenetically distinct and therefore each has distinct 
characteristics of infection and different likelihoods of causing DHF in different areas; for 
example, it was suggested that DENV-2 and DENV-3 are twice as likely to result in severe 
dengue disease as DENV-4 during secondary infection in hospitalised children in Thailand 
(Fried et al., 2010), but in Singapore, infection with DENV-1 was more highly associated with 
DHF than DENV-2 and DENV-3 (Yung et al., 2015).  
Overall, the outcome of dengue infection is influenced by complex interactions between 




1.3. Dengue virus genome organisation and virion particle 
1.3.1. DENV virion structure  
The DENV virion particle is icosahedral, approximately 50 nm in diameter (Kuhn et al., 2002). 
Three structural proteins, C, prM/M and E are the components of the virion particles. The outer 
surface of the DENV particle is comprised of the E glycoprotein and M protein which function 
in host-viral interactions for fusion and entry, antigenic determination and aid viral assembly 
and budding (Zhang et al., 2004). Below the outer shell is an internal lipid bilayer derived from 
the host endoplasmic reticulum (ER), in which the E and M proteins are both anchored via 
their C-terminal domains. This membrane surrounds the virion’s nucleocapsid core which is 
comprised of multiple copies of the C protein and the viral genomic RNA (Zhang et al., 2003). 
The external surface structure and protein composition is distinct between the immature and 
mature particles. While the mature virion has a smooth surface, comprised of 90 E protein 
homodimers arranged in a herringbone pattern (Kuhn et al., 2002), the external surface of the 
immature virion is composed of 60 trimers of prM-E heterodimers which form protruding spikes 
(Perera and Kuhn, 2008; Zhang et al., 2003).  
1.3.2. DENV genome organisation 
The viral genome contains a single positive-strand, non-segmented, ~10.7 kb RNA genome. 
This genome encodes a single long open reading frame (ORF) that is flanked by 5¢ and 3¢ 
untranslated regions (UTRs) (Figure 1.1). Translation of the single ORF generates a large 
polyprotein that is co- and post-translationally cleaved into 10 proteins: 3 structural proteins, 
C, prM/M and E, and 7 non-structural (NS) proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, 





Figure 1.1: Diagram of the DENV genome. Diagram of the 10.7 kb DENV genome showing the single 
ORF that encodes 10 viral proteins (C, prM/M, E, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5), 
and the flanking 5’ and 3’ UTRs.  
 
1.3.3. C protein  
The DENV C protein is a small dimeric protein of approximately 12 kDa, with an alpha-helical 
structure.  Multiple C copies form the nucleocapsid core that surrounds a single copy of the 
viral genome (Jones et al., 2003). Within infected cells, DENV C localises to both the 
cytoplasm and the nucleus and has a range of functions, both as a structural component of 
infectious virions, and in the viral replication cycle. DENV C accumulates around ER-derived 
lipid droplets (LDs), and this localisation is necessary for DENV replication. Association with 
LD structures possibly provides a mechanism by which the C protein encapsidates the 
genome, by forming a scaffold to allow encapsidation during nucleocapsid assembly (Samsa 
et al., 2009). DENV C has also been shown to be involved in pathogenesis; when localised to 
the nucleus, the C protein physically interacts with the human death domain-associated 
protein, Daxx. This interaction was previously shown to be involved in apoptosis of infected 
liver cells in vitro, and may play a role in clinical manifestations during severe dengue disease 
that lead to hepatic failure (Limjindaporn et al., 2007; Netsawang et al., 2010).  
1.3.4. prM and M proteins  
The prM pre-membrane protein is a 26 kDa precursor to the mature M protein. The primary 
function of prM is as a chaperone to mediate proper folding and secretion of E protein. During 
virion maturation, prM associated with E on the outer surface of immature virions undergoes 
furin cleavage, and the pr pre-peptide is retained in association with E and is thought to prevent 
premature fusion of virions with host intracellular membranes. pH-dependent dissociation of 
pr enables E to become fusogenic and virions to become infectious (Yu et al., 2008; Zybert et 
al., 2008). However, it has been shown that the cleavage of prM to M is not very efficient, and 
cell lines release high numbers of virion particles that still contain uncleaved prM (Zybert et 
al., 2008). During infection, antibodies to prM can be detected, however these are non-
neutralising and possibly actually promote antibody-dependent enhancement of the host 
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immune response (Dejnirattisai et al., 2010). Non-structural functions of prM/M are largely 
unknown; however, one study has shown that prM interacts with host vacuolar-ATPases (V-
ATPases) which acidify intracellular organelles. V-ATPase mediates the low pH-dependent 
endosomal pathway entry of DENV, suggesting that the prM-V-ATPase interaction may play 
a role in mediating low pH-dependent processes such as viral entry, secretion, and exocytosis. 
It was also suggested that this interaction is important for viral replication, which was 
significantly reduced upon treatment with a V-ATPase inhibitor (Duan et al., 2008).  
1.3.5. E protein  
The E protein is a glycoprotein of approximately 53 kDa, consisting of 495 amino acid residues 
(Kuhn et al., 2002; Zhang et al., 2003). As a class II fusion protein, it is composed of three 
domains: Domain I, the central domain; Domain II, an elongated domain that bears the fusion 
loop which is directly involved in the fusion of viral and cellular membranes; Domain III, an Ig-
like structure with a stem that connects the structure to the transmembrane anchor, and is 
responsible for recognising host cell receptors (Harrison, 2015; Kielian, 2006).  
The DENV E protein functions in viral-host cell receptor interactions that subsequently allow 
viral fusion and entry into host cells (Modis et al., 2003), however DENV binds to a wide range 
of host receptors, thus specific binding sites on the E protein for cellular receptors remain 
unclear (Cruz-Oliveira et al., 2015). As the surface protein of infectious DENV particles, it is 
the major antigenic determinant of dengue infection that elicits a neutralising antibody 
response within the host (de Alwis et al., 2012; Crill et al., 2009). While the majority of 
antibodies raised against DENV during infection recognise various epitopes on the E protein, 
antibodies against the prM and NS1 proteins can also be expressed during infection, but to a 
lesser extent or with a poorer neutralising effect (Beltramello et al., 2010).  
1.3.6. NS1 protein  
The DENV NS1 protein is a 46-50 kDa glycoprotein that is found in various cellular locations 
and displays a wide range of distinct functions during infection. During infection, DENV 
modifies host cellular membranes to form convoluted membranes (CM), vesicle packets (VP), 
and establish sites of replication, termed replication complexes (RC). An ER membrane-bound 
form of NS1 localises to VPs and cytoplasmic vacuoles that facilitate viral RNA replication and 
it is widely known that NS1 plays a central role during early stages of viral RNA replication 
(Mackenzie et al., 1996; Muller and Young, 2013; Watterson et al., 2016). While the exact 
mechanism remains elusive, it is thought that NS1 may play a structural role by anchoring the 
replication complex to the membrane through interactions with NS4A and NS4B at the ER 
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membrane (Lindenbach and Rice, 1999; Muller and Young, 2013). A critical function of NS1 
in the assembly of infectious DENV particles has also been described, with multiple NS1 
mutants found to release up to 100-fold fewer infectious particles than wild-type, with negligible 
or minor defects in viral RNA replication or NS1 protein stability (Scaturro et al., 2015). The 
authors also describe NS1 interactions with DENV structural proteins, E and prM, which they 
suggested could mediate its function during viral assembly. Additionally, NS1 can be found on 
the surface of the plasma membrane, and can also be secreted from infected cells during 
infection (Young et al., 2000); both of these forms of NS1 are highly immunogenic and play a 
paradoxical role by eliciting both a protective host immune response and inducing 
inflammatory cytokine release that contributes to immune-modulated pathogenicity (Beatty et 
al., 2015; Modhiran et al., 2015; Modhiran et al., 2017). Secreted NS1 also aids in subversion 
of the host immune response through inhibition of complement activation (Avirutnan et al., 
2011; Avirutnan et al., 2010).  
1.3.7. NS2A protein 
NS2A is a 22 kDa hydrophobic protein found on the ER membrane of infected cells (Xie et al., 
2013) that has been shown to play an important role in viral RNA replication by co-localising 
with dsRNA, NS4A, and other non-structural proteins NS1, NS3 and NS5 within the viral RC 
in VPs (Mackenzie et al., 1998). It also plays an important role in viral assembly by contributing 
to the remodelling of membranes and formation of virus-induced membrane structures that 
contain the sites of viral RNA replication and of viral assembly (Nemésio and Villalaín, 2014). 
It has also been suggested that NS2A may function as a transporter of the partially-assembled 
replicase complex via hydrophobic interactions with NS4A, consisting of viral RNA, NS2A, 
NS3 and NS5, from the replication complex to the site of virion assembly (Leung et al., 2008; 
Liu et al., 2003; Xie et al., 2015). Interestingly, it has been proposed that two distinct sets of 
NS2A molecules function in either DENV RNA replication or DENV particle assembly, and 
these are either located in viral replication complexes in the rough ER, or at viral assembly 
sites in rough ER lumen and Golgi vesicles, respectively (Xie et al., 2015). Additionally, NS2A 
has also been implicated in evasion of the host immune response through inhibition of the 
type I interferon (IFN) signalling pathway (Muñoz-Jordan et al., 2003, 2005).  
1.3.8. NS2B protein 
NS2B is a 14 kDa integral ER membrane protein that is comprised of three domains: a central 
region of 47 amino acids that acts as an essential cofactor to facilitate proper folding and 
catalytic function of the viral NS3 protease, which is flanked by two hydrophobic 
transmembrane regions that anchor the NS2B-NS3 complex in the ER membrane (Clum et 
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al., 1997; Falgout et al., 1991, 1993). The NS2B-NS3 serine protease functions in proteolytic 
processing of the viral polyprotein encoded by the single ORF in the DENV genome; NS2B-
NS3 is responsible for cleavages at the NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4A/2K, and 
NS4B/NS5 junctions (Lindenbach et al., 2007). NS2B-NS3 is also implicated in evasion of the 
host immune response during infection by targeting the human adaptor protein, stimulator of 
the interferon gene (STING), for proteolytic degradation (Aguirre et al., 2012). Recently, it was 
shown that cyclic GMP-AMP synthase (cGAS) is also degraded during DENV infection; cGAS 
is a cytosolic DNA sensor that binds to viral nucleic acids and specifically activates STING as 
part of the type I IFN induction pathway. Interestingly, degradation of cGAS was mediated by 
the NS2B cofactor alone, was not dependent on the formation of the NS2B-NS3 protease 
complex or on NS3 alone, and this was the first report of an IFN antagonist function for NS2B 
by itself (Aguirre et al., 2017). By targeting STING and cGAS for degradation, DENV is able 
to disrupt the type I IFN signalling pathway and evade these branches of the innate immune 
response (Aguirre et al., 2012). While its role as a cofactor for the NS3 protease is its most 
well-studied function, NS2B has also been tentatively suggested to function as a viroporin that 
forms pore-like structures in lipid environments (Dionicio et al., 2018; León-Juárez et al., 
2016); however, further investigation is required to assess this viroporin effect and its potential 
functional relevance during DENV infection.  
1.3.9. NS3 protein  
NS3 is a large, 70 kDa, multifunctional protein, that localises to CMs and RCs on the ER 
membrane (Welsch et al., 2009), and possesses several domains that play distinct and 
essential roles in the viral life cycle. As mentioned previously, NS3 possesses an N-terminal 
serine protease domain that requires NS2B as a cofactor to become catalytically-active, and 
functions in viral polyprotein processing (Falgout et al., 1991, 1993). At its C-terminus, NS3 
encodes a region with RNA triphosphatase (RTPase), RNA-stimulated nucleoside 
triphosphatase (NTPase), and, interestingly, both RNA helicase and strand annealing 
activities (Gebhard et al., 2012; Li et al., 1999; Wang et al., 2009a), all of which are essential 
functions for viral genome replication. NS3 has been shown to localise to convoluted 
membranes (CM) on the ER (Welsch et al., 2009), which, together with its known functions in 
viral genome replication, suggest that NS3 is an integral part of the viral replication complex. 
In addition to its well-characterised interaction with NS2B to form the NS2B-NS3 serine 
protease complex, NS3 also interacts with other viral and host proteins to carry out various 
roles during infection. During DENV infection, host fatty acid biosynthesis pathways are altered 
and it is thought that this plays a role in the establishment of viral RCs. NS3 has been shown 
to interact strongly with and recruit the host fatty acid synthase (FASN) enzyme to sites of 
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replication, and also increase fatty acid synthesis in a dose-dependent manner (Heaton et al., 
2010), however the exact mechanism by which NS3 stimulates fatty acid biosynthesis is yet 
to be elucidated. Overall, this suggests that NS3 plays a role in enhancing viral replication not 
only through its function as a protease together with NS2B, but also by modulating host fatty 
acid biosynthesis pathways. DENV-mediated modulation of fatty acid biosynthesis is 
discussed in more detail in Section 1.6. NS2B-NS3 also plays a role in pathogenesis by 
inducing host cell apoptosis (Lin et al., 2014). The viral protease interacts with members of 
the IkB family of inhibitory proteins that, upon degradation, activate translocation of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) transcription factor to the 
nucleus, which activates target genes that encode cytokines, chemokines and proteins 
involved in apoptosis. NS2B-NS3 cleaves both IkBa and IkBb, leading to infected cell death 
and haemorrhage development in mice (Lin et al., 2014). 
1.3.10. NS4A protein 
NS4A is a small, 16 kDa hydrophobic protein that is still relatively poorly characterised 
compared to other DENV proteins. During polyprotein processing, the N-terminus of NS4A is 
generated by NS2B-NS3-mediated cleavage (Miller et al., 2007). NS4A co-localises with 
DENV E protein and dsRNA to sites of viral replication and induces intracellular membrane 
alterations that are thought to form the basis of RC generation (Miller et al., 2007; Welsch et 
al., 2009). NS4A also directly interacts and co-localises with vimentin, a host protein that 
undergoes reorganisation during DENV infection, and through its interaction with NS4A is 
thought to form a structural scaffold to anchor DENV RCs in the ER membrane (Teo and Chu, 
2014). Furthermore, NS4A also interacts with NS4B in the RC, and mutants containing 
mutations that disrupted this interaction are defective in viral replication (Zou et al., 2015b). 
Together, these factors suggest that NS4A is an important component of the viral replication 
complex.  
NS4A has been shown to play a key role in the regulation of host cell autophagy during 
infection in a cell type-specific manner. DENV induces autophagy in epithelial cells which 
enhances viral replication and protects from cell death, while in macrophages apoptosis was 
induced. In one study, each DENV gene was expressed individually in Madin-Darby Canine 
Kidney (MDCK) cells and protection against cell death induced by camptothecin (CPT), a 
DNA-damaging agent, was measured. NS4A was shown to be the only protein that protected 
the cells from cell death, decreasing CPT toxicity by 35%, almost to a similar extent as infection 
with whole virus which decreased CPT toxicity by 40%. The authors also showed that NS4A-
expressing cells induced autophagy to a similar extent as infection with live DENV virus 
(McLean et al., 2011).  
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1.3.11. NS4B protein 
NS4B is a small hydrophobic, integral membrane protein of 27 kDa that resides in ER 
membranes. During viral polyprotein processing, the 2K fragment facilitates translocation of 
NS4B from the cytoplasm to the ER lumen and is then removed from the NS4B N-terminus by 
host signalase. Mutational analyses have shown that functional NS4B is essential for viral 
replication, and NS4B co-localisation with NS3, NS4A and dsRNA in the perinuclear region, 
as well as ER protein markers, but not Golgi markers or lipid droplets, suggests that NS4B 
plays an integral role in viral replication and not a later stage of infection (Miller et al., 2006; 
Zou et al., 2015b; a). NS4B dissociates NS3 from ssRNA, thus enabling it to bind to a new 
duplex and enhancing the function of NS3 as an RNA helicase (Umareddy et al., 2006), and 
this direct NS3-NS4B interaction is critical for successful viral replication (Chatel-Chaix et al., 
2015). DENV NS4B has also been shown to be a key viral modulator of the host immune 
response, allowing immune evasion to enhance viral infection. During infection NS4B inhibits 
the phosphorylation and activation of signal transducer and activator of transcription 1 
(STAT1) (Muñoz-Jordan et al., 2003); STAT1 is an important component of the type I IFN 
pathway which functions as the first line of defence against viral infections and therefore is a 
key determinant of infection progression (Morrison et al., 2012; Shresta et al., 2004). The 
function of NS4B as an antagonist of host immune responses is a focus of this project and is 
discussed in more detail in Section 1.5. Elucidating the specific roles of NS4B in viral 
replication and as an antagonist of the host innate immune response has been of great focus, 
and these key functions have led to the development of antiviral compounds that specifically 
target the flavivirus NS4B (van Cleef et al., 2013; Xie et al., 2011, 2015b), however none of 
these have yet reached the clinical trial stage.   
1.3.12. NS5 protein  
NS5 is the largest of the DENV proteins (~102 kDa) and is found in the cytoplasm and nucleus 
of infected cells. At its N-terminus there is a methyltransferase domain (MTase) with putative 
guanylyltransferase activity that is responsible for capping viral RNA in a two-step reaction, 
such that the cap resembles the 5¢ capped eukaryotic mRNA which prevents its degradation 
and enhances interaction with the ribosome for translation (Issur et al., 2009; Zhao et al., 
2015a). Capping the viral RNA also enables the virus to avoid detection by pathogen 
recognition receptors (PRR) that detect dsRNA or uncapped 5¢ triphosphate RNA, such as 
retinoic acid inducible gene I (RIG-I) or melanoma differentiation-associated protein 5 (MDA5) 
(Chang et al., 2016). At its C-terminus, NS5 possesses an RNA-dependent RNA polymerase 
(RdRp) domain that replicates viral RNA. During infection, the positive sense viral RNA is 
released into the cytoplasm where the NS5 RdRp transcribes it as a negative sense strand, 
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and then uses the negative strand from the dsRNA intermediate to synthesise viral positive 
strand RNA which is then used for translation or packaged into new virion particles (Sahili and 
Lescar, 2017). A linker sequence connects the two domains which determines their relative 
positions and provides distinct molecular conformations that may be required for its functions; 
mutation studies of linker residues suggest that the flexible linker domain is important for NS5 
RdRp activity and viral replication (Lim et al., 2013; Zhao et al., 2015b).  
NS5 functions as an antagonist of the type I IFN response by directly interacting with STAT2 
and ubiquitin ligase E3 recognin 4 (UBR4) to promote the proteosomal degradation of STAT2, 
thus blocking the signalling pathway leading to the production of type I IFN (Ashour et al., 
2009). The NS5 protein has also been implicated in induction of interleukin-8 (IL-8) expression 
and secretion. IL-8 is a chemokine that is found in elevated levels in patients with DHF and is 
thought to be a key determinant of DENV pathogenesis (Clyde et al., 2006; Li et al., 2010). 
NS5 expression increased transcription of three transcription factors involved in IL-8 mRNA 
induction: CAAT/enhancer binding protein (c/EBP), and to a lesser extent, NF-kB and 
activating protein 1 (AP-1) (Medin et al., 2005). Thus, DENV NS5 is an important determinant 
for establishment of infection, subversion of host immunity, and DENV pathogenesis.  
 
1.4. Overview of DENV replication cycle in human hosts  
Upon infection following a blood meal taken by an infected mosquito vector, DENV infects a 
wide range of human host cell types. The primary targets for DENV infection are phagocytes 
of the mononuclear lineage, including monocytes, macrophages, dendritic cells (DC) and 
Langerhans cells. As the infected leukocytes travel through the lymphatic system, DENV is 
able to spread and viral antigens can be found in the liver, spleen, lymph nodes, kidney and 
thymus of infected hosts (Jessie et al., 2004; Rodenhuis-Zybert et al., 2010).  
1.4.1. Binding and entry  
DENV entry into target cells is mediated by the E protein which facilitates binding to cellular 
receptors, and enable fusion of viral and cellular membranes (Crill and Roehrig, 2001; 
Harrison, 2015; Heinz et al., 2004).  
DENV enters target cells via receptor-mediated clathrin-dependent endocytosis (Van Der 
Schaar et al., 2008). Since DENV infects a wide range of target cells, it is able to exploit 
multiple different cell surface receptors to enable viral entry including, but not limited to, 
dendritic cell-specific intercellular adhesion molecular-3-grabbing non-integrin (DC-SIGN) on 
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DCs, mannose receptor (MR) on macrophages and heparan sulfate (Chen et al., 1997; Cruz-
Oliveira et al., 2015; Miller et al., 2008; Tassaneetrithep et al., 2003). Upon internalisation, 
virus-receptor complexes are delivered to Rab5-positive early endosomes, which mature into 
Rab7-positive late endosomes. Low pH in the late endosomes triggers a conformational 
change in the E protein to allow fusion of viral and cellular membranes. The nucleocapsid 
escapes the endosomes and then uncoats to release the viral RNA into the cytosol (Krishnan 
et al., 2007; Van Der Schaar et al., 2008).  
1.4.2. DENV genome replication and the replication complex 
Once in the cytosol, the viral RNA is translated into a single polyprotein in association with 
ER-derived membranes. The polyprotein is then co- and post-translationally cleaved by both 
cellular proteases and the viral NS2B-NS3 protease to generate the 10 viral proteins. 
Translation and processing of the polyprotein is a fundamental process that must occur before 
viral genome replication can proceed; once the proteins are generated, the virus can then 
switch to genome replication (Clyde et al., 2006; Fischl and Bartenschlager, 2011). Viral non-
structural proteins are involved in replication, as described in more detail from Section 1.3.6.  
DENV induces invaginations of the ER membrane, primarily via the NS4A protein, which forms 
structures with different morphologies, including VP and CM structures (Miller et al., 2007; 
Welsch et al., 2009). These structures serve as a scaffold for the viral RC that contains viral 
proteins, RNA, and likely also host cell factors being exploited for viral replication. The lumen 
of these structures are connected to the cytosol via a pore, which allows entry of nucleotides 
and other factors required for replication and exit of newly-synthesised copies of the viral 
genome to be packaged into progeny virions (Welsch et al., 2009).  
The non-structural proteins primarily coordinate replication of the viral genome and assembly 
of virus particles. NS3 and NS5 play enzymatic roles; NS3 has helicase, RTPase, NTPase 
and, together with NS2B, serine protease activities, while NS5 functions as a MTase and 
RdRp (Lindenbach and Rice, 2007). NS2A, NS4A and NS4B are all non-enzymatic; NS2A is 
thought to function in both viral replication and assembly (Xie et al., 2015a), NS4A is thought 
to induce ER membrane invaginations (Miller et al., 2007), and NS4B is essential for 
replication but while the primary mechanism is still unknown, it has been shown that NS4B 
dissociates ssRNA from NS3 to enhance replication (Miller et al., 2006; Umareddy et al., 
2006). NS1 is known to be essential for both viral replication and assembly, but its exact 
function also remains elusive (Muller and Young, 2013).  
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In the replication complex, the positive-sense genomic RNA template is copied asymmetrically 
to favour generation of excess positive-sense RNA, as this serves as both viral genome and 
mRNA, however the mechanism by which asymmetric RNA replication occurs has not yet 
been described (Clyde et al., 2006; Lindenbach et al., 2007).  
1.4.3. Virion assembly and maturation  
Once all proteins are translated and RNA is replicated, the RNA interacts with the C protein to 
form the nucleocapsid; the flavivirus nucleocapsid has no regular geometry and appears highly 
unstructured, unlike in the virions of other groups such as alphaviruses of the Togaviridae 
family (Freire et al., 2013). The nucleocapsid buds into the ER lumen, and the host-derived 
lipid membrane is acquired surrounding the nucleocapsid. This membrane also contains prM-
E heterodimers that become incorporated to form immature DENV virions via interaction with 
the nucleocapsid (Apte-Sengupta et al., 2014). 
Immature DENV particles undergo maturation as they are transported along the secretory 
pathway through the trans-Golgi network (TGN), which is an acidic environment and induces 
a pH-dependent, reversible, conformational change in the E proteins. This conformational 
change in the E protein enables access and subsequent cleavage of the prM proteins by furin, 
a cellular protease found in the TGN. Following cleavage of prM into its’ components, the M 
protein exists as a transmembrane protein beneath the E protein outer layer, while the pre-
peptide (pr) remains associated with the E protein (Yu et al., 2008).  
It has been previously shown that processing of prM to M using host furin or a furin-like 
protease, during maturation is required for infectivity of the virion particles. One study 
compared the infectivity of fully immature DENV-2 particles cultured in cell lines that lack 
functional furin with DENV-2 cultured in cell lines that possessed the furin protease. The 
authors determined, through calculation of the ratio of genome-containing particles (GCP) to 
infectious units (IU), that immature particles were at least 10,000-fold less infectious due to 
the absence of functional furin (Zybert et al., 2008). Another study showed that furin cleavage 
occurs only under acidic conditions at pH 5.0 to 6.0 and while uncleaved virions at pH 8.0 and 
pH 6.0 are mildly infectious, there is a 1000-fold increase in infectivity following low pH-
dependent furin cleavage (Yu et al., 2008). 
The mature virions are released into the cytoplasm from the TGN and are transported to the 
outer cell membrane where they are released by exocytosis. When the virion reaches the pH-
neutral extracellular environment, the pr peptide dissociates and exposes the E protein in the 
mature particle to allow E protein-mediated viral-host fusion to infect new cells. Neutral pH-
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dependent dissociation of pr peptides from E proteins is thought to be a mechanism that 
prevents premature fusion of the mature virion with host membranes prior to release (Perera 
and Kuhn, 2008; Yu et al., 2008).  
 
1.5. Dengue virus evasion of the host innate immune response  
1.5.1. Activation of the innate immune response during DENV infection 
The innate immune response is the host’s first line of defence against viral infection and is 
responsible for limiting viral spread during the early stages of infection. Several host PRRs 
have been reported to recognise DENV antigens as pathogen-associated molecular patterns 
(PAMPs) which then go on to activate various branches of the innate immune response 
(Sprokholt et al., 2018). Viral dsRNA and ssRNA produced as replication intermediates are 
recognised by the cytoplasmic helicases RIG-I and MDA5 that detect intracellular viral nucleic 
acids (Loo et al., 2008; Loo and Gale, 2011; Nasirudeen et al., 2011), and Toll-like receptors 
(TLRs) that patrol extracellular and endosomal compartments. TLRs that are activated upon 
DENV infection include TLR3, TLR7, TLR8 and TLR9 (Barton, 2007; Xagorari and Chlichlia, 
2008), and differential expression of these TLRs was reported in DCs of patients with dengue 
fever compared to DHF which may play an important role in disease progression (Torres et 
al., 2013).  
Triggering of PRRs by DENV leads to the activation of various intracellular signalling pathways 
that contribute to defence against infection, such as the protective IFN response and the 
inflammatory response. Activation of the transcription factor NF-kB results in the 
transcriptional activation and expression of proinflammatory cytokines and chemokines. While 
this is protective in many cases, overexpression of these inflammatory molecules can 
contribute to the pathogenesis associated with dengue disease. DC-SIGN, MR and C-type 
lectin domain family 5, member A (CLEC5A) are receptors found on the surface of innate 
immune cells, such as DCs, macrophages, monocytes and neutrophils that interact with the 
DENV E protein. DC-SIGN and MR primarily function in enabling DENV entry into target cells, 
however CLEC5A activation results in expression of high levels of IL-1b, IL-6, IL-8, IL-18 and 
tumour necrosis factor (TNF), all of which are pro-inflammatory cytokines (Chen et al., 2008; 
Sprokholt et al., 2018). Additionally, TLR4 can recognise the DENV NS1 protein which also 
results in the release of proinflammatory cytokines and chemokines and may be associated 
with DENV pathogenicity (Modhiran et al., 2015, 2017).  
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1.5.2. The type I interferon signalling pathway  
Upon virus recognition by PRRs infected immune cells such as DCs and macrophages 
produce high levels of type I IFNs, IFNa and IFNb, within hours of infection and thus IFN 
production is often considered to be a critical first line of defence (Shresta et al., 2004). Type 
I IFNs have three major functions: i) to induce an antiviral response that serves to limit viral 
infection; ii) to modulate the innate immune response to promote optimal antigen presentation, 
modulate NK cell functions, and regulate the inflammatory response; iii) to activate the 
adaptive immune system and enhance the antiviral immune response and induce antigen-
specific B and T cell responses and immunological memory (Ivashkiv and Donlin, 2015). 
Upon antigen recognition, RIG-I and MDA5 interact with an adaptor protein called 
mitochondrial antiviral signalling protein (MAVS) which interacts with STING to recruit and 
phosphorylate the kinases IkB kinase (IKK) and TANK-binding kinase 1 (TBK1). IKK and TBK1 
activate the transcription factors IFN regulatory factor 3 (IRF3) and NF-kB, which 
transcriptionally induce the expression of IFNa/b. IFNa/b is then secreted out of infected cells 
(Castillo Ramirez and Urcuqui-Inchima, 2015; Liu et al., 2015). On the surface of neighbouring 
cells, secreted IFNa/b binds to the transmembrane IFNa receptor (IFNAR) which activates the 
receptor-associated Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) kinases. JAK1 and 
TYK2 phosphorylate the cytoplasmic transcription factors STAT1 and STAT2, which causes 
pSTAT1 and pSTAT2 to dimerise and form a heterotrimeric complex with IRF9 called IFN-
stimulated gene factor 3 (ISGF3). ISGF3 translocates to the nucleus and binds a specific 
genetic element called the interferon-stimulated response element (ISRE), found in the 
promoter region of IFN-stimulated genes (ISGs) (Ivashkiv and Donlin, 2015).  
ISGs encode proteins with a plethora of antiviral functions, including the inhibition of viral 
genome replication and translation of viral proteins, degradation of nucleic acids and proteins, 
regulation of the inflammatory and adaptive immune responses, and modulation of host 
cellular pathways that are utilised by the virus, such as lipid metabolism (Ivashkiv and Donlin, 
2015; Schneider et al., 2014). IFN-inducible transmembrane proteins (IFITM) are ISG-
encoded proteins with a wide range of antiviral functions at any stage of viral entry, and IFITM2 
and IFITM3 have been shown to inhibit DENV infection, and siRNA knockdown of IFITM3 
leads to an increase in DENV replication (Brass et al., 2009; Jiang et al., 2010). ISG20 has 
been identified as an inhibitor of DENV infection (Jiang et al., 2010) and is thought to degrade 
viral RNA and potentially indirectly act on cellular factors that are necessary for viral replication 
or transcription (Zheng et al., 2017). Viperin is another IFN-encoded protein that is upregulated 
during DENV infection and inhibits DENV genome replication and infectious particle release 
that limits infection progression (Helbig et al., 2013; Jiang et al., 2010).  
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1.5.3. DENV as an antagonist of the type I IFN immune response  
The type I IFN response is a critical determinant of pathogenicity and as such, many viruses 
have evolved to express proteins that can actively function in evasion of the type I IFN 
response to enhance their own replication. During DENV infection, subversion of the immune 
response is primarily mediated by the viral non-structural proteins.  
NS2A, NS4A and NS4B can disrupt signalling through RIG-I and MAVS by inhibiting TBK1 
and IRF3 phosphorylation (Dalrymple et al., 2015; He et al., 2016), and the NS2B/NS3 
protease cleaves STING and targets cGAS for degradation  which, upon DNA binding, 
activates STING (Aguirre et al., 2012, 2017; Yu et al., 2012). Through these mechanisms 
DENV is able to disrupt the initial induction of IFNa/b and reduce its production in infected 
cells. Following IFNa/b production the NS2A, NS4A and NS4B proteins can block STAT1 
phosphorylation and nuclear translocation and inhibit activation of the ISRE promoter, with 
NS4B having the strongest inhibitory effect (Muñoz-Jordan et al., 2003, 2005). Additionally, 
NS5 binds to STAT2 and targets it for ubiquitination and proteasomal degradation, leading to 
reduced levels of STAT2 in infected cells (Ashour et al., 2009), and also inhibits STAT2 
phosphorylation and activation (Mazzon et al., 2009). Together, inhibition of the function of 
STAT1 and STAT2 interferes with the IFNa/b signalling pathway and inhibits downstream 
activation of expression of key antiviral ISGs. Additionally, it has been suggested that induction 
of the formation of intracellular vesicles to function as sites for viral replication could be a 
mechanism by which DENV passively evades the immune response through avoiding 
intracellular recognition (Castillo Ramirez and Urcuqui-Inchima, 2015; Welsch et al., 2009).  
Altogether, mechanisms by which DENV evades the innate immune response are critical 
determinants of infection progression and pathogenicity. Due to their important functions in 
immune evasion, mutations in the non-structural proteins, particularly NS4B, that would 
diminish these function have been proposed as a strategy for the development of dengue live 





Figure 1.2: DENV antagonism of the type I IFN response. DENV particles enter target cells using 
receptors such as DC-SIGN, MR and CLEC5A and uncoat to release viral RNA genomes into the 
cytoplasm which are recognised by RIG-I and MDA5. RIG-I and MDA5 interact with MAVS which 
interacts with STING to phosphorylate IKK and TBK1. The DENV NS2B/NS3 protease cleaves STING 
(A). IKK and TBK1 activate IRF3 and NF-kB transcription factors which induce the expression of IFNa/b; 
the DENV NS2A, NS4A and NS4B proteins inhibit the activation of TBK1 and IRF3 (B). IFNa/b is 
secreted from infected cells and binds to IFNAR on the surface of neighbouring cells. This activates the 
JAK1 and TYK2 kinases, which phosphorylate STAT1 and STAT2 cytoplasmic transcription factors. 
The DENV NS2A, NS4A and NS4B proteins block STAT1 phosphorylation and nuclear translocation 
(C), while NS5 protein targets STAT2 for ubiquitination and proteasomal degradation (D). STAT1, 
STAT2 and IRF9 form a heterotrimer which translocates to the nucleus and binds the ISRE which 









1.6. Dengue virus interaction with host lipid metabolism pathways  
Viruses commonly exploit various aspects of host lipid metabolism pathways and lipid stores 
to promote their own replication cycle and enhance infection. Interactions between viruses 
and lipids have been shown to facilitate cell attachment and entry, to form replication 
complexes that allow viral genome replication, and to allow viral assembly and secretion 
(Heaton and Randall, 2011). Sterol biosynthesis pathways are downregulated upon viral 
infection and activation of the IFN response, which suggests that lipid metabolism constitutes 
a target for regulation mediated by the host immune response (Blanc et al., 2011). Additionally, 
LDs are intracellular organelles that function as cellular stores of triglycerides and cholesterol 
esters and are closely linked to energy and lipid homeostasis, and they have increasingly been 
shown to play a role in modulating the host immune response. LDs play a role in antigen cross 
presentation, autophagy and production of inflammatory mediators and ISGs such as viperin 
localise to LDs in response to viral infection (Saka and Valdivia, 2012).  
1.6.1. DENV modulation of cellular lipids and lipid metabolism pathways 
Cellular lipids play important roles at various stages throughout the DENV replication cycle. 
Soon after DENV infection, total intracellular cholesterol levels increase which is mediated by 
enhanced activation of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), a key rate-
limiting enzyme in cholesterol biosynthesis pathways, and an increase in low density 
lipoprotein receptor (LDLR) on the surface of infected cells to increase cholesterol synthesis 
and uptake, respectively (Soto-Acosta et al., 2013). An increase in fatty acid synthesis is also 
stimulated, mediated by the DENV NS3 protein which recruits the FASN enzyme to sites of 
viral replication and allows establishment of RC structures (Heaton et al., 2010). Early DENV 
infection is also associated with an increase in lipid raft formation (Soto-Acosta et al., 2013) 
and host receptors required for DENV entry into cells, such as DC-SIGN, are have been found 
to co-localise with lipid rafts; it was suggested that this association enhances interaction of 
virus particles with DC-SIGN to facilitate entry into DCs, a major target cell for DENV infection 
(Cambi et al., 2004). Upon DENV infection, the number of LDs per cell is also increased and 
LDs are thought to be exploited by DENV for multiple functions. Mature DENV C protein 
localises to the surface of LDs and proper localisation was found to be essential for the 
formation of infectious particles (Samsa et al., 2009). However, co-localisation of LDs and viral 
replication complexes has not been observed (Welsch et al., 2009) so LDs may play a more 
indirect role in the viral replication cycle (Fischl and Bartenschlager, 2011). Interestingly, an 
alternative function for LDs has also been reported; DENV-induced autophagy regulates lipid 
metabolism, and in cells with high numbers of autophagosomes it was observed that there is 
an associated decrease in lipid droplet area, reduced levels of triglycerides, and increased b-
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oxidation. Autophagy is known to be required for DENV replication, and a model was proposed 
whereby autophagy-dependent depletion of cellular lipid stores results in the release of free 
fatty acids which undergo b-oxidation in mitochondria to generate ATP that is used to facilitate 
viral RNA replication (Heaton and Randall, 2010). Altogether, this suggests that DENV 
infection induces both anabolic and catabolic alterations to lipid metabolism. While depleting 
LDs and increasing intracellular ATP levels through b-oxidation provides energy that may 
facilitate viral replication, simultaneously increasing lipid biosynthesis may enable the 
formation of membrane-bound replication complexes through membrane remodelling (Heaton 
et al., 2010; Heaton and Randall, 2010; Miller et al., 2007; Soto-Acosta et al., 2013; Welsch 
et al., 2009).  
During viral uptake and transport through the endosomal pathway, DENV utilises late 
endosome membrane-specific lipids, bis(monoacylglycerol)phosphate and 
phosphatidylserine, to mediate entry into late endosomes via fusion with the viral E protein 
(Zaitseva et al., 2010).  
Loss of cholesterol in the viral envelope through pre-treatment with a cholesterol-depleting 
drug, methyl-beta-cyclodextrin (MCD) results in inhibition of fusion between the virion 
envelope and the late endosomal membrane such that virion uncoating and release of the 
nucleocapsid into the cytosol is prevented (Carro and Damonte, 2013). DENV replication can 
also be inhibited by pharmacological inhibition of cholesterol biosynthesis or LD metabolism 
(Carro and Damonte, 2013; Rothwell et al., 2009; Samsa et al., 2009). Thus, interference with 
host lipid metabolism pathways could be an attractive target for antiviral drug development.  
 
1.7. Dengue virus and flavivirus persistence  
There is evidence that several members of the Flaviviridae family, such as Zika virus (ZIKV), 
hepatitis C virus (HCV), Murray Valley encephalitis virus (MVE), JEV, West Nile virus WNV 
and tick-borne encephalitis virus (TBEV) are capable of causing persistent infection (Barzon 
et al., 2016; Gritsun et al., 2003; Large et al., 1999; Murray et al., 2010; Poidinger et al., 1991; 
Ravi et al., 1993). Isolation of viable viral particles, antigens, or RNA from patient samples 
long after the initial acute illness can indicate persistent infection, and this can also be evident 
in blood donation samples and cell culture studies (Mlera et al., 2014; Murray et al., 2010; 
Poidinger et al., 1991).  
There have been several observed mechanisms that contribute to persistence in flaviviruses, 
the most important being subversion of host immune responses and regulation of apoptosis 
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and autophagy. During infection, the IFN response is activated within hours but flaviviruses 
commonly induce intracellular membrane rearrangements that are capable of hiding viral 
antigens, thus delaying activation of the IFN pathway and expression of antiviral ISGs (Overby 
et al., 2010; Welsch et al., 2009). Chronic infections and HCV persistence are well 
documented and associated with immune evasion strategies such as blocking RIG-I and 
MAVS signalling during the IFN response and persistent presence of viral antigen that 
chronically activates T cells leading to exhaustion and loss of T cell function (Baril et al., 2009; 
Breiman et al., 2005; Rehermann, 2009).  
Immune evasion is primarily a temporary mechanism by which the virus establishes infection, 
however to establish persistent infection a common mechanism is virus-mediated regulation 
of autophagy and prevention of apoptosis. It has been observed that establishment of 
persistent infection by flaviviruses in vitro is characterised by an acute phase in which most of 
the cells are killed but a small population of cells survive and, while still infected, proliferate, 
suggesting that  apoptotic host factors must be modulated (Mlera et al., 2014). Indeed, in vitro, 
the DENV NS4A protein was shown to upregulate the number of autophagosomes to promote 
autophagy which prevented cell death and enhanced viral replication in epithelial cells and 
fibroblasts. However, this is cell type-specific as apoptosis was enhanced in macrophages 
(McLean et al., 2011). Prevention of cell death in cell types naturally infected by DENV, yet 
increased apoptosis in immune cells such as macrophages, could be potential mechanisms 
by which DENV could theoretically establish persistent infection.  
However, despite observations of modulation of autophagy and apoptosis by DENV, a major 
question still remains regarding whether or not DENV can cause persistent infections similarly 
to other flaviviruses. Mosquitoes and mosquito cell lines become persistently-infected with 
DENV (Chen et al., 1994; Igarashi, 1979; Juárez-Martínez et al., 2013; Salas-Benito and De 
Nova-Ocampo, 2015), however only few studies have shown that DENV can establish 
persistent human infections in vitro in which DENV infection persisted in human monocyte cell 
lines for several months (Kurane et al., 1990; Nakao et al., 1989). It was suggested that 
differences in host immune responses influence the difference in infection outcomes, with the 
Ae. aegypti RNA interference (RNAi) innate immune response being a critical factor for 
allowing maintenance of persistent infection in the mosquito (Sánchez-Vargas et al., 2009).  
Overall, previous evidence for persistent DENV infection and any clinical correlates in humans 
is sparse.  
1.7.1. Discovery of a persistently-infecting dengue virus mutant  
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Preceding this project, Dr. Andrew Davidson and colleagues at the University of Bristol 
discovered a cell line persistently-infected with DENV-2. Baby hamster kidney (BHK)-21 cells 
were found to be infected with DENV-2, as confirmed by agarose gel electrophoresis analysis 
of RT-PCR products produced from extracellular RNA and immunofluorescence assay (IFA) 
analysis of the BHK-21 cells using an antibody against the DENV E protein (Figure 1.3A and 
B). This infection was non-cytopathic and found to be persistent as the infection was 
maintained during cell passaging.  
Supernatant from the cultures of persistently-infected BHK-21 cells was transferred to cultures 
containing either uninfected C6/36 (mosquito) or Vero (mammalian) cells and was sufficient 
to infect the naïve cells (Figure 1.3C), which demonstrated that the cell lines were infected 
and producing viable, infectious particles. Once infection of C6/36 and Vero cells was 
established, it was also found to be persistent. DENV-2 RNA and protein levels were 
measured by qRT-PCR and western blot (Figure 1.3D and E); these showed that the 
persistently-infected cells were expressing lower levels of wild-type DENV-2 RNA at all time-
points, and lower levels of NS5 protein than wild-type infected cells 30 hours post-infection. 
The viral genome from supernatants collected from BHK, C6/36 and Vero cells was 
sequenced, and mutations that were found are summarised in Table 1.1. The only mutation 
that was present in the genome of viruses isolated from supernatant collected from all cell 
types was at nucleotide 7021 (ACA à GCA), encoding a non-silent mutation that changed 
threonine (Thr) to alanine (Ala). This residue is located at position 66 encoded by the NS4B 
gene (NS4BT66A). Another mutation present in the genome of all viruses except for those 
isolated from Vero cells was at nucleotide 7020 (CTA à CTG) which encoded a silent mutation 
next to the T66A amino acid mutation.  
37 
 




(D) (E)  
Figure 1.3: Discovery of BHK-21 cell line persistently-infected with DENV-2. Presence of DENV-2 
RNA in supernatant of persistently-infected BHK-21 cells was confirmed by agarose gel electrophoresis 
on RT-PCR cDNA products (A). Intracellular presence of DENV E protein was confirmed by 
immunofluorescent staining using an anti-E mAb (B). Supernatant containing infectious particles 
collected from persistently-infected BHK-21 cell cultures was transferred to C6/36 and Vero cell 
cultures; infection in C6/36 and Vero cells was confirmed by immunofluorescent staining for the DENV 























E and NS5 proteins (C). qRT-PCR was performed to measure the levels of DENV-2 RNA from the 
persistently-infected and wild-type-infected BHK-21 cells (D). Western blot for NS5 shows DENV-2 
protein levels in persistently-infected, wild-type-infected, and replicon-containing BHK-21 cells (E). The 
figure was provided by Dr Andrew Davidson.  
 
Table 1.1: Summary of mutations in the genome of a persistently-infecting virus aligned to the 
wild-type DENV-2 genome. Viral RNA was extracted from the supernatant of BHK, C6/36 and Vero 
cell lines persistently-infected with DENV-2 and sequenced by RT-PCR and Sanger sequencing. The 
only mutation present in viral samples isolated from supernatant from all cell types was in the NS4B 
gene (*). Data provided by Dr Andrew Davidson. 
 
The NS4BT66A mutation was engineered into a reverse genetic system by Dr Rebecca Ward 
using the plasmid pDVWS601, and this showed that the mutation was sufficient for 
establishing a persistent DENV-2 infection. The resulting virus, called v601-NS4BT66A, was 
used to establish a persistent infection in two human embryonic kidney (HEK293T) cell lines 
(Ismail, 2015), termed H-v601-Per1 and H-v601-Per2 from here onwards, which were used 
throughout this project. Interestingly, upon infection of the naïve cells, the majority of cells in 
the population died, while a small subset of the population survived and proliferated to form 
the persistently-infected cell population. 
Cell lines expressing subgenomic reporter replicons were also previously created to study the 
effects of this NS4BT66A mutation (Ismail, 2015) and were used throughout this project. In the 
replicon construct, pRepDV-GP2A, the structural protein gene sequences have been deleted 
except for sequences encoding the first 27 amino acids of the C protein and the last 24 amino 
acids of the E protein. The deleted sequence was replaced with a fusion gene expressing 
enhanced green fluorescent protein (eGFP) for replicon detection, and puromycin N-
Gene NT 




change BHK 1 BHK 2 C6/36 Vero 
NS3 6336 - - - G à A CTG à CTA Leu 
NS4A 6461 - C à T C à T - GCA à GTA Ala à Val 
NS4A 6463 T > G G à T G à T - GTG à TTG Val à Leu 
NS4A 6494 C à T C à T C à T - GCG à GTG Ala à Val 
NS4A 6502 - - - C à G CAT à GAT His à Asp 
2K 6786 - T à A T à A - GTT à GTA Val  
NS4B 7020 A à G A à G A à G - CTA à CTG/A Leu 




acetyltransferase (PAC) for selection by puromycin (Massé et al., 2010). Another replicon 
encoding plasmid, pRepDV-GP2A-NS4BT66A, was also engineered to be identical to the 
pRepDV-GP2A sequence but containing the base mutations at nucleotides 7020 and 7021 to 
encode the NS4BT66A mutation. RNA transcribed from the plasmids pRepDV-GP2A and 
pRepDV-GP2A-NS4BT66A replicons was transfected into HEK293T cells and selected for 
stable expression of the replicon RNA (Ismail, 2015) (termed H-Rep and H-Rep-4BT66A, 
respectively from here onwards).  
RNAseq was performed for high-throughput transcriptomic analysis and transcriptome data 
was obtained prior to the commencement of this project (provided by Dr Andrew Davidson 
and Dr Rosmani Ismail). Total intracellular RNA was extracted from six cell samples in 
duplicate: HEK293T, H-v601-Per1, H-v601-Per2, H-Rep, H-Rep-4BT66A and HEK293T cells 
infected with wild-type DENV-2 virus, (termed H-v601 from here onwards). In short, low quality 
reads were filtered out after sequencing, and differential gene expression analysis was carried 
out using Tophat and Cufflinks software tools to ultimately generate pairwise comparisons of 
the RNAseq reads between each dataset and significant differences in gene expression 
between each of the cell types were identified.  
We were particularly interested in how, when v601-NS4BT66A was introduced to naïve cell 
cultures, only a small subset of the cells in the original culture survived, proliferated and 
became persistently-infected. It was hypothesised that, as well as potential defects in protein 
function conferred by the NS4BT66A mutation, there may be cellular defects in the surviving cell 
population which allowed cell proliferation and acted to create a balance between host and 
virus that facilitated establishment of a persistent infection.  
 
1.8. Aims of this project  
The overall aim of this Masters project was to discover mechanisms by which the NS4BT66A 
mutation facilitated establishment of a persistent DENV-2 infection in human cells, and 
determine whether there is a defect in the persistently-infected cells that allowed 
establishment of a persistent infection.  
The specific aims of the project were to:  
1. determine whether the NS4BT66A mutation has an effect on the ability of the virus to 
subvert the type I IFN response in host cells.  
2. bioinformatically analyse the transcriptomics dataset to:  
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a. identify any cellular pathways that are differentially modulated by persistently-
infecting virus, relative to DENV-2 wild-type and 
b. determine if there are any defects in cellular pathways that facilitated the 
establishment of persistent virus infection.  
3. cure H-v601-Per1 and H-v601-Per2 cell lines of virus using antiviral drugs and analyse 
the cells to identify any potential defects in cellular pathways that have allowed 







Chapter 2. Materials and Methods. 
2.1. Cell culture methods. 
2.1.1. Cell culture maintenance. 
Human embryonic kidney 293 T (HEK293T) cells were maintained by successive passage in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Lonza, Belgium) containing L-glutamine and 
4.5 g/l glucose and supplemented with 10% foetal bovine serum (FBS; Invitrogen, 
ThermoFisher, USA), 100 μg/ml streptomycin and 100 units (U)/ml penicillin (Sigma-Aldrich, 
USA), and 0.1 mM non-essential amino acids (Invitrogen, ThermoFisher). Cells were grown 
in culture vessels in a humidified incubator at 37 °C with 5% carbon dioxide (CO2) unless 
otherwise specified. When passaging, cell monolayers were detached with 1X trypsin 
(Invitrogen, ThermoFisher) in phosphate-buffered saline (PBS; Lonza).  
2.1.2. Maintenance of replicon-containing cell lines.  
Replicon-containing cell lines were previously established as detailed in (Ismail, 2015). In 
short, linearised plasmids were transcribed in vitro, the RNA was extracted and transfected 
into HEK293T cells. Replicon-positive cells were selected using 3.5 μg/ml puromycin 
(SantaCruz Biotechnology, USA) and confirmed by detection of GFP expression. Replicon-
containing cells used in this study were established using the DENV-2 replicon plasmid 
pRepDV-GP2A, and the plasmid pRepDV-GP2A-NS4BT66A which encodes a DENV-2 replicon 
containing a T66A mutation in the NS4B gene (as described in (Ismail, 2015)). These cells 
were maintained similarly to the control HEK293T cells as described in Section 2.1.1, but with 
the addition of 3.5 μg/ml puromycin with each passage.  
2.1.3. Maintenance of persistently-infected cells.  
Two cell lines persistently-infected with v601-NS4BT66A, H-v601-Per1 and H-v601-Per2, were 
previously established by Dr Rosmani Ismail (as described in (Ismail, 2015)), as detailed in 
Section 1.7.1. These cells were maintained similarly to HEK293T cells, as detailed in Section 
2.1.1, in the biological safety level 3 (BSL3) laboratory.  
2.1.4. Infection of HEK293T cells with DENV-2 virus. 
HEK293T cells were infected with DENV-2 New Guinea C strain (NGC), produced from the 
DENV-2 infectious clone, pDVWS601 (Gualano et al., 1998; Pryor et al., 2001). The stock 
virus titre was 3.7 x 107 plaque-forming units (PFU)/ml, and cells were infected at a multiplicity 
of infection (MOI) > 5.  
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1.5 x 105 HEK293T cells in cell culture media as described in Section 2.1.1 were seeded into 
24 well plates and incubated at 37 °C for 24 hours (h). Media was removed and each cell 
monolayer was washed twice with PBS. 0.2 ml of virus stock in culture supernatant was added 
to each well, and plates were incubated for 1.5 h at 37 °C, and gently rocked every 15 min. 
Virus-containing supernatant was removed, 1 ml of Eagle’s minimum essential media (EMEM; 
(Lonza) supplemented with 10% FBS and non-essential amino acids) was added to each cell, 
and plates were incubated for at least 24 h before cells were used for further experiments.  
2.1.5. Cryopreservation and restoration of cell stocks.  
Cells were grown to ~80% confluency, to ensure healthy cells were cryopreserved, before 
being detached with trypsin and resuspended in DMEM media. The cells were centrifuged at 
150 x g for 5 minutes, and the supernatant removed. The cell pellet was resuspended in 
freezing medium (70% FBS, 20% DMEM containing 10% FBS, 10% dimethyl sulfoxide 
(DMSO; Sigma-Aldrich)). 3-5 x 106 cells/ml were transferred in 1 ml aliquots into cryotubes in 
a homogenous cell suspension. The cryotubes were kept in an isopropanol chamber and 
stored at -70 °C overnight before being transferred to liquid nitrogen and stored in the gas 
phase above the liquid.  
To thaw cells, cryotubes were placed in a 37 °C water bath to thaw the cells rapidly. The cell 
suspensions were transferred to DMEM media, centrifuged at 150 x g for 7 min and the 
supernatant containing DMSO was removed. The cell pellet was resuspended in DMEM media 
and transferred into an appropriate culture vessel which was then incubated at 37 °C.  
2.1.6. Long-term treatment of virus-infected cells with drugs. 
Cells persistently-infected with virus or containing replicons were treated with drugs to cure 
the cells of virus/replicons in order to analyse various cellular pathways and characteristics.  
Drugs used were: 4-hydroxyphenylretinamide (4-HPR; Enzo, UK), mycophenolic acid (MPA; 
SantaCruz Biotechnology), 2’-C-methylcytidine (2CMC; Sigma-Aldrich), and ribavirin (RBV; 
Sigma-Aldrich). 5 mg 4-HPR was dissolved in 1.28 ml DMSO to make a working stock of 10 
mM. 100 mg MPA was dissolved in 2 ml DMSO to make a stock of 50 mg/ml. 10 mg RBV was 
dissolved in 818 μl DMSO to make a 50 mM working stock. A 20 mM working stock of 2CMC 
was made by dissolving 5 mg of 2CMC in 970 μl nuclease-free water.  
HEK293T, H-v601-Per1 or H-v601-Per2 cells were seeded into T25 flasks and incubated for 
24 h until approximately 10-20% confluent. Media was removed and replaced with media 
containing appropriate concentrations of drug. Any cells that reached 80-100% confluency 
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were passaged as detailed in Section 2.1.1, and the drug was replaced at the appropriate 
concentration.  
2.1.7. Cell viability assay.  
96 well plates were seeded with 3 x 104 cells per well and incubated for 16 h. Media was 
replaced with DMEM media containing appropriate concentrations of drugs to be tested. 2 
days and 4 days post-drug addition, the Vybrant® MTT Cell Proliferation Assay Kit 
(ThermoFisher Scientific, USA) was used according to the manufacturer’s instructions to 
determine cell proliferation and viability in the presence or absence of drugs. Cell culture 
media was removed and replaced with 110 μl of 1.2 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenultetrazolium bromide) (MTT) in phenol red-free FluoroBrite™ DMEM media 
(Invitrogen, ThermoFisher) supplemented with 10% FBS, non-essential amino acids, and 2 
mM L-glutamine (Invitrogen, ThermoFisher). Plates were incubated at 37 °C for 4 h. 1 g SDS 
was dissolved in 10 ml of 0.01 M hydrochloric acid (HCl), and 100 μl of the SDS-HCl mixture 
was added to each well and mixed thoroughly. The plates were incubated at 37 °C for 4 h. 
Plates were read using a spectrophotometer (SpectraMax 190 Microplate Reader) at 570 nm.  
 
2.2. DNA/RNA analysis. 
2.2.1. Intracellular RNA isolation by TRIzol™ or RiboZol™. 
Cells to be used for intracellular RNA isolation were grown to 80% confluency in a T75 flask. 
Media was removed and 1 ml TRIzol™ Reagent (Invitrogen, ThermoFisher) or RiboZol™ RNA 
extraction reagent (AMRESCO) was added per flask and pipetted up and down several times 
to lyse cells and homogenise. Each cell lysate was incubated for 5 min, before 0.2 ml of 
chloroform (Fisher Chemical, USA) was added. Samples were incubated for 3 min and 
centrifuged for 15 min at 12,000 x g at 4 °C. The upper aqueous phase containing RNA was 
carefully transferred to a new microfuge tube such that no interphase or organic layer was 
also transferred. To precipitate the RNA, 0.5 ml of isopropanol (Sigma-Aldrich) was added to 
the aqueous phase. Samples were incubated for 10 min, centrifuged for 10 min at 12,000 x g 
at 4 °C, and the supernatant removed. RNA samples were washed by re-suspending the pellet 
in 1 ml of 75% ethanol (Sigma-Aldrich) diluted in nuclease-free water (Invitrogen, 
ThermoFisher), mixed by vortexing, and centrifuged for 5 min at 7500 x g at 4 °C. Supernatant 
was discarded, and the RNA pellet air-dried for 10 min. To solubilise the RNA, the pellet was 
resuspended in 30 μl of nuclease-free water and incubated at 60 °C for 10 min. Final RNA 
samples were stored at -70 °C before use in further downstream applications.  
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2.2.2. Intracellular RNA isolation. 
This method was used when inclusion of a DNase I incubation step was desired.  
To prepare cells for intracellular RNA isolation, cells were detached using trypsin, 
resuspended in DMEM media, and counted using a disposable haemocytometer (Kova 
International, USA). 2 x 106 cells were collected, suspended in a total volume of 10 ml DMEM 
media, and centrifuged at 300 x g for 5 min after which the supernatant was removed. The cell 
pellet was resuspended in 25 ml PBS, centrifuged at 300 x g for 5 min, and the supernatant 
was removed again.  
RNA extraction was performed using an SV Total RNA Isolation Kit (Promega, USA) according 
to the manufacturer’s instructions for the spin protocol, and once completed the RNA samples 
were stored at -70 °C before further processing.   
2.2.3. Extracellular RNA isolation.  
140 μl cell culture supernatant was sampled from cell cultures and used for extracellular RNA 
extraction using the QIAamp Viral RNA Mini Kit (Qiagen, Germany) following the 
manufacturer’s instructions for the spin protocol. Samples were stored at -70 °C until required 
for further use.   
2.2.4. Determination of nucleic acid concentration. 
Nucleic acids were analysed by spectrophotometry using a Nanodrop ND-1000 
Spectrophotometer to determine the concentration (ng/μl) and ratios of absorbance values 
(260/230 and 260/280).  
2.2.5. One-step reverse-transcription polymerase chain reaction (RT-PCR).  
RNA samples were converted to RT-PCR products using a One Taq One-Step RT-PCR Kit 
(New England Biolabs, USA). 25 μl RT-PCR reaction mix, 2 μl 10 pmol/μl forward primer, 2 μl 
10 pmol/μl reverse primer, and 2 μl reverse transcriptase enzyme mix were mixed into a 
mastermix.  Primers used for specific detection of viral RNA are shown in Table 2.1, or total 
cellular RNA was detected using a random hexamer primer (ThermoFisher Scientific). A 
volume containing an appropriate concentration of RNA was added, and the mix was adjusted 
to 50 μl with nuclease-free water. A GS1 thermocycler machine (G-Storm, UK) was used, and 
set to program 1 ( 
Table 2.2) to generate RT-PCR products with lengths of < 1 kb, or program 2 for RT-PCR 
products with lengths of > 1 kb.  
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2.2.6. Two-step RT-PCR. 
For the reverse-transcription step of the two-step RT-PCR reaction, a volume containing 200 
ng of the RNA sample was mixed with 1 μl 10 pmol/μl primer and made up to a total of 10 μl 
with nuclease-free water. The RNA-primer mixture was heated to 70 °C for 5 min, and then 
immediately chilled on ice. A mastermix containing 1.6 μl nuclease-free water, 4 μl ImProm-
II™ 5X reaction buffer (Promega), 2.4 μl 25 mM MgCl2 to a final concentration of 3 mM 
(Promega), 1 μl 10 mM deoxynucleotide (dNTP) mix for a final concentration of 0.5 mM 
(Promega), and 1 μl ImProm-II™ reverse transcriptase (Promega), per sample, was created 
and added to the RNA-primer mixture. Program 3 ( 
Table 2.2) was used for the first step of this reaction to generate RT-PCR products. Primers 
used for specific detection of viral RNA are shown in Table 2.1, or total cellular RNA was 
detected using a random hexamer primer (ThermoFisher Scientific).  
For the PCR step, a mastermix was created containing 14.35 μl nuclease-free water, 2.5 μl 
10X Maxima Hot Start Taq buffer (ThermoFisher Scientific), 2.5 μl 2 mM dNTP mix, 1.25 μl 10 
pmol/μl forward primer, 1.25 μl 10 pmol/μl reverse primer, 2 μl 25 mM MgCl2, and 0.15 μl Taq 
DNA polymerase (ThermoFisher Scientific), per reaction. 1 μl template RT-PCR product was 
added to 24 μl mastermix for a 25 μl reaction, and Program 4 ( 
Table 2.2) was used to amplify the RT-PCR product.  
Table 2.1: DENV-specific primers. Names and sequences of DENV-2-specific primers used for either 
RT-PCR or viral genome sequencing during this project. 
 



























* “r” indicates a reverse primer. 
 
 
Table 2.2: RT-PCR settings. RT-PCR cycle settings showing the time spent at that temperature, and 
for how many cycles. 




< 1 kb) 
48 °C 15 min 1 
94 °C 1 min 1 
94 °C 15 sec 
40 55 °C 30 sec 
68 °C 30 sec 
68 °C 5 min 1 




> 1 kb) 
48 °C 30 min 1 
94 °C 1 min 1 
94 °C 15 sec 40 
 55 °C 30 sec 































68 °C 4 min 
68 °C 5 min 1 




25 °C 5 min 1 
42 °C 1 h 1 
70 °C 15 min 1 




95 °C 10 min 1 
95 °C 15 sec 
30-40 
60 °C 60 sec 
4 °C Stored infinitely 
 
2.2.7. Agarose gel electrophoresis.  
Gels consisted of 1% agarose (Bioline, USA) in 1X TBE buffer (89 mM Tris base, 89 mM boric 
acid, 2 mM ethylenediaminetetraacetic acid (EDTA)) and 0.5 μg/ml ethidium bromide (Sigma-
Aldrich). GeneRuler 1 kb Plus DNA Ladder (ThermoFisher Scientific) was used to allow 
estimation of the size and concentration of the products. 5 μl RT-PCR product was mixed with 
1 μl 6X DNA Loading Dye (ThermoFisher Scientific, USA), and the gels were run at 100 V for 
approximately 1 h. The gel bands were then visualised, and photos were recorded using a 
UVP Biodoc-It™ Imaging System (Analytik Jena, Germany).   
For analysis of smaller RT-PCR products, 4% agarose in 1X TBE buffer and 0.5 μg/ml 
ethidium bromide gels were used, and an O’RangeRuler 20 bp low molecular weight DNA 
ladder (ThermoFisher Scientific) was used to estimate the product size and concentration. 10 
μl of RT-PCR product samples were combined with 2 μl 6X DNA Loading Dye (ThermoFisher 
Scientific), gels were run at 100 V for approximately 1 h, and visualised using the UVP Biodoc-
It™ Imaging System.  
2.2.8. Purification of PCR products.  
For the purification of RT-PCR products, the GeneJET PCR Purification Kit (ThermoFisher 
Scientific) was used and the protocol was performed according to the manufacturer’s 
instructions. Samples were stored at -20 °C.  
2.2.9. DNA sequencing and analysis.  
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Samples were sent with an accompanying primer (Table 2.1) to Eurofins Genomics (Germany) 
for sequencing. Sequencing alignments were performed using the Nucleotide Basic Local 
Alignment Search Tool (BLASTn) online resource.  
2.2.10. Quantitative real-time PCR (qPCR). 
200 ng of each RNA sample was converted to a cDNA in a reverse transcription reaction as 
per Section 2.2.6 using a random hexamer primer (Promega). Each cDNA sample was either 
retained at 10 ng/μl or diluted with nuclease-free water to a final concentration of 5 ng/μl.  
Validation of gene-specific qPCR primers (Table 2.3) was performed using PCR (Section 
2.2.6) on cDNA samples and agarose gel electrophoresis (Section 2.2.7).  
qPCR mastermixes were created for primer sets listed in Table 2.3, containing 4 μl nuclease-
free water, 6.25 μl Maxima SYBR Green qPCR Master Mix (2X) containing ROX 
(ThermoFisher Scientific), and 1.25 μl primer, per well. For DENV-specific primers listed in 
Table 2.4, the mastermixes contained 4.5 μl nuclease-free water, 6.25 μl Maxima SYBR Green 
qPCR Master Mix (2X) containing ROX, 0.375 μl forward primer and 0.375 μl reverse primer, 
per well. 11.5 μl of this mastermix was added to each well, and 1 μl of template RT-PCR 
product was added per well.  
For generation of standard curves to determine primer efficiency, cDNA samples were serially 
diluted 1:10, with a starting concentration of either 10 ng/μl or 5 ng/μl, to generate 4 template 
concentrations, and were added to wells containing mastermix in triplicate. For experimental 
qPCR reactions, a template cDNA sample was added to wells in either duplicate or triplicate. 
No template controls (NTC) were included with each run for all primers being tested. A 
Stratagene Mx3000P qPCR machine was used with the thermal profile cycle shown in Table 
2.5.  
2.2.11. Double-delta Ct (ΔΔCt) analysis.  
Relative fold change in gene expression between cell types was expressed using the double-
delta Ct (ΔΔCt) analysis. The ΔΔCt value was calculated for each gene in each cell type, as 
detailed in (Livak and Schmittgen, 2001), using Microsoft Excel. Gene expression values 
obtained from control HEK293T cells were used as calibrators. Expression of target genes in 





Table 2.3: Gene-specific primers used for qPCR. 
 
Table 2.4: DENV-specific primers used for qPCR and their sequences. 
 





Gene Source Catalogue no. Amplicon length (bp) 
ACTB Qiagen QT01680476 146 
GAPDH Qiagen QT00079247 95 
HMGCS1 Qiagen QT00055531 123 
HMGCR Qiagen QT00004081 87 
IDI1 Qiagen QT00030912 133 
INSIG1 Qiagen QT00090314 81 
MSMO1 Qiagen QT00017871 97 
 
Primer DENV-2 target  Primer sequence (5’ à  3’) 
C14A C gene AATATGCTGAAACGCGAGAGAAACCGCG 
DV2-C69Br C gene CCCATCTCTTCAGTATCCCTGCTGTTGG 
DV_3’UTR_f 3’ UTR TTAGAGGAGACCCCTCCC 
DV_3’UTR_r 3’ UTR  TCTCCTCTAACCTCTAGTCC 
 
Temperature Time Number of cycles 
95 °C 10 min 1 
95 °C 15 sec 
40 
60 °C 1 min 
95 °C 30 sec 1 
55 °C 30 sec 1 




2.3. Cell imaging. 
2.3.1. Immunofluorescence assays (IFA).  
Coverslips were incubated in 0.1 mg/ml poly-D-lysine (Sigma-Aldrich) for 5 min, before being 
washed twice with PBS. Cells were detached using trypsin and resuspended in DMEM media, 
before centrifuging at 150 x g for 8 min and resuspension in DMEM media. Cells were seeded 
at an appropriate density onto coverslips in 24 well trays and the culture volume adjusted to 1 
ml with DMEM media, followed by incubation at 37 °C for 24 h.  
If required for the experiment, cells were first treated with interferon-α (IFN-α; Sigma-Aldrich) 
as detailed in Section 2.3.2 prior to fixation.  
Cells were fixed by treatment with 4% (w/v) paraformaldehyde (PFA) for 5 min at room 
temperature, before washing with PBS 3 times and then permeabilised with 1% (v/v) Triton-
X-100 (Sigma-Aldrich) before washing with PBS 3 times. Alternatively, cells were fixed and 
simultaneously permeabilised with methanol for 5 min at -20 °C. Coverslips were then 
transferred to 6-well trays and blocked using 10% FBS in PBS for at least 1 h at room 
temperature while shaking.  
Coverslips were stained with 100 μl of 1% FBS in PBS containing an appropriate dilution of 
the primary antibody (for a summary of antibodies used in this project, please see Table 2.6) 
for 1 h, before washing with PBS 4 times for 5 min per wash. Coverslips were then drained 
and covered with 100 μl 1% FBS in PBS containing an appropriate dilution of secondary 
antibody for 1 h, before washing 4 times with PBS for 5 min each time.  
After antibody binding, the coverslips were mounted onto microscope slides with VectaShield 
mounting medium (Vector Laboratories, Inc., USA) containing DAPI for fluorescent nuclear 
staining. The edges of the coverslips were sealed with nail polish, and they were stored in a 
box to block out light at 4 °C until ready for imaging under a fluorescent microscope (Section 
2.3.4).  
2.3.2. IFN treatment.  
Prior to cell fixation, cells were treated with 500 μl DMEM media containing IFNα at a 
concentration of 1000 U per ml. IFNα-treated cells (IFNα+) were incubated at 37 °C for 1 h. 
IFNα-containing media was removed, and cells were washed twice with PBS before the 




Table 2.6: Summary of the antibodies used during this project for IFA. Primary and secondary 
antibodies used for IFA in this project, their targets, type of antibody, antibody dilution, and their source 
and catalogue number. 
 
2.3.3. Cholesterol staining with Filipin III. 
Coverslips were treated with poly-D-lysine as detailed in Section 2.3.1. Cells were prepared 
as detailed previously, and approximately 7 x 104 cells were seeded onto coverslips in a 24 
well plate, and made up to 1 ml volume with DMEM media. Cells were incubated at 37 °C for 
48 h. After 24 h, the cells could be infected with DENV-2 if necessary for the experiment, as 
detailed in Section 2.1.4.   
After incubation, media from the cells was removed and cells were washed once with PBS. 
Cells were then fixed with 4% (w/v) PFA for 10 min, quenched with 50 mM ammonium chloride 




type Dilution Source Catalogue no. 





pSTAT1 Rabbit mAb 1:100 
Cell Signalling 
Technologies  7649 










DENV-2 E protein Mouse mAb 1:500 
Absolute 
Antibody (UK) Ab0023-2.0 







Secondary antibodies Dilution Source Catalogue no. 
Alexa Fluor® 568 goat anti-mouse IgG (H+L) 1:1000 Invitrogen A11004 







each step. Cells were transferred to 6 well plates and blocked in 10% FBS in PBS for 1 h at 
room temperature while shaking.  
Cells were then covered with 100 μl diluted primary antibody for 1 h, and washed with PBS 4 
times for 5 min per wash. Cells were then treated with 100 μl of diluted Alexa Fluor® 568 
secondary antibody for 1 h, and washed twice with PBS for 5 min per wash.  
Nuclei were stained with TO-PRO-3 nuclear stain (ThermoFisher Scientific). Cells were 
covered with 100 μl of TO-PRO-3 at a 1:1000 dilution in PBS for 15-20 min, protected from 
light, and then washed twice with PBS for 5 min per wash.  
Intracellular cholesterol was stained using filipin III (Sigma-Aldrich). 1 mg filipin III was 
dissolved in 200 μl DMSO to make a 5 mg/ml stock, which was further diluted in PBS to make 
a working stock of 100 μg/ml. Cells were covered with 100 μl of 100 μg/ml filipin III for 25 min, 
protected from light, before washing with PBS 3 times for 5 min per wash. Coverslips were 
mounted onto microscope slides using Vectashield without DAPI.  
An SP5-II tandem scanner confocal with ‘hybrid’ GaAsP detectors was used for imaging to 
reduce photobleaching of filipin III. Filipin III exhibits fluorescence at a UV excitation of 360 
nm and emission of 480 nm (Maxfield and Wüstner, 2012), and TO-PRO-3 exhibits far-red 
fluorescence with excitation at 642 nm and emission at 661 nm.   
2.3.4. Fluorescence imaging.  
Samples were imaged at the Wolfson Bioimaging Facility, University of Bristol. The widefield 
microscope used was a Leica DMI6000 inverted epifluorescence microscope fitted with a 
Leica DFC365FX monochrome CCD camera. Confocal microscopes used were a Leica SP5-
AOBS confocal laser scanning microscope attached to a Leica DMI6000 inverted 
epifluorescence microscope, and a ‘hybrid’ SP5-II tandem scanner confocal with GaAsP 
detectors that boost low signal and therefore reduces photobleaching.  
2.3.5. Image analysis.  
Images were captured using LAS X software (Leica Microsystems, UK) and post-processing 
was carried out on LAS X, FIJI-Image J (FIJI, USA), and Serif PhotoPlus X6 (Serif, UK).  
Quantitation of fluorescence was performed using CellProfiler software (CellProfiler, USA) and 
a program assembled by Dr Dominic Alibhai at the Wolfson Bioimaging Facility. The program 
identified fluorescence in the nuclei and fluorescence in the cytoplasm of cells imaged on the 
confocal microscope and quantified fluorescence. It then calculated the ratio of nuclear 
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fluorescence to cytoplasmic fluorescence to determine localisation of the target protein in the 
cells.  
 
2.4. Statistical analysis.  
One-way or two-way analysis of variance (ANOVA) tests and Tukey’s multiple comparisons 
post-hoc tests were carried out using GraphPad Prism version 7 software.  
 
2.5. Transcriptomics analysis.  
RNAseq analysis was previously carried out by Dr Andrew Davidson, University of Bristol, on 
six cell lines: HEK293T (Mock), H-Rep, H-Rep-4BT66A, H-v601-Per1, H-v601-Per2, and DENV-
2 virus-infected cells (H-v601). In short, total intracellular RNA was isolated from the cells 
which was analysed at the Beijing Genomics Institute (BGI) using an Illumina HiSeq 2000 
sequencer. High-quality reads were filtered out, and Tophat and Cufflinks software suite tools 
in the Galaxy Platform (https://usegalaxy.org/) (Trapnell et al., 2012) were used for differential 
gene expression analysis. The reads were aligned to the human genome (Human (Homo 
sapiens) (B38):hg38) using Tophat2, assembled and merged using Cufflinks and Cuffmerge. 
Cuffdiff (in the Cufflinks suite of software) generated an output file that contained pairwise 
comparisons from each of the six datasets and identified significant differences in levels of 
gene expression in each pairwise comparison. More details can be found in (Ismail, 2015).  
This data was then analysed as part of this project using the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) version 10.0 to identify gene/protein interaction 
networks, and the Database for Annotation, Visualisation and Integrated Discovery (DAVID) 







Chapter 3. Characterisation and transcriptomic analysis of cell lines  
Following identification of the NS4BT66A mutation, Dr Rosmani Ismail performed experiments 
to investigate whether the mutation altered any properties of the NS4B protein that potentially 
allowed establishment of persistent infection. NS4B is a hydrophobic membrane protein which 
often presents challenges when utilising techniques to allow protein expression, purification, 
and characterisation. As such, several techniques were used to express and study the NS4B 
protein, including transient gene expression followed by cellular localisation (by IFA) and ISG 
expression antagonism assays. However the NS4BT66A mutation did not affect the localisation 
of NS4B, nor its ability to antagonise JAK/STAT signalling using the assays employed (Ismail, 
2015). Flp-In™T-Rex™ 293 (Flp) cell lines expressing either the NS4B or NS4BT66A proteins 
were also generated and used for high-throughput mass spectrometry (MS) based 
immunoprecipitation analysis to identify any altered interactions between NS4B and NS4BT66A 
amongst cellular proteins; however, this analysis did not yield conclusive results. Results from 
these studies suggested that the T66A amino acid mutation potentially only operates in the 
context of the viral polyprotein, and that alterations in host pathways could also be involved in 
allowing persistent infection. Previously, high-throughput RNA sequencing (RNAseq) and 
comparative transcriptomic analysis of mock and DENV-infected cells and has been utilised 
to study changes to the host cell transcriptome that occur in response to viral infection and 
replication (Fink et al., 2007; Liew and Chow, 2006; Sessions et al., 2013; Ubol et al., 2008). 
In addition to utilising this technique for studying the effect of viral infection on the host cell 
transcriptome, we aimed to also study effects that are potentially altered between wild-type 
infection and persistent infection.  
3.1. Introduction to cell lines and transcriptomics data.  
A virus encoding the NS4B codon change T66A (v601-4BT66A) was generated by reverse 
genetics from the plasmid pDVWS601, containing a full length cDNA clone corresponding to 
the genome of the DENV-2 strain New Guinea C (Gualano et al., 1998; Pryor et al., 2001). 
HEK293T cells were infected with v601-4BT66A at an MOI of 2.0 in duplicate. Over 90% of the 
cells displayed clear cytopathic effect (CPE) and died, however the remaining cells continued 
to grow to confluency. The duplicate cell population were passaged further and were found to 
be 100% infected at passage 2 (P2) by IFA analysis. The two cell lines were thereafter 
persistently-infected with v601-4BT66A and were termed H-v601-Per1 and H-v601-Per2.  
Replicons are viral sub-genomes that contain the viral non-structural genes, but lack the 
structural genes; therefore, they are capable of viral replication but do not produce infectious 
virions and as such are relatively bio-safe and permissible for use in a lower containment level 
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laboratory. HEK293T cell lines expressing replicons were generated prior to the 
commencement of this project by Dr. Rosmani Ismail (Ismail, 2015). The replicon plasmid 
pRepDV-GP2A was engineered to contain a fusion gene encoding enhanced GFP which 
allows visualisation by immunofluorescence microscopy, and puromycin N-acetyltransferase 
which allows puromycin selection, in place of the viral structural genes (Massé et al., 2010). 
The replicon plasmid pRepDV-GP2A-NS4BT66A, was constructed from pRepDV-GP2A and is 
identical except that it contains nucleotide sequence changes encoding the NS4BT66A 
mutation. The pRepDV-GP2A and pRepDV-GP2A-NS4BT66A replicon plasmids were 
linearised and transcribed in vitro to produce replicon RNA transcripts, which were transfected 
into HEK293T cells. Replicon-containing cell lines were selected for by the addition of 3.5 
μg/ml puromycin to generate the H-Rep and H-Rep-4BT66A cell lines, respectively (Figure 3.1).  
 
 
Figure 3.1: Generation of replicon-containing cell lines. The replicon plasmid pRepDV-GP2A and 
pRepDV-GP2A-NS4BT66A are identical except for presence of the NS4BT66A mutation. These plasmids 
were linearised and transcribed in vitro to produce RNA transcripts which were transfected into 
HEK293T cells. 3.5 μg/ml was used to select for cells containing either replicon plasmid. Replicon 
expression was confirmed by RT-PCR and IFA.   
 
Prior to the commencement of this project, RNAseq analysis was performed by Dr. Andrew 
Davidson and Dr Rosmani Ismail. RNAseq is used for high-throughput transcriptomics 
analysis using deep-sequencing technologies to analyse the whole cell transcriptome (Wang 
et al., 2009b). Cell lines included in the analysis were as follows: uninfected control HEK293T 
cells, “Mock”; persistently-infected cells, “H-v601-Per1” and “H-v601-Per2”; cells infected for 
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24 h with wild-type DENV-2 v601 virus, “H-v601”; cells containing replicons encoding the wild-
type NS4B gene, “H-Rep”; cells expressing the replicons containing the NS4BT66A mutation, 
“H-Rep-4BT66A”. Pairwise comparisons between the transcriptome of each cell line provided 
differential fold changes in gene expression, which were then analysed using bioinformatic 
methods. This enabled identification of genes and pathways of interest that constituted targets 
for further investigation during this project.  
 
3.2. Characterisation of all cell lines.  
The identity of the cell lines and the stability of the NS4BT66A mutation in v601-4BT66A or 
pRepDV-GP2A-NS4BT66A during passaging were confirmed prior to use in further 
experiments. At several passage numbers, RT-PCR products spanning the NS4B genes of 
the RepDV-GP2A and RepDV-GP2A-NS4BT66A replicons were produced using RNA isolated 
from H-Rep and H-Rep-4BT66A cells, respectively, and sequenced to confirm the presence or 
absence of the NS4BT66A mutation and its stability. Replicon expression in the H-Rep and H-
Rep-4BT66A cell lines was further confirmed by detection of NS1 protein by IFA, as genes 
encoding the DENV structural proteins are absent in the replicon sequences. Similarly, RNA 
from H-v601-Per1 and H-v601-Per2 cells was isolated and the NS4B gene of the v601-4BT66A 
virus was amplified by RT-PCR and sequenced. The presence of a persistently-infecting virus 
in these cells was further confirmed by detection of the DENV E protein by IFA.  
 
3.2.1. Agarose gel electrophoresis on RT-PCR products from H-Rep and H-Rep-4BT66A 
cells.  
H-Rep and H-Rep-4BT66A cells (at passage 4) were cultured and intracellular RNA was 
extracted from cells at passage 9 (P9), 15 (P15), and 19 (P19). RT-PCR was performed to 
generate RT-PCR products corresponding to the NS4B gene with an expected size of 493 bp. 
Agarose gel electrophoresis was performed to confirm production of the NS4B gene RT-PCR 
products from each cell type. A typical result is shown in Figure 3.2. No NS4B RT-PCR product 
was produced using RNA extracted from the control HEK293T cells, while clear bands were 
displayed using RNA from the H-Rep and H-Rep-4BT66A cells for RT-PCR. The bands detected 




Figure 3.2: Confirmation of the DENV genome in H-Rep and H-Rep-4BT66A cells. Intracellular RNA 
was extracted from HEK293T, H-Rep, and H-Rep-4BT66A cells at passage 15 using the SV Total RNA 
Isolation Kit. RT-PCR using primers DV2_6823 and DV2_7295r generated RT-PCR products 
corresponding to the NS4B gene. RT-PCR products were purified using a GeneJet PCR Purification 
Kit, and agarose gel electrophoresis was performed on the purified products to detect the RT-PCR 
product (~500 bp) in each sample, and the product size estimated using a GeneRuler 1 kb Plus DNA 
Ladder. 
 
3.2.2. DNA sequencing of pRepDV-GP2A and pRepDV-GP2A-NS4BT66A NS4B genes.  
The presence and stability of the NS4BT66A mutation in the RepDV-GP2A-NS4BT66A replicon 
NS4B gene was confirmed by sequencing. RT-PCR products derived from RNA extracted 
from H-Rep and H-Rep-4BT66A cells at P9, P15, and P19 were sequenced by Eurofins 
Genomics using a modified version of Sanger sequencing. Table 3.1 shows a summary of all 
mutations compared to the wild-type DENV-2 genome sequence.  
The NS4B gene in RepDV-GP2A had not mutated from the wild-type DENV-2 genome in P9 
or 15 samples, however in the P19 sample there was a nonsynonymous mutation at nucleotide 
7279 (G à A) which conferred an amino acid change of Val to Met at position 152 in the NS4B 
gene (V152M); this mutation had a mixed peak of occurrence in a 1:1 ratio, suggesting it was 
potentially a heterologous population for this mutation. The nucleotide 7020/7021 (AA à GG) 
mutation was retained in all H-Rep-4BT66A samples at P9, P15, and P19, conferring an amino 
acid change of Thr to Ala at position 66 in the NS4B gene (T66A). In addition to the expected 
NS4BT66A mutations, a nonsynonymous mutation at nucleotide 6905 (T à C) conferred an 
amino acid change of Ile to Thr at position 27 in the NS4B gene (I27T). This mutation was 
present in all H-Rep-4BT66A samples and in each, displayed a mixed peak of occurrence 
suggesting a heterologous population for this mutation. Another mutation at nucleotide 7099 
(C à T) encoding a Pro to Ser amino acid change at position 92 in the NS4B gene (P92S) 
was found in H-Rep-4BT66A samples from P9 and P15, however these mutations showed mixed 
peaks of occurrences, and the mutation was lost in the P19 sample, suggesting this was an 
unstable transient mutation in the population.  
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Table 3.1: Mutations in the NS4B genes of the RepDV-GP2A and RepDV-GP2A-NS4BT66A replicons. RNA was extracted from H-Rep and H-Rep-4BT66A 
cells at passage 9, 15, and 19 and RT-PCR products spanning the NS4B gene from RepDV-GP2A and RepDV-GP2A-NS4BT66A replicons, respectively 
generated. The RT-PCR products were sequenced by Sanger sequencing, and BLASTn alignment tools identified mutations in the NS4B gene that differed 
from the wild-type DENV-2 genome sequence (NCBI gene accession number: AF038403.1). 
Passage 
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3.2.3. Agarose gel electrophoresis on RT-PCR products from H-v601-Per1 and H-
v601-Per2 cells.  
H-v601-Per1 and H-v601-Per2 cells were cultured (from passage 4) and analysed for the 
presence of persistently-infecting virus. Extracellular RNA was extracted from cells at passage 
8 (P8) and intracellular RNA was extracted from cells at P10. RT-PCR generated products 
corresponding to the size of the DENV NS4B gene. Agarose gel electrophoresis showed that 
the NS4B gene RT-PCR product was produced using RNA isolated from both H-v601-Per1 
and H-v601-Per2 intracellular and extracellular samples, but absent using RNA isolated from 
control HEK293T cell samples (Figure 3.3). The PCR product was approximately 500 bp in 
length, as expected. 
 
Figure 3.3:  Confirmation of the DENV genome in H-v601-Per1 and H-v601-Per2 cells. H-v601-
Per1 and H-v601-Per2 cells were cultured, extracellular RNA was extracted from P8 cells, and 
intracellular RNA was extracted from P10 cells. RT-PCR was performed on the RNA using the DENV 
NS4B gene-specific primers, DV2_6823 and DV2_7295r, to generate an RT-PCR product 
corresponding to the NS4B gene.  Agarose gel electrophoresis was performed to detect the RT-PCR 
product (~500 bp) in each sample, and the product size estimated using a GeneRuler 1 kb Plus DNA 
Ladder. 
 
3.2.4. Sequencing the v601-4BT66A virus from H-v601-Per1 and H-v601-Per2 cells.  
The NS4B gene of persistently-infecting virus were amplified from extracellular and 
intracellular RNA from H-v601-Per1 and H-v601-Per2 cells by RT-PCR and sequenced to 
confirm the presence of the NS4BT66A mutation. All mutations discovered in the NS4B gene of 
these samples when aligned to the wild-type DENV-2 NS4B gene sequence are summarised 
in Table 3.2.  
The same mutations were discovered in both H-v601-Per1 and H-v601-Per2 cells from both 
the extracellular and intracellular RNA. In both H-v601-Per1 and H-v601-Per2 cells, the 
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expected NS4BT66A mutation was retained. However, there was a mixed peak in occurrence 
of the A à G nucleotide change at position 7021 in H-v601-Per1 extracellular samples and H-
v601-Per1 and H-v601-Per2 intracellular RNA samples, with a minor population of virus 
containing “A” suggesting a partial reversion of the mutation in a minority of the population. In 
addition, there was a non-silent mutation at nucleotide 6915 (A à G) that conferred an amino 
acid change from Ile à Met at position 30 in the NS4B gene (I30Met). This mutation often had 
a mixed peak of occurrence between G and A nucleotides, and thus is potentially not stable 
in the whole population.  
 
3.2.5. IFA to confirm replicon presence in H-Rep and H-Rep-4BT66A cells. 
The DENV NS1 protein was detected by IFA to confirm the presence of the RepDV-GP2A and 
RepDV-GP2A-NS4BT66A replicons in the H-Rep and H-Rep-4BT66A cells, respectively (Figure 
3.4). Red fluorescence indicates the presence of NS1 in both the H-Rep and H-Rep-4BT66A 
cells, which is absent in the control HEK293T cells. Further confirmation was provided by the 
examination of GFP fluorescence as both replicons contain a gene encoding GFP in place of 
the structural genes. GFP fluorescence was detected in both H-Rep and H-Rep-4BT66A cells, 
and not in the control cells.  
 
3.2.6. IFA to detect DENV E protein in H-v601-Per1 and H-v601-Per2 cells.  
The presence of persistently-infecting virus in the H-v601-Per1 and H-v601-Per2 cells was 
further confirmed by detection of the structural DENV E protein by IFA (Figure 3.5). The DENV 
E protein was only present in the H-v601-Per1 and H-v601-Per2 samples and was absent in 




Table 3.2: Mutations in the NS4B gene of the virus isolated from cultures of H-v601-Per1 and H-v601-Per2 cells. Extracellular and intracellular RNA was 
extracted from samples of H-v601-Per1 and H-v601-Per2 cell samples at P8 and P10, respectively. RT-PCR generated RT-PCR products corresponding to the 
































Per1  6915 ATA ATG/A 30 I Met 
 
H-v601-
Per1  7020 & 7021 CTA ACA CTG G/ACA 65 & 66 L T L A 
 
H-v601-














Per1  6915 ATA ATG/A 30 I Met 
 
H-v601-
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H-v601-
Per2  6915 ATA ATG 30 I Met 
 
H-v601-





Figure 3.4: Detection of DENV NS1 in H-Rep and H-Rep-4BT66A cells. HEK293T, H-Rep and H-Rep-
4BT66A cells were grown on coverslips. 24 h post-seeding, the cells were fixed with 4% 
paraformaldehyde, permeabilised with 1% Triton-X-100, and blocked with 10% FBS in PBS. Coverslips 
were then treated with a 1:200 dilution of mouse anti-NS1 primary antibody, and 1:1000 dilution of goat 
anti-mouse IgG secondary antibody conjugated with a 568 Alexa Fluor® (red) to detect the presence 
of DENV-2 NS1 protein expression, before mounting using VectaShield with DAPI to stain the nuclei 
(blue). Replicons contain a GFP-expressing gene (green). Fluorescence was detected using a widefield 
microscope (Leica DMI6000 inverted epifluorescence microscope fitted with a Leica DFC365FX 






Figure 3.5: IFA detection of DENV E protein in H-v601-Per1 and H-v601-Per2 cells. H-v601-Per1 
and H-v601-Per2 cells were seeded on to coverslips and after 24 h, were fixed with 4% 
paraformaldehyde and permeabilised in 1% Triton-X-100. The samples were blocked in 10% FBS in 
PBS, then stained with primary mouse anti-DENV E antibody at a 1:500 dilution, followed by anti-mouse 
secondary antibody conjugated with a 568 Alexa Fluor® (red) at a 1:1000 dilution. Cover slips were 
mounted using VectaShield with DAPI to stain the nuclei (blue), and imaged on a widefield microscope 
(Leica DMI6000 inverted epifluorescence microscope fitted with a Leica DFC365FX monochrome CCD 
camera) with a 40x objective. 
 
 
3.2.7. Quantification of DENV RNA expression in each sample by qPCR.  
To quantify the levels of DENV-2 viral RNA present in each of the sample sets, two DENV-
specific primer sets were tested, corresponding to the DENV-2 3¢UTR and capsid (C) gene. 
The expected product size of the 3¢UTR primer set was 97 bp, and of the C gene primer set 
was 169 bp. Both of these observed bands displayed the expected approximate product sizes, 





Figure 3.6: Agarose gel electrophoresis to confirm target gene-specific binding of qPCR primer 
sets. Total intracellular RNA from HEK293T and H-v601-Per1 cells was extracted and converted to RT-
PCR product by reverse transcription. PCR was performed using each primer set on H-v601-Per1 RT-
PCR product to test DENV-specific primers. 5 μl RT-PCR product and 1 μl 6 X loading dye was loaded 
in to each well of a 1% agarose gel and run at 100 V for approximately 1 h. O’RangeRuler 20 bp DNA 
ladder was used to estimate product sizes. 
 
 
Primers specific for the DENV 3¢UTR were used for qRT-PCR because, despite generating a 
weaker band than the C-specific primers, they could be used for detection of both v601-4BT66A 
virus and the RepDV-GP2A and RepDV-GP2A-NS4BT66A replicons which do not contain the 
full sequence of the C gene. HEK293T cells were infected with v601 for 24 h at an MOI of > 
5, to generate H-v601 cells, which were used as a calibrator when calculating the relative 
expression of DENV viral RNA in all other cell lines. In other words, viral RNA expression in 
H-v601 cells was set at 1, and relative expression of viral RNA in all other cell lines was 
calculated relative to this.  
H-v601-Per1 and H-v601-Per2 had significantly less viral RNA present than the H-v601 cells 
(p < 0.0001 for both), with H-v601-Per2 expressing more than H-v601-Per1 (Figure 3.7). Both 
persistently-infected cell lines were expressing greater levels of viral RNA than both replicon-
containing cells; H-v601-Per2 was significantly greater than H-Rep and H-Rep-4BT66A (p = 
0.019 and 0.047, respectively). There were no detectable levels of viral RNA in the control 





Figure 3.7: Quantification of DENV RNA in each cell line by qPCR. Cell lines at passage 6 (P6) 
were seeded and incubated for 48 h; HEK293T cells were seeded, after 24 h were infected with v601 
virus at an MOI of > 5, and incubated at 37 °C for 24 h. Total intracellular RNA was extracted from all 
cell lines at the same time, and 200 ng RNA was converted to RT-PCR product by reverse transcription. 
This was repeated for cells at passage 8 (P8). The DENV-2 3’UTR primer was used for the qPCR 
reaction; each sample set was analysed 3 times by qPCR, and each sample was analysed in triplicate 
on each plate and results were combined. GAPDH was used as a reference gene for all reactions. 
Relative gene expression fold change was determined using the double-delta Ct (ΔΔCt) method with 
gene expression in H-v601 cells used as the calibrator; error bars show standard deviation. * = p > 0.05; 




3.3. Bioinformatic analysis of RNAseq transcriptomics data.  
RNAseq was performed prior to the commencement of this project in order to analyse the 
transcriptome of the different cell lines with the aim of studying differences in specific gene or 
pathway expression between different cell lines. Cell lines analysed by RNAseq were: 
HEK293T (Mock), H-v601-Per1, H-v601-Per2, H-Rep, H-Rep-4BT66A, and wild-type DENV-2-
infected HEK293T cells (H-v601). Persistently-infected cells and replicon-containing cells 
were generated at the same time using the same parental HEK293T cells. RNAseq analysis 
was performed when cells were at P4 following several passages performed for initial 
propagation.  
In short, cells were seeded into T25 flasks and grown under identical conditions in duplicate 
until ready for harvest at 60% confluency. Total intracellular RNA was isolated using the TRIzol 
method, and equal amounts of RNA samples were sent to the Beijing Genomics Institute (BGI) 
for RNAseq analysis using an Illumina HiSeq 2000 sequencer. Differential gene expression 
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analyses was performed on the RNAseq data using the Tophat and Cufflinks software tools 
in the Galaxy Platform (https://usegalaxy.org/) (Trapnell et al., 2012). The reads were first 
aligned to the human genome (Human (Homo sapiens) (B38): hg38) using Tophat2, then the 
transcripts were assembled and merged using Cufflinks and Cuffmerge. Cuffdiff was then 
used to detect differentially expressed genes and transcripts in each pairwise comparison 
between datasets for each of the 6 samples corresponding to each cell line analysed. A 
summary of this process is provided in Figure 3.8.  The resulting data file provided values that 
corresponded to the levels of expression for each gene in each of the different cell lines, and 
pairwise comparisons of these values between cell lines gave Log2 fold change values in gene 
expression and highlighted significant differences in gene expression between each cell line. 
Analysis of this transcriptomics data was carried out as part of this project to direct further 
experiments. 
In total, 27893 genes were identified. Of these, 726 genes were significantly differentially 
regulated, while 3862 genes were upregulated or downregulated by at least two-fold in at least 
one of the pairwise comparisons. The genes that were differentially expressed significantly 
and by at least two-fold in pairwise comparisons of interest, i.e. between Mock and all other 
samples, and between samples infected with virus/expressing replicons that either possess 
or do not possess the NS4BT66A mutation, were identified. These gene sets were then analysed 
by DAVID to identify clusters of genes with related functions that may be enriched in the 
datasets (Table 3.3).  
Host immunity pathways were upregulated during persistent infection relative to mock and 
wild-type infection. Genes that were upregulated in H-v601-Per1 and H-v601-Per2 relative to 
Mock were enriched in the “Antiviral response” function; while “Immunity/type I IFN pathway” 
was enriched in genes that were upregulated during persistent infection in H-v601-Per1 and 
H-v601-Per2 cells relative to wild-type infection in H-v601 cells. “Antiviral Response” genes 
were also enriched in genes that were upregulated during wild-type infection relative to Mock, 
but to a lesser extent than the persistently-infected cells. Unfolded protein response and ER-
functionally related genes were upregulated in H-v601 relative to Mock, and also relative to 
persistent infection. Genes that were upregulated in H-v601 relative to H-v601-Per1 and H-
v601-Per2 were also enriched for “Lipid metabolism” functionally-related genes, while 
“Lipid/sterol metabolism” was downregulated in H-v601-Per1 relative to Mock.  
Genes of particular interest that constituted potential targets for further validation experiments 
were those that were specifically downregulated during persistent infection while also 




Figure 3.8: Overview of RNAseq analysis and generation of the transcriptomics dataset analysed 
for this project. Total intracellular RNA was extracted from HEK293T, H-v601-Per1, H-v601-Per2, H-
Rep and H-Rep-4BT66A cells, and H-v601 cells 24 hours post-infection with wild-type DENV-2. Samples 
were generated in duplicate, and RNAseq analysis was performed at the BGI. Bioinformatic analysis 
was performed to ultimately generate a data file showing values corresponding to gene expression 
levels in each cell line. Pairwise comparisons of these values provided Log2 fold change values in gene 




Table 3.3: Results summary of DAVID analysis on genes differentially expressed by at least two-
fold or significantly. Genes that were differentially expressed in each pairwise comparison of interest 
were identified and analysed by DAVID to identify enriched clusters of genes in the datasets that were 
functionally related. Two-fold up- or downregulated in Sample X vs. Sample Y indicates that the genes 
were up- or downregulated by at least two-fold in Sample Y, relative to Sample X.  
* = Clusters of genes that are involved in the same host pathways were identified and assigned a 
functional annotation using analysis by DAVID). The top three most enriched functional annotations for 
each pairwise comparison with an EASE score ≥ 1.3 (which corresponds to a p value < 0.05) are listed, 
with the corresponding EASE score. If there were fewer than three functional annotations with an EASE 







Functional annotation (EASE score)* 
Two-fold upregulated  
Mock vs.  
H-v601 
241 
Endoplasmic reticulum (4.54); IRE1-mediated unfolded 
protein response (UPR) (3.41); antiviral response (2.12) 
Mock vs.  
H-v601-Per1  
436 
Antiviral response (8.18); glycoprotein/extracellular region 
(2.85) 
Mock vs.  
H-v601-Per2  
305 
Antiviral response (7.96); growth factor activity (2.7); 
glycoprotein/extracellular region (1.93) 
Mock vs.    
H-Rep 519 
Nucleus/transcription (4.84); glycoprotein/signal peptide 
(2.29); apoptosis (1.74) 
Mock vs.  
H-Rep-4BT66A  
565 Nucleus/transcription (8.18); zinc finger region (3.59); 
antiviral response (2.66)  
H-Rep vs.  
H-Rep-4BT66A  
296 
Nucleus/DNA-binding (3.36); metal ion-binding site (2.52); 
antiviral response (1.99) 
H-v601-Per1 
vs. H-v601 
308 Unfolded protein binding (4.10); protein processing in ER 




Endoplasmic reticulum (7.56); protein processing in the 
ER (4.3); lipid metabolism (1.78) 
Two-fold downregulated  
Mock vs.  
H-v601 
409 Nucleus/DNA-binding (3.12); nucleosome (1.99) 
Mock vs.  
H-v601-Per1  
214 Nucleus (2.18); lipid/sterol metabolism (1.82) 
Mock vs.  
H-v601-Per2  
188 Nucleus (2.24) 
Mock vs.    
H-Rep 965 
Cell junction (4.96); Ubl conjugation (3.95); glycoprotein 
(3.41) 
Mock vs.  
H-Rep-4BT66A  
916 Homeodomain-like (3.65); cell junction (2.36) 
H-Rep vs.  
H-Rep-4BT66A  








vs. H-v601 766 





Immunity/type I IFN pathway (7.46); glycoprotein (3.37); 
cell junction (3.32) 
Significantly upregulated 
Mock vs.  
H-v601 
28 No functional annotations with EASE score ≥ 1.3 found 
Mock vs.  
H-v601-Per1  
51 
Antiviral defence (7.26); NF-kB signalling pathway (2.5); 
type I IFN signalling pathway (1.76) 
Mock vs.  
H-v601-Per2  
25 Antiviral defence (3.05); protein binding (1.3) 
Mock vs.    
H-Rep 80 Transcription regulation (4.11); glycoprotein (1.3) 
Mock vs.  
H-Rep-4BT66A  
98 Transcription regulation (5.7); TNF-mediated signalling 
pathway (1.6); innate immunity (1.35) 
H-Rep vs.  
H-Rep-4BT66A  
17 Type I IFN signalling pathway (3.63) 
H-v601-Per1 
vs. H-v601 
33 No functional annotations with EASE score ≥ 1.3 found 
H-v601-Per2  
vs. H-v601 
22 No functional annotations with EASE score ≥ 1.3 found 
Significantly downregulated 
Mock vs.  
H-v601 
13 No functional annotations with EASE score ≥ 1.3 found 
Mock vs.  
H-v601-Per1  
3 No functional annotations with EASE score ≥ 1.3 found 
Mock vs.  
H-v601-Per2  
5 No functional annotations with EASE score ≥ 1.3 found 
Mock vs.    
H-Rep 141 
Intermediate filament protein (2.3); negative regulation of 
transcription from RNA polymerase II promoter (1.97); 
DNA-binding (1.95) 
Mock vs.  
H-Rep-4BT66A  
134 Intermediate filament protein (1.86); glycoprotein (1.53); 
leucine-rich repeat (1.35) 
H-Rep vs.  
H-Rep-4BT66A  
10 No functional annotations with EASE score ≥ 1.3 found 
H-v601-Per1 
vs. H-v601 76 
Antiviral defence (8.62); immunity (3.83); negative 
regulation of type I IFN production (3.23) 
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3.3.1. Bioinformatic analysis of genes specifically downregulated during persistent 
infection.  
164 genes were identified that were both downregulated in H-v601-Per1 and H-v601-Per2 
cells relative to Mock, and upregulated in H-v601 cells relative to Mock (Supplementary Table 
1). DAVID analysis of these 164 genes identified a functional annotation cluster, “Cholesterol 
Biosynthetic Process”, with the greatest enrichment score of 3.29. The following cluster was 
“Chromosome” with an EASE score of 1.3, and all other clusters had EASE scores < 1.3. The 
“Cholesterol Biosynthetic Process” cluster contained 6 genes: HMGCR, HMGCS1, INSIG1, 
IDI1, MSMO1, and SQLE. STRING functional protein association analysis on the same 164 
genes was performed to identify any protein-protein interactions within the gene set (Figure 
3.9). The top three Biological Process (GO) pathways based on ascending p value were 
highlighted using coloured nodes which indicate proteins involved in each pathway. The top 
three pathways identified using STRING were “Cholesterol Biosynthetic Process”, “Alcohol 
Biosynthetic Process” and “Organic Hydroxy Compound Biosynthetic Process”. The cluster of 
proteins highlighted in red in Figure 3.9 correspond to the cholesterol biosynthetic process, 
and were the same proteins identified by the DAVID analysis. Due to the importance of lipids 
during flavivirus infections (for more details see Section 1.6), genes involved in cholesterol 
biosynthesis constituted an attractive target for further validation experiments and this 
pathway subsequently became a focus for experiments in this project. 
 
Table 3.4: Summary of top three enriched pathways identified using DAVID and STRING from 
genes specifically downregulated during persistent infection and upregulated during wild-type 
DENV-2 infection. Genes that were downregulated in H-v601-Per1 and H-v601-Per2 cells relative to 
Mock, and upregulated in H-v601 cells relative to Mock were identified and analysed by DAVID and 
STRING. The top three functional annotation clusters, corresponding EASE score (only showing 
clusters with EASE score ≥ 1.3) and number of genes in each cluster identified by DAVID analysis is 
shown. The top three biological process (GO) pathways identified by STRING, corresponding p values 

















3.29 6 Cholesterol biosynthetic process 0.000361 6 
Chromosome 1.3 7 Alcohol biosynthetic process 0.000361 8 
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Figure 3.9: STRING analysis on genes that were downregulated in H-v601-Per1 and H-v601-Per2 
cells, and upregulated in H-v601 cells, relative to mock. Pairwise comparisons between the 
transcriptome of HEK293T (Mock), H-v601-Per1, H-v601-Per2, and H-v601 cells was performed. All 
genes that were differentially expressed by at least two-fold in at least one pairwise comparison were 
identified, and from these, 164 genes that were downregulated in H-v601-Per1 and H-v601-Per2 
relative to mock, and upregulated in H-v601 relative to mock were further identified. STRING analysis 
was performed on these 164 genes to identify clusters of associated proteins or protein-protein 
interactions. Highlighted nodes in colour indicate proteins in the top three Biological Process (GO) 
pathways identified by the STRING software according to ascending p value. Red indicates the pathway 
“Cholesterol Biosynthetic Process” (p = 0.000361); blue indicates “Alcohol Biosynthetic Process” (p = 
0.000361); green indicates “Organic Hydroxy Compound Biosynthetic Process” (p = 0.0007).   
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3.3.2. Bioinformatic analysis of genes specifically upregulated during persistent 
infection.  
673 genes were identified that were upregulated in H-v601-Per1 or H-v601-Per2 relative to 
Mock and H-v601 cells (Supplementary Table 2). STRING analysis was performed on these 
673 genes (Figure 3.10) to visualise clusters of interactions between proteins encoded by 
these genes. These genes were then further analysed by DAVID to identify functionally-related 
clusters of genes that are upregulated during persistent infection. The top annotation cluster 
with an enrichment score of 6.73 was “Response to virus”, with the next two being “Growth 
factor activity” and “Post-synaptic cell membrane” with enrichment scores of 4.9 and 4.72, 
respectively (Table 3.5). In the “Response to virus” functional annotation cluster, there were 
35 genes identified. Additionally, STRING analysis identified enriched pathways and the top 
three pathways are shown in Table 3.5, with the top pathway “Response to virus”, followed by 
“Cell-cell signalling” and “Response to external stimulus” (p = 1.87 x 10-8, 1.87 x 10-8, and 1.87 
x 10-8, respectively). STRING analysis was then performed on the smaller group of 35 genes 
(Figure 3.11) to further characterise and filter them to identify potential targets for further 
validation experiments. This revealed 24 genes enriched in the “Response to virus” pathway 
(p = 8.21 x 10-36), 27 genes in the “Response to other organism” pathway (p = 6.74 x 10-31), 
and 26 genes in the “Response to biotic stimulus” pathway (p = 1.51 x 10-28). C19orf66, CD70, 
CLU, CYP1A1 and GDF15 were the only genes encoding proteins that did not have a known 
interaction with any other proteins encoded by genes in the list, however C19orf66, CD70, 
CLU and CYP1A1 are known ISGs or have known roles in the innate immune response 
(Echebli et al., 2017; Lulli et al., 2016; Sonn et al., 2010; Suzuki et al., 2016). Similarly, CCL27 
was not highlighted by STRING as being involved in any of the top three enriched pathways, 
yet is a known ISG (Moerman-Herzog and Nakagawa, 2015). Overall, 32 genes were identified 
as ISGs that were upregulated in H-v601-Per1 or H-v601-Per2 compared to Mock and wild-
type DENV-2-infected cells: ACTA2, BCL3, BST2, C19orf66, CCL20, CCL27, CD70, CLU, 
CXCL1, CXCL10, CXCL11, CXCL8, CYP1A1, DDX58, DDX60, DHX58, FOSL1, HSPB1, 
IFI44, IFIH1, IFIT1, IFIT2, IFIT3, IFITM1, IFITM2, IFITM3, IFNB1, ISG15, ISG20, NFKBIA, 







Table 3.5: Summary of top three functional annotation clusters identified by DAVID and enriched 
pathways identified by STRING from genes specifically upregulated during persistent infection. 
Genes upregulated in H-v601-Per1 or H-v601-Per2 relative to Mock and H-v601 were analysed by 
DAVID or STRING software. The top three functional annotation clusters, the corresponding EASE 
score, and number of genes in each cluster identified by DAVID analysis is shown. The top three 
biological process (GO) pathways identified by STRING, corresponding p values and the number of 













p value Number of proteins 
Response to 
virus 6.73 35 
Response to 
virus 1.87 x 10
-8 29 
Growth 
factor activity 4.9 20 
Cell-cell 
signaling 1.88 x 10
-8 60 









Figure 3.10: STRING analysis on genes that were upregulated in H-v601-Per1 and H-v601-Per2, 
relative to Mock and H-v601. 673 genes were identified that were upregulated in H-v601-Per1 and H-
v601-Per2 relative to Mock and H-v601 by at least two-fold. STRING analysis was performed on these 
673 genes to identify functionally-related clusters of genes within the data. Highlighted nodes in colour 
indicate proteins in the top three Biological Process (GO) pathways identified by the STRING software 
according to ascending p value. Red indicates the pathway “Response to virus” (p = 1.87 x 10-8); blue 
indicates “Cell-cell signalling” (p = 1.88 x 10-8); green indicates “Response to external stimulus” (p = 





Figure 3.11: STRING analysis on 35 “Response to virus” genes. In the transcriptomics dataset, 673 
genes were identified to be upregulated in H-v601-Per1 and H-v601-Per2 cells by at least two-fold, 
relative to Mock and H-v601 cells. DAVID analysis on these genes revealed 35 genes that were 
included in the “Response to virus” annotation cluster. STRING analysis was performed to determine if 
these 35 genes encoded proteins that had known interactions; proteins identified as part of enriched 
biological process (GO) pathways are highlighted by coloured nodes. 24 genes were in the enriched 
“Response to virus” pathway (p = 8.21 x 10-36) (red); 27 genes were in the “Response to other organism” 
pathway (p = 6.74 x 10-31) (blue); 26 genes in the “Response to biotic stimulus” pathway (p = 1.51 x 10-








3.4. Investigation into the effects of persistent DENV infection on cholesterol 
biosynthesis pathways. 
Cholesterol is a multi-functional lipid that plays key functions in many aspects of cellular 
biology and immunology, and critically for this project, cholesterol biosynthesis plays an 
important role during viral infection as outlined in more detail in Section 1.6. Cholesterol 
biosynthesis is a highly complex process that takes place in multiple subcellular locations and 
utilises many different enzymes to generate a number of intermediate molecules before 
cholesterol can be synthesised. There are several branches of the cholesterol biosynthesis 
pathway, including the mevalonate and sterol branches; for a comprehensive overview of the 
cholesterol biosynthesis pathway, please see Mazein et al., 2013.  
3.4.1. Introduction to target cholesterol biosynthesis genes.   
Genes of interest for this project were those involved in cholesterol biosynthesis that were 
downregulated in H-v601-Per1 and H-v601-Per2 cells, and upregulated in H-v601 cells, 
relative to Mock because this would indicate differential expression of a cellular pathway that 
potentially supports persistent infection. Genes identified through bioinformatics analysis 
were: HMGCR, HMGCS1, IDI1, INSIG1, MSMO1 and SQLE.  HMGCR, HMGCS1, IDI1, 
MSMO1 and SQLE encode enzymes that are involved in both the mevalonate and sterol 
branches of the cholesterol biosynthesis pathway (Goldstein and Brown, 1990), while INSIG1 
plays a key role in the regulation of cholesterol homeostasis (Yabe et al., 2002; Ye and 
DeBose-Boyd, 2011) (Figure 3.12). Sterol regulatory element-binding proteins (SREBPs) are 
ER membrane-bound transcription factors that mediate the feedback system regulating 
cholesterol and fatty acid biosynthesis pathways. In short, when sterols are abundant in ER 
membranes, SREBPs bind SREBP-cleavage-activating protein (Scap), a membrane protein, 
which then binds INSIG proteins (Radhakrishnan et al., 2004). This retains the 
INSIG/Scap/SREBP complex in the ER membrane and the expression of SREBP target genes 
is not induced. Under sterol deprivation, INSIG proteins dissociate from Scap and are rapidly 
deubiquitinated and degraded (Gong et al., 2006). The Scap/SREBP complex enters the Golgi 
network where SREBPs undergo sequential proteolytic cleavage events by S1P and S2P, and 
the transcription factor domain of SREBP is released into the nucleus to transcriptionally 
activate the expression of its target genes (Ye and DeBose-Boyd, 2011).  HMGCR, HMGCS1, 
IDI1, INSIG1, and SQLE are all directly regulated by SREBPs (Horton et al., 2003; Maxwell et 
al., 2003; Sharpe and Brown, 2013; Tabor et al., 1999). 
During DENV infection, it has previously been shown that expression or activity of genes 
involved in cholesterol biosynthesis pathways, and accordingly, intracellular cholesterol levels 
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are increased (Rothwell et al., 2009; Soto-Acosta et al., 2017). Out of the identified targets, 
HMGCR is the enzyme that has been most widely studied in the context of DENV infection. 
Previously, using immunofluorescence techniques, the intracellular HMGCR protein level was 
found to be unaltered during DENV infection relative to mock (Peña and Harris, 2012). 
However, the dephosphorylated form of HMGCR is more active and DENV infection has been 
shown to reduce the phosphorylation level of HMGCR by 70% relative to mock-infected cells; 
this suggests that the phosphorylation state of HMGCR plays a role in increasing intracellular 
cholesterol levels during infection (Soto-Acosta et al., 2013). Here, the transcriptomics data 
suggested that expression of the HMGCR gene may be modulated during DENV infection, 
where HMGCR was upregulated during DENV-2 infection relative to mock by more than 2-
fold but during persistent infection it was downregulated by more than 2-fold.  
 
 
Figure 3.12: Overview of the cholesterol biosynthesis pathway and SREBP-mediated regulation 
of this pathway.  In the cholesterol biosynthesis pathway (A), HMGCS1 converts acetyl-CoA and 
acetoacetyl-CoA into HMG-CoA; HMGCR converts this into mevalonate which is converted into 
isopentenyl-diphosphate. IDI1 isomerises isopentenyl-diphosphate into dimethylallyl diphosphate, and 
these two molecules are transformed into geranyl diphosphate, then farnesyl diphosphate. This is 
converted to squalene, and SQLE converts this into squalene epoxide. From here, lanosterol is 
A B C 
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generated by MSMO1, which is converted to zymosterol then finally cholesterol. Under sterol and fatty 
acid deprivation (B), Scap and SREBPs form a complex that is transported via COP-II-containing 
vesicles from the ER membrane to the Golgi network, where SREBPs are cleaved by S1P and S2P 
proteases to release the transcription factor domain of SREBPs into the nucleus. SREBPs then 
transcriptionally activate the expression of target genes. When cholesterol and fatty acids are abundant 
(C), INSIG proteins bind Scap which retains the Scap/SREBP complex in the ER membrane, thus 
preventing cholesterol and fatty acid biosynthesis genes from being expressed by SREBP. Enzymes 
encoded by genes identified by our bioinformatics analysis are displayed in red.  
 
3.4.2. Using qPCR to validate the transcriptomics results on cholesterol biosynthesis-
related genes.  
The transcriptomics results indicated that cholesterol biosynthesis-related genes, HMGCR, 
HMGCS1, IDI1, INSIG1, MSMO1, and SQLE were downregulated during persistent infection, 
and upregulated during wild-type DENV-2 infection by at least 2-fold. Genes for which primer 
sets were readily available were chosen for further validation using qPCR: HMGCR, HMGCS1, 
IDI1, INSIG1 and MSMO1. Persistently-infected cells and replicon-containing cells were 
generated at the same time using the same parental HEK293T cells. Cells at P4 were 
analysed by RNAseq and frozen for storage. In this project, the same P4 cells were restored 
and maintained for several passages before qPCR analysis was carried out on cells at P6 and 
P8. Total intracellular RNA was extracted from HEK293T (Mock), H-v601-Per1, H-v601-Per2, 
H-Rep, H-Rep-4BT66A and HEK293T cells infected with v601 wild-type DENV-2 (H-v601), and 
converted to cDNA for qPCR analysis in order to investigate changes in target gene 





Figure 3.13: An overview of qPCR workflow. HEK293T, H-v601-Per1, H-v601-Per2, H-Rep and H-
Rep-4BT66A cells were seeded into 24 well plates and incubated at 37 °C for 48 h. After 24 h, HEK293T 
cells were infected with v601 (MOI > 5), and incubated for another 24 h to generate the H-v601 cell line. 
Total intracellular RNA was extracted from the cells, and RNA was converted to cDNA by reverse 
transcription with a random hexamer primer. This was performed on cells at passage 6 (P6) and P8. 
Random primed cDNA was used for every subsequent step at a concentration of 5 ng/μl. Gene-specific 
primer sets for qPCR and successful reverse transcription reaction were tested using PCR and agarose 
gel electrophoresis to confirm gene-specific binding and successful generation of RT-PCR products. 
Dilution series of RT-PCR products were prepared and used to generate standard curves to determine 
primer efficiency. qPCR mastermixes containing SYBR green with ROX, gene-specific primers and 
nuclease-free water were created and added to a 96 well qPCR plate. Template RT-PCR product was 
mixed with the mastermix in each well, in triplicate per sample. qPCR reactions were repeated 3 times 
for P6 samples, and twice for P8 samples. These results were combined and analysed by double-delta 
Ct (ΔΔCt) analysis for normalisation and to indicate relative expression fold changes of target genes. 
 
3.4.3. Optimisation of qPCR reactions.  
The gene specific primers were first checked for successful binding and specific amplification 
of the correct target gene sequence using PCR and agarose gel electrophoresis (Figure 3.14). 
The expected product sizes of each primer set are as follows: ACTB = 147 bp; GAPDH = 95 
bp; HMGCR = 87 bp; HMGCS1 = 123 bp; IDI1 = 133 bp; INSIG1 = 81 bp; MSMO1 = 97 bp. 
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All approximate sizes of observed bands on the gel corresponded to the expected product 
sizes, however the ACTB primer set produced a very faint band relative to other gene-specific 
primer sets (Figure 3.14). As the transcriptomics dataset indicated that ACTB expression 
changed between different cell lines, ACTB was not used as a reference gene and was not 
analysed further; thus, GAPDH was used as a reference gene for all experiments.  
 
 
Figure 3.14: Agarose gel electrophoresis to confirm target gene-specific binding of qPCR primer 
sets. Total intracellular RNA from HEK293T and H-v601-Per1 cells was extracted and converted to 
cDNA by reverse transcription. PCR was performed using each primer set on the HEK293T RT-PCR 
product sample to test the cholesterol biosynthesis-related gene-specific primers. 5 ng of cDNA and 1 
μl 6 X loading dye was loaded into each well of a 1% agarose gel and run at 100 V for approximately 1 
h. O’RangeRuler 20 bp DNA ladder was used to estimate product sizes. 
 
 
Additionally, standard curves for each primer set were generated using 10-fold serial dilutions 
of template RT-PCR product with a starting concentration of 10 ng/µl or 5 ng/µl to calculate 
the primer efficiencies (graphs not shown). Primer efficiency measures the rate at which the 
polymerase enzyme converts the reagents into amplicons and should ideally fall in the range 
of 90-110% (Taylor et al., 2010). The efficiency of primer sets for GAPDH, and all cholesterol 
biosynthesis-related genes ranged from 92.3-110.5%, with the exception of the HMGCS1 
primer which demonstrated an efficiency of 134.4%. However, a common cause of high primer 
efficiency is the formation of primer-dimers or non-specific amplicons (Taylor et al., 2010), but 
it was clear from the results of agarose gel electrophoresis on genes amplified using the same 
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primer set that no non-specific binding or primer-dimer formation had occurred (Figure 3.14). 
Thus, it was concluded that all primer sets were suitable for further qPCR analysis.  
3.4.4. qPCR on cholesterol biosynthesis-related genes.  
qPCR was used to analyse the expression of HMGCR, HMGCS1, IDI1, INSIG1 and MSMO1 
in all cell lines, including uninfected HEK293T (Mock), wild-type DENV-2-infected HEK293T 
(H-v601), H-v601-Per1, H-v601-Per2, H-Rep and H-Rep-4BT66A. As described above in Figure 3.13, 
total intracellular RNA was extracted from these cells at both P6 and P8, and qPCR was 
performed either 2 or 3 times on samples from each passage number, and results from all 
assays were pooled to generate the results shown in  
Figure 3.15. The results show relative quantitation, meaning GAPDH was used as a reference 
gene for analysis of target gene expression, and the expression of each target gene in mock 
cells was used as a calibrator to calculate relative fold changes in gene expression in the other 
cell lines.  
The expression of HMGCR was significantly reduced in the H-v601-Per1 and H-v601-Per2 
cell types relative to Mock (p = <0.0001 and 0.0003, respectively); these results were 
consistent with the transcriptomics data which suggested HMGCR was downregulated during 
persistent infection. However, HMGCR was not upregulated during wild-type DENV-2 infection 
as suggested in the transcriptomics data, and in fact was also significantly reduced in H-v601 
cells relative to Mock (p = 0.0085). Expression of HMGCR was significantly reduced in both 
H-Rep and H-Rep-4BT66A relative to Mock (p = <0.0001 for both) and H-v601 (p = 0.0224 and 
0.0466, respectively). However, there was no significant difference in HMGCR expression 
between either H-v601-Per1 or H-v601-Per2 and H-v601, or between H-Rep and H-Rep-
4BT66A, i.e. with or without the presence of the NS4BT66A mutation ( 
Figure 3.15).  
Expression of HMGCS1 was significantly reduced in both H-v601-Per1 and H-v601-Per2 
relative to Mock (p = <0.0001 for both), however HMGCS1 expression was not significantly 
altered between Mock and H-v601 as was predicted by the transcriptomics data. HMGCS1 
was significantly downregulated in H-Rep and H-Rep-4BT66A, relative to Mock (p = <0.0001 for 
both), H-v601 (p = <0.0001 for both) and H-v601-Per2 (p = 0.0475 and 0.0352, respectively), 
but not H-v601-Per1. Interestingly, HMGCS1 was significantly downregulated in H-v601-Per1 
and H-v601-Per2 relative to H-v601 (p = 0.0003 and 0.0074, respectively), indicating there 
was differential expression of HMGCS1 between cells infected with wild-type virus and cells 
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persistently-infected with v601-4BT66A, however there was no significant difference in expression 
between H-Rep and H-Rep-4BT66A ( 
Figure 3.15).   
IDI1 was significantly downregulated in H-v601-Per2, H-Rep and H-Rep-4BT66A relative to 
Mock (p = 0.0031, <0.0001 and <0.0001, respectively), but there was no significant difference 
in expression between H-v601-Per1 or H-v601 and Mock. IDI1 was also significantly 
downregulated in H-Rep and H-Rep-4BT66A relative to all virus-infected cell lines H-v601-Per1, 
H-v601-Per2 and H-v601 (p = <0.0001 for all). IDI1 expression was significantly reduced in H-
v601-Per1 and H-v601-Per2 relative to H-v601 (p = 0.0067 and 0.0001, respectively), again 
indicating differential expression of this gene between cells infected with wild-type DENV-2 
and v601-4BT66A, however there was no significant difference in expression between H-Rep 
and H-Rep-4BT66A ( 
Figure 3.15).  
The expression of INSIG1 was only significantly reduced in H-Rep and H-Rep-4BT66A relative 
to Mock (p = <0.0001 for both), but there was no significant difference in expression between 
H-v601-Per1, H-v601-Per2 or H-v601 and Mock, which is inconsistent with the results from 
the transcriptomics analysis. Again, INSIG1 was significantly downregulated in H-Rep relative 
to all virus-infected cell lines, H-v601-Per1, H-v601-Per2 and H-v601 (p = 0.0001, 0.0019 and 
<0.0001, respectively), and in H-Rep-4BT66A (p = 0.0002, 0.0030 and <0.0001, respectively). 
There was a significant difference in expression of IDI1 between H-v601-Per2 and H-v601 (p 
= 0.0077), but not between H-v601-Per1 and H-v601 or H-Rep and H-Rep-4BT66A, suggesting 
a mild difference in expression of INSIG1 between persistent infection and wild-type infection 
as it was only observed in one of the persistently-infected cell lines ( 
Figure 3.15).  
MSMO1 was significantly reduced in H-v601-Per2, H-Rep and H-Rep-4BT66A relative to Mock 
(p = 0.0405, 0.0037 and 0.0045, respectively), but not in H-v601-Per1 or H-v601. MSMO1 in 
H-Rep and H-Rep-4BT66A was significantly reduced relative to H-v601 (p = 0.0079 and 0.0098, 
respectively), however not compared to H-v601-Per1 or H-v601-Per2 as was observed for 
other genes. Additionally, there was no significant difference in MSMO1 expression between 
cell lines infected with viruses or containing replicons that either did or did not express the 
NS4BT66A mutation ( 
Figure 3.15).  
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Figure 3.15: qPCR quantification of cholesterol biosynthesis genes. Cells were seeded into 24 
well plates and incubated for 48 hours total. After 24 hours, HEK293T cells were infected with v601 
(MOI > 5) and incubated for 24 hours; this was the H-v601 cell line. After the incubation period, cells 
were lysed and total intracellular RNA was extracted from cell lines at passage 6 (P6) and P8. 200 ng 
of each RNA sample was converted to RT-PCR product by a reverse transcription reaction using a 
random hexamer primer, and diluted to a final concentration of 5 ng/μl. 4 μl nuclease-free water, 6.25 
μl Maxima SYBR Green mastermix, and 1.25 μl of each primer set, and 1 μl of template RT-PCR product 
was mixed in each well of a 96 well qPCR plate. Gene-specific primers for HMGCR, HMGCS1, IDI1, 
INSIG1 and MSMO1 from QIAgen were used. The qPCR reaction was performed 3 times on P6 
samples, and 2 times on P8 samples, and in triplicate on each plate, and the results combined. GAPDH 
was used as a reference gene for all reactions. Relative gene expression fold change was determined 
using the double-delta Ct (ΔΔCt) method with gene expression in HEK293T cells used as the calibrator; 




3.4.5. Cellular staining for cholesterol.  
To investigate the different effects of wild-type and persistent DENV infection on intracellular 
cholesterol levels and localisation, intracellular cholesterol was stained using filipin III. Filipin 
is a polyene antibiotic first isolated from Streptomyces filipinensis which is sterol-binding and 
fluorescent, and is commonly used for visualization of free cholesterol and to detect sterol-rich 
areas within cells using fluorescence microscopy (Boutté et al., 2011; Maxfield and Wüstner, 
2012). Filipin III is the predominant component of filipin and has a high affinity for binding to 
cholesterol (Volpon and Lancelin, 2000).  
A specific Filipin III detection protocol was specifically designed for this experiment (Section 
2.3.3). It was also of interest to investigate whether there was any increase in co-localisation 
of cholesterol with viral replication complexes; thus, fixed cells were stained for dsRNA using 
primary and fluorophore-conjugated secondary antibodies. Cell nuclei were stained using TO-
PRO-3, before staining intracellular cholesterol with filipin III. Coverslips were mounted onto 
microscope slides using VectaShield without DAPI as filipin III is detected at the same 
wavelength. As filipin fluorescence photobleaches rapidly, a tandem scanner confocal 
microscope with hybrid detectors was used, and filipin solutions were protected from light at 
all times throughout the protocol. However, despite having these protective measures in place, 
photobleaching during the cell imaging process was still significant. Therefore, filipin 
fluorescence levels on images should not be taken as an indication of cholesterol abundance 




In uninfected cells, cholesterol was detected in the cell membranes with uniform distribution 
(Figure 3.16). There was some faint staining for dsRNA in the HEK293T cells, however 
compared to dsRNA staining in all virus-infected cells this was much lower in the uninfected 
cells and therefore could potentially be attributed to unspecific background fluorescence.  In 
the wild-type DENV-2-infected cells, cholesterol distribution appeared disrupted, with 
cholesterol staining appearing more punctate and irregular when compared to cholesterol 
distribution in the HEK293T cells. Additionally, there appeared to be some moderate co-
localisation of cholesterol and dsRNA in the H-v601 cells in the peri-nuclear areas, as 
indicated by white arrows in Figure 3.16. In the H-v601-Per1 cells, distribution of cholesterol 
was still slightly irregular when compared to uninfected control cells, with cholesterol staining 
in the membranes appearing thinner and with more punctate areas. dsRNA did not appear to 
be co-localised with cholesterol in this sample, and was localised closer to the nucleus. In H-
v601-Per2 cells, cholesterol distribution in the membranes appeared much more irregular than 
all other samples, while dsRNA localisation seemed mutually-exclusive to cholesterol 
localisation. Overall, these results could indicate that while cholesterol may slightly co-localise 
and be recruited to viral replication complexes during wild-type infection, during persistent 






Figure 3.16: Staining intracellular cholesterol with filipin III. HEK293T, H-v601-Per1, and H-v601-
Per2 cells were seeded onto coverslips in a 24 well plate. After 24 h, HEK293T cells were infected with 
v601 virus to generate wild-type DENV-2-infected cells. Cells were incubated at 37 °C. After 24 h, cells 
were fixed with 4% PFA, quenched with 50 mM ammonium chloride, permeabilised by 1% Triton-X-
100, and blocked in 10% FBS in PBS. dsRNA (red) was stained with mouse anti-dsRNA primary 
antibody at a 1:200 dilution, followed by a goat anti-mouse secondary antibody conjugated with a 568 
Alexa Fluor® at a 1:1000 dilution. Nuclei (blue) were stained with TO-PRO-3 at a 1:1000 dilution, 
protected from light. Intracellular cholesterol (green) was stained with filipin III at a concentration of 100 
μg/ml, protected from light, before mounting onto microscope slides using VectaShield without DAPI. 









3.5. Investigation into the type I IFN response.  
The type I IFN response is known to be an important factor in a host’s response to viral 
infection, including during DENV infection. Consequently, this is also a common pathway for 
viruses to target for inhibition or evasion of the host innate immune response, as discussed in 
more detail in Section 1.5.3.  
3.5.1. Type I IFN response and persistent DENV infection.  
As previously described in Section 3.3.2, bioinformatic analysis of a transcriptomics dataset 
was used to discover 673 genes that were specifically upregulated in the persistently-infected 
cells, H-v601-Per1 and H-v601-Per2, relative to Mock and wild-type DENV-2-infected cells, 
H-v601. Within these, through functional annotation and protein interaction analyses, 32 
genes encoding ISGs that express proteins with antiviral functions were identified: ACTA2, 
BCL3, BST2, C19orf66, CCL20, CCL27, CD70, CLU, CXCL1, CXCL10, CXCL11, CXCL8, 
CYP1A1, DDX58, DDX60, DHX58, FOSL1, HSPB1, IFI44, IFIH1, IFIT1, IFIT2, IFIT3, IFITM1, 
IFITM2, IFITM3, IFNB1, ISG15, ISG20, NFKBIA, OASL, and RSAD2. Genes encoding 
proteins that have roles within the type I IFN signaling pathways, such as JAK1, JAK2, STAT1, 
STAT2, IRF9, were not found to be differentially expressed by at least two-fold during infection 
with wild-type virus or during persistent infection, relative to Mock. This may indicate that 
components of the signaling pathway are not targeted by the virus for subversion of the host 
antiviral response at a transcriptional level. As it is known that STAT1 and STAT2 proteins are 
targeted by DENV viral proteins to facilitate infection (Ashour et al., 2009; Muñoz-Jordan et 
al., 2003, 2005), it is likely that this modulation of STAT1 and STAT2 by the virus occurs only 
at a post-translational stage, rather than by modifying gene expression levels.  
3.5.2. Effect of persistent infection on STAT1.  
To study the effect of the NS4BT66A mutation on the virus’s ability to inhibit the activation and 
nuclear localisation of STAT1 during the host immune response, STAT1 was imaged in the 
different cell lines (Figure 3.17). During the host immune response, IFNa/b is produced which 
binds to the IFNAR receptor and induces the type I IFN pathway during which STAT1, in 
complex with STAT2 and IRF9, is phosphorylated and translocated to the nucleus (Ivashkiv 
and Donlin, 2015). The ratio of nuclear/cytoplasmic fluorescence indicating localisation of 
STAT1 was calculated using CellProfiler software; a fluorescence ratio of > 1 indicates nuclear 
localisation (Figure 3.18).  
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IFNα treatment resulted in significant nuclear translocation of STAT1 in the HEK293T, H-v601, 
H-v601-Per2 and H-Rep-4BT66A cells compared to cells of the same cell line that were left 
untreated with IFNα (p = <0.0001 for all), however there was no significant difference in 
nuclear localisation of STAT1 upon IFNa treatment in H-v601-Per1 or H-Rep cells (Figure 
3.17).  
When cells were left untreated with IFNα, STAT1 in H-v601-Per1, H-v601-Per2, H-Rep and 
H-Rep-4BT66A was significantly more localised to the nucleus than in the control HEK293T cells 
(p = <0.0001, 0.0045, <0.0001, and <0.0001, respectively), while in the H-v601 cells, STAT1 
was significantly more localised to the cytoplasm compared to untreated HEK293T cells (p = 
0.0002) (Figure 3.17).  
When cells were treated with IFNa, nuclear localisation of STAT1 was significantly lower in H-
v601 and H-v601-Per1 cells, relative to uninfected cells (p = <0.0001 for both); however, 
STAT1 was significantly more localised to the nucleus in the H-v601-Per2 and H-Rep-4BT66A 
cells, relative to uninfected cells (p = 0.0027 and <0.0001, respectively). There was no 
significant difference in STAT1 localisation between uninfected cells and H-Rep. STAT1 was 
significantly more nuclear localised in H-v601-Per2 cells than in H-v601 cells (p = <0.0001), 
and in H-Rep-4BT66A cells than in H-Rep cells (p = <0.0001) (Figure 3.17).  
Overall, these results suggested that the presence of the NS4BT66A mutation alters the effect 
of DENV-2 infection on the host type I IFN immune response during wild-type or persistent 
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Figure 3.17: IFA to detect STAT1 in all cell lines. HEK293T, H-v601-Per1, H-v601-Per2, H-Rep, and 
H-Rep-4BT66A cells were seeded onto coverslips in 24 well plates and incubated at 37 °C for 24 h. 
HEK293T cells were infected with v601 for 1.5 h, the virus was removed, and all cells were incubated 
for a further 24 h. Cells were either left untreated; termed IFN- (A), or treated with 1000 U/ml IFNα for 
1 h; termed IFN+ (B). Cells were fixed with 4% paraformaldehyde, permeabilised with 1% Triton-X-100, 
and blocked with 10% FBS in PBS. STAT1 proteins were stained with a rabbit anti-STAT1 antibody at 
a 1:400 dilution, followed by a goat anti-mouse secondary antibody conjugated with a 568 Alexa Fluor® 
at a 1:1000 dilution. Coverslips were mounted onto microscope slides using VectaShield with DAPI, 
and imaged using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DMI6000 






Figure 3.18:  Quantification of the nuclear/cytoplasmic fluorescence ratio of STAT1 in all cell 
lines. STAT1 was stained in HEK293T, H-v601, H-v601-Per1, H-v601-Per2, H-Rep, and H-Rep-4BT66A 
cells that had either been left untreated or treated with IFNα prior to fixation, and images were captured 
using a Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DMI6000 inverted 
epifluorescence microscope with 63x objective, and a 2.5x optical zoom. The images were analysed by 
CellProfiler software using a program that quantifies the fluorescence corresponding to STAT1 that is 
detected within the nucleus and within the cytoplasm of each cell in each image. From this, an average 
nuclear/cytoplasmic fluorescence ratio is calculated; for each dataset, averages were calculated from 
between 142 and 311 objects. Graphs were created using GraphPad Prism 7; two-way ANOVA and 
Tukey’s multiple comparison post-hoc tests were used for statistical analysis. 
 
 
3.5.3. Effect of persistent infection on STAT2.  
STAT2 was stained in HEK293T, H-Rep and H-Rep-4BT66A cells to study the effect of the 
presence of the DENV non-structural proteins encoded by the replicons, and to investigate 
whether any effects on STAT2 were altered by the presence of the NS4BT66A mutation (Figure 
3.19). Localisation of STAT2 proteins was quantified using CellProfiler which calculated the 
nuclear/cytoplasmic fluorescence ratio; a ratio of > 1 indicates nuclear localisation.  
Under activation by IFNα treatment, STAT2 in the IFN+ HEK293T cell lines displayed clear 
translocation from the cytoplasm to the nucleus, relative to IFN- cells (p = <0.0001). With no 
exogenous IFNα present, STAT2 localisation to the nucleus was greater in the H-Rep and H-
Rep-4BT66A cells than the HEK293T cells (p = 0.0183 and 0.0015, respectively) although the 
overall amounts of STAT2 appeared less. This could potentially be caused by the presence of 
replicon genomes inducing a small immune response, thus a relatively small activation of the 
type I IFN response causing STAT2 translocation to the nucleus, however this activation of 
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the type I IFN pathway may not be as great as during the presence of exogenous IFNα prior 
to cell fixation.  
In cells that were treated with IFNα prior to fixation, nuclear localisation of STAT2 in the 
HEK293T cells was greater than both H-Rep and H-Rep-4BT66A cells (p = <0.0001 for both). 
However, neither H-Rep or H-Rep-4BT66A cells displayed significant translocation of STAT2 to 
the nucleus upon IFNα treatment. Once again, the amounts of STAT2 appeared to be much 
less in the replicon containing cells. These results were somewhat expected because it is 
known that the phosphorylation and activation of STAT2 is blocked and STAT2 is targeted for 
proteasomal degradation by NS5 (Ashour et al., 2009; Mazzon et al., 2009) which is encoded 
by both replicon constructs. This experiment was carried out on biosafe replicon-containing 
cells, but as the results indicated no differential effect caused by the NS4BT66A mutation, the 
experiment was not repeated using virus-infected cells. 
 
A   
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Figure 3.19: IFA to detect STAT2 in HEK293T, H-Rep and H-Rep-4BT66A cells. Cells from each cell 
line were seeded onto coverslips in 24 well plates and incubated at 37 °C for 24 h. Cells were either left 
untreated, termed IFN- (A), or treated with 1000 U/ml IFNα for 1 h, termed IFN+ (B). Cells were fixed 
with 4% paraformaldehyde, permeabilised with 1% Triton-X-100, and blocked with 10% FBS in PBS. 
Cells were treated with rabbit anti-STAT2 antibody at a 1:200 dilution, followed by a secondary goat 
anti-rabbit secondary antibody conjugated to a 568 Alexa Fluor® at a 1:1000 dilution. Coverslips were 
mounted onto glass slides using VectaShield with DAPI, and imaged with a Leica SP5-AOBS confocal 
laser scanning microscope attached to a Leica DMI6000 inverted epifluorescence microscope with 63x 
objective, and a 2.5x optical zoom.  
 
 
Figure 3.20 STAT2 nuclear/cytoplasmic fluorescence ratio quantification in HEK293T, H-Rep and 
H-Rep-4BT66A cells. STAT2 proteins were stained in HEK293T, H-Rep and H-Rep-4BT66A cells that 
were either untreated or treated with IFNα prior to fixation, and cells were imaged using a Leica SP5-
AOBS confocal laser scanning microscope attached to a Leica DMI6000 inverted epifluorescence 
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microscope with 63x objective, and a 2.5x optical zoom. Fluorescence corresponding to STAT2 proteins 
was quantified using CellProfiler software in the cytoplasm and in the nucleus, and the 
nuclear/cytoplasmic fluorescence ratio was calculated to indicate intracellular localisation of the 
proteins. Graphs were generated using GraphPad Prism 7; statistical analysis was performed using a 




3.6. Discussion  
3.6.1. Initial characterisation of cell lines.  
The H-Rep and H-Rep-4BT66A cell lines were confirmed to be stably expressing DENV-2 
replicons by RT-PCR and IFA to detect the DENV NS1 protein. The NS4B genes of the 
RepDV-GP2A and RepDV-GP2A-NS4BT66A replicons were sequenced, and the NS4BT66A 
mutation was found to be present in the RepDV-GP2A-NS4BT66A replicon up to at least 19 
passages in all cells within the population. The other mutations discovered in the RepDV-
GP2A-NS4BT66A replicon NS4B sequence, NS4BI27T and NS4BP92S, showed mixed peaks of 
occurrence and NS4BP92S was also lost in the P19 samples, suggesting these mutations were 
not stable in the population. The only mutation discovered in the NS4B gene of the RepDV-
GP2A replicon, NS4BV152M, was only present in P19 samples in a 1:1 ratio. This mutation could 
have arisen due to some selective pressure or been a random mutation that arose due to 
continued passaging of the cells over time; however, the cells were shut down shortly after 
this analysis and therefore the cause of this mutation was not investigated further. 
The presence of intracellular and extracellular virus persistently-infecting the H-v601-Per1 and 
H-v601-Per2 cell lines was confirmed by RT-PCR and IFA for the DENV E protein. There were 
two nonsynonymous mutations that were discovered in intracellular and extracellular RNA 
isolated from H-v601-Per1 and H-v601-Per2 samples: NS4BI30Met and NS4BT66A. The 
NS4BT66A mutation was present in all samples, however there was a mixed peak of occurrence 
in the H-v601-Per1 extracellular RNA and both H-v601-Per1 and H-v601-Per2 intracellular 
RNA samples, although the peak corresponding to the mutated G nucleotide was predominant 
(Table 3.2). This suggests that the cell population was not homogenous for this mutation, and 
the NS4BT66A mutation in the viral genome is less stable than in the replicon sequence, which 
was present in all replicon-containing cells up to passage 19. However, there was also not a 
strong selective pressure for the sequence to revert back to wild-type. There were also mixed 
peaks of occurrence for the NS4BI30Met mutation, suggesting that this was potentially an 
unstable mutation in the population.  
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The relative amount of viral RNA was analysed using qPCR, which showed that both 
persistently-infected and replicon-containing cell lines had significantly lower quantities of viral 
RNA than wild-type infected cells at 24 h post-infection with a high MOI (>5) (Figure 3.7), 
suggesting that replication of the v601-4BT66A virus in the persistently-infected cells was either 
not as efficient as the wild-type virus, due to a defect in RNA synthesis or inhibition by host 
cell processes. This was also shown previously by Dr. Andrew Davidson and colleagues, who 
also used qPCR to show that persistently-infected BHK-21 cells expressed 10-100-fold fewer 
viral genomes/ml than wild-type from 18-70 hours post-infection (Figure 1.3). However, it 
would be beneficial to conduct further experiments using distinct techniques to quantify the 
viral load and compare this between wild-type and persistently-infecting viruses.  
3.6.2. Bioinformatic analysis of a transcriptomics dataset.  
The aim of analysing transcriptomics data from the various cell lines was to identify cellular 
pathways that are differentially expressed during either wild-type or persistent infection which 
may indicate a mechanism facilitating persistent infection. Analysis of genes that are 
downregulated during persistent infection and upregulated during wild-type infection revealed 
enrichment of genes involved in cholesterol biosynthesis pathways. This suggests that 
downregulation of cholesterol biosynthesis potentially constitutes a mechanism by which the 
v601-4BT66A virus establishes a persistent phenotype during infection. Alternatively, this could 
be a defective pathway in the H-v601-Per1 and H-v601-Per2 host cells that enables 
maintenance of persistent infection. In total, 6 genes were identified as potential targets for 
further validation experiments: HMGCR, HMCGS1, IDI1, INSIG1, MSMO1 and SQLE. 
Conversely, 32 genes involved in the antiviral response were identified that are upregulated 
during persistent infection, relative to mock and wild-type infection which suggested that the 
antiviral immune response to DENV infection is enhanced during persistent infection 
compared to wild-type.  
3.6.3. The effect of persistent infection on host cholesterol biosynthesis pathways.  
qPCR analysis revealed that expression of HMGCR, HMGCS1, MSMO1 and IDI1 were 
reduced in H-v601-Per2 cells, and HMGCR and HMGCS1 were reduced in H-v601-Per1 cells 
relative to mock-infected cells. These results validated the transcriptomics data which showed 
that these genes were downregulated in H-v601-Per1 and H-v601-Per2 compared to 
uninfected Mock cells. However, according to the transcriptomics results this reduction was 
by at least 2-fold, which was only the case for HMGCS1 out of 5 genes tested.  
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It was evident that HMGCS1, IDI1, and to a lesser extent, INSIG1 were differentially expressed 
during wild-type and persistent infection, suggesting that the presence of the NS4BT66A 
mutation may alter the effect of DENV-2 infection on cholesterol biosynthesis gene expression. 
However, this was not corroborated by any observable differences in the expression of any of 
the genes analysed between H-Rep and H-Rep-4BT66A which express identical replicon 
constructs that only differ by the presence of the NS4BT66A mutation. None of these genes 
were significantly differentially-expressed between H-Rep and H-Rep-4BT66A cells in the 
transcriptomics data, thus this result was somewhat expected. Cell lines stably expressing 
replicon constructs could be considered persistently-infected, which may inherently influence 
their effect on the host cell transcriptome. This would suggest that it may not be presence of 
the NS4BT66A mutation in the persistently-infecting virus that causes downregulation of these 
genes, but rather a result of the persistent infection itself.  
Overall, the qPCR results confirm the transcriptomics results in that genes involved in 
cholesterol biosynthesis are generally downregulated during persistent infection. Interestingly, 
suppression of expression of genes involved in cholesterol biosynthesis pathways could 
indicate an increase in cholesterol abundance following viral infection because the expression 
of these genes is activated when cholesterol levels are low, and this has been observed with 
the expression of HMGCR and LDLR following DENV-2 infection (Rothwell et al., 2009). 
However, the transcriptomics data suggested that the cholesterol biosynthesis genes 
investigated showed increased expression during wild-type DENV-2 infection compared to 
mock, but this observation was not corroborated by the qPCR results as the expression of 
none of these genes were significantly increased in H-v601 compared to mock-infected cells, 
thus, this requires further investigation going forwards.  
Downregulation of cholesterol biosynthesis genes during persistent infection could potentially 
constitute a mechanism by which the v601-4BT66A virus is able to persistently-infect host cells 
without causing normal progression of infection as seen during wild-type DENV-2 infection. 
However, the effects of wild-type infection on the target genes under investigation remain 
unclear due to conflicting results between transcriptomic and qPCR analyses. Other studies 
surrounding the expression of genes involved in lipid metabolism pathways have shown that 
these changes in expression are highly dynamic and time-dependent; the expression and 
activity of an enzyme in the fatty acid biosynthesis pathway, stearoyl-CoA desaturase 1 
(SCD1), was found to be crucial during early DENV-2 infection, and SCD1 mRNA levels 
increased 6 hours post-infection, decreased 12 hours post-infection, and increased again 24 
hours post-infection (Gullberg et al., 2018). This suggests that changes in expression of target 
genes identified through our transcriptomics analysis may have been observed due to the time 
100 
 
at which samples were taken, thus, it would be beneficial to include a time-course experiment 
for further validation in the future.  
To investigate whether patterns of intracellular cholesterol are modified during wild-type or 
persistent infection, cholesterol was stained using filipin III and dsRNA was stained to 
represent sites of viral replication in the cells. The results suggested that while there may be 
a degree of co-localisation between cholesterol and viral replication sites during wild-type 
infection, there was no co-localisation during persistent infection.  
Further work is required to investigate the effect of wild-type and persistent infection on genes 
and proteins involved in the cholesterol biosynthesis pathway. The expression of six of these 
genes is already known to be regulated by SREBP transcription factors (Horton et al., 2003; 
Maxwell et al., 2003; Sharpe and Brown, 2013; Tabor et al., 1999), thus, it would be interesting 
to investigate and compare the effect of wild-type and persistent DENV infection on SREBP 
transcription factor activity which has not been described previously. If infection with DENV 
does alter the activity of SREBP transcription factors this could explain why the expression of 
these genes is altered during both wild-type and persistent DENV infection. On a protein level, 
it has been shown that wild-type DENV infection increases activity of HMGCR through its 
dephosphorylation (Soto-Acosta et al., 2013, 2017), thus it would be interesting to assess and 
compare the phosphorylation levels of HMGCR during persistent infection with v601-4BT66A 
also. Similar experiments comparing the activity of the other proteins identified through our 
analyses, HMGCS1, IDI1, INSIG1, MSMO1 and SQLE, during infection would also be of 
interest. In addition, utilizing a method of quantifying intracellular cholesterol levels to compare 
these between types of infection would be beneficial for this work; while staining with filipin III 
enables co-localisation studies between cholesterol and viral replication sites, the rapid 
photobleaching property of this molecule renders the images inadequate for 
immunofluorescence-based quantification. It has been shown using a colourimetric assay that 
total intracellular cholesterol levels increased by 15% and 20% at 1 and 6 hpi, respectively, 
during DENV infection (Soto-Acosta et al., 2013), thus, it would be interesting to determine 
whether total intracellular cholesterol levels change during persistent infection.  
Taken together, the results suggest that virus-induced modifications to intracellular cholesterol 
levels, localisation and gene expression differ between infection with wild-type DENV-2 and 
v601-4BT66A. This suggests that the NS4BT66A mutation may have an effect on the ability of 
DENV to modify these aspects of cellular lipid metabolism to promote viral replication. 
Alternatively, defects in the host cholesterol biosynthesis pathways of the small population of 
cells that survived upon initial infection with v601-4BT66A may be a factor that facilitated 
establishment of persistent infection.  
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3.6.4. The effect of persistent infection on the host innate immune response.  
Using bioinformatics analysis, 32 genes involved in the innate immune response were 
identified to be upregulated in persistently-infected cells compared to mock and DENV-2-
infected cells. DENV is known to evade the host type I IFN response by inhibiting and 
degrading components of the type I IFN pathway such as STAT1, STAT2 and STING (Aguirre 
et al., 2012; Ashour et al., 2009; Muñoz-Jordan et al., 2003, 2005), which ultimately prevents 
the expression of ISGs that possess antiviral functions. All of the 32 genes identified in the 
bioinformatics analysis are ISGs and play a role in eliminating viral infections, as such, it 
makes sense that their expression was not induced by wild-type infection due to the IFN-
antagonistic functions of DENV; however, it is interesting that their expression was 
upregulated during persistent infection with v601-4BT66A. Previously, qPCR analysis revealed 
that ISGs such as ISG15 and OASL were significantly activated in H-v601-Per1, H-v601-Per2 
and H-Rep-4BT66A cells compared to control HEK293T and H-Rep cells (Ismail, 2015). The 
author concluded that the NS4BT66A mutation may influence production of chemokines which 
may control viral replication and regulate the maintenance of persistent infection (Ismail, 
2015).  It is also possible that the NS4BT66A mutation does not fully abrogate DENV-mediated 
inhibition of the IFN response, but weakens it, thus allowing ISGs to be expressed and perhaps 
the subset of ISGs that are activated are insufficient for full clearance of the virus.   
Immunofluorescence staining of STAT1 in all different cell lines showed that STAT1 became 
more localised to the nucleus in HEK293T, wild-type DENV-2-infected, H-v601-Per2 and H-
Rep-4BT66A cells upon IFNa treatment compared to equivalent cells that remained untreated. 
This result was expected because addition of IFNa activates the type I IFN response pathway 
which induces translocation of the ISGF3 heterotrimer containing STAT1, STAT2 and IRF9 to 
the nucleus (Ivashkiv and Donlin, 2015). However, there was no significant difference in 
nuclear localisation of STAT1 in H-v601-Per1 or H-Rep cells upon IFNa treatment. In the H-
Rep cells, blocking of nuclear translocation may be a result of the expression of a wild-type 
NS4B protein; NS4B is known to interfere with the type I IFN pathway (Muñoz-Jordan et al., 
2003, 2005), and thus this result may have been observed because of this function of the 
NS4B protein. However, that does not explain why nuclear translocation of STAT1 was 
observed in the wild-type DENV-2-infected cells which also express wild-type NS4B protein. 
Additionally, the pattern of STAT1 distribution observed in uninfected HEK293T cells was 
unexpected as STAT1 should typically only be localised to the cytoplasm in the absence of 
exogenous IFNa because the type I IFN pathway should be inactive. An expected result would 
be more similar to the pattern of STAT2 distribution in uninfected HEK293T cells observed in 
Figure 3.19, yet there was signal corresponding to STAT1 present in the nucleus of uninfected 
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HEK293T cells (Figure 3.17). This may be a result of non-specific binding by the STAT1 
antibody. Ideally, an antibody that specifically detects phosphorylated-STAT1 (pSTAT1) 
should have been used for this experiment, such that STAT1 would only be detectable when 
the type I IFN pathway is active and STAT1 becomes phosphorylated. However, several 
attempts to perform this experiment using an anti-pSTAT1 antibody proved inconclusive due 
to very high background signal and likely non-specific binding detected on each attempt. 
Nevertheless, the anti-STAT1 antibody was still able to detect an accumulation of STAT1 upon 
exogenous IFNa treatment as anticipated.  
Without the addition of exogenous IFNa, compared to uninfected cells, STAT1 was localised 
to the nucleus in H-v601-Per1, H-v601-Per2, H-Rep and H-Rep-4BT66A cells, but more 
localised to the cytoplasm in wild-type DENV-2-infected cells (Figure 3.17). Increased nuclear 
localisation of STAT1 in both persistently-infected cell lines and replicon-containing cells 
without IFNα treatment could suggest that persistent infection with v601-4BT66A virus and 
presence of replicons elicits an immune response to some degree, even without the presence 
of exogenous IFNα to activate the type I IFN signaling pathway. On the other hand, DENV-2 
virus, though it should also have been detected by the host immune response in these cells 
in the absence of exogenous IFNa, may be capable of suppressing this response, thus 
preventing type I IFN pathway activation and inhibiting STAT1 nuclear localisation. 
Following the addition of exogenous IFNa, STAT1 was more localised to the cytoplasm in 
wild-type DENV-2-infected and H-v601-Per1 cells, and more localised to the nucleus in H-
v601-Per2 and H-Rep-4BT66A compared to mock uninfected cells. The results showing that 
wild-type DENV infection inhibited STAT1 activation and translocation to the nucleus (Figure 
3.17) are consistent with a previous study which showed that phosphorylated STAT1 was 
undetectable in 77% of NS4B-expressing cells treated with IFNb (Muñoz-Jordan et al., 2003). 
Additionally, while there was no difference in localisation between uninfected and H-Rep cells, 
STAT1 in H-Rep-4BT66A cells was more localised to the nucleus than in H-Rep cells. This was 
also observed in H-v601-Per2 than in wild-type DENV-2-infected cells. Overall, these results 
suggest that presence of the NS4BT66A mutation may attenuate the ability of the mutated NS4B 
protein in either the v601-4BT66A virus or RepDV-GP2A-NS4BT66A replicon to inhibit the 
translocation of STAT1 proteins to the nucleus of H-v601-Per2 and H-Rep-4BT66A cells. 
However, this effect was not evident in the H-v601-Per1 cells, which suggests that this 
potential effect of the NS4BT66A  mutation in the persistently-infecting virus may be relatively 
mild compared to that observed in the replicon-containing cells.  Additionally, the Thr à Ala 
mutation is located at position 66 in the NS4B protein; it been shown that residues at the N-
terminus are important for IFN signalling inhibition by blocking ISRE promoter activation but 
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residues 77 to 125 were critical (Muñoz-Jordan et al., 2005), therefore perhaps T66 does not 
play a critical function in blocking IFN signalling and the NS4BT66A mutation may not fully 
abrogate this function of the NS4B protein. 
STAT2 clearly translocated from the cytoplasm of untreated HEK293T cells to the nucleus 
with IFNa treatment, which was as expected following activation of the type I IFN pathway 
(Ivashkiv and Donlin, 2015). However, the level of STAT2 signal remained lower in the 
replicon-expressing cells H-Rep and H-Rep-4BT66A than that observed in uninfected HEK293T 
cells both with and without IFNa treatment. This result was not wholly unexpected because 
STAT2 is known to be targeted for proteasomal degradation and its phosphorylation inhibited 
by the DENV NS5 protein (Ashour et al., 2009; Mazzon et al., 2009), and a fully functional, 
wild-type NS5 protein is encoded by both replicon constructs. Thus, there was no observable 
difference in the effect on STAT2 distribution between H-Rep and H-Rep-4BT66A Figure 3.17.  
Using the results from immunofluorescence experiments on STAT1, we hypothesised that this 
NS4BT66A mutation may attenuate the ability of the DENV NS4B protein to inhibit components 
of the type I IFN pathway, thus allowing antiviral ISGs to be expressed as shown by our 
transcriptomics data. Interestingly, ISGs can still be expressed despite the observable 
reduction in STAT2 during infection compared to uninfected cells, with or without the NS4BT66A 
mutation (Figure 3.19). This suggests a STAT2-independent mechanism is potentially 
responsible for activating the expression of ISGs in the persistently-infected cells; this could 
be STAT1-dependent as the NS4BT66A mutation potentially prevents full inhibition of STAT1 
function, or possibly dependent on alternative pathways such as the type II IFN pathway which 
becomes activated in response to IFNg production and, unlike IFNa, is not thought to be 
antagonised by DENV-2 infection (Ho et al., 2005). However, while STAT1-independent 
mechanisms of IFN signalling activation have been described (Blaszczyk et al., 2015), 
evidence of STAT2-independent mechanisms are relatively limited. Consequently, since 
STAT2 is known to be highly important for production of IFNa/b (Blaszczyk et al., 2016), further 
experiments using distinct techniques to IFA should also be performed to determine whether 
STAT2 is completely lost within the cells, or whether, despite being expressed at much lower 
levels than in uninfected cells, it is still present at sufficient levels to activate ISG expression. 
Taken together, these results raise the question of how persistent infection is maintained 
despite the expression of ISGs with antiviral activity. Upregulation of ISGs in H-v601-Per1 and 
H-v601-Per2 cells but not wild-type-infected cells suggests an enhancement of the antiviral 
IFN response to DENV infection during persistent infection compared to wild-type, which could 
represent a potential mechanism by which persistent infection is maintained. Type I IFNs have 
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pleiotropic effects during viral infections and the signalling pathways been shown to 
paradoxically regulate the antiviral response, particularly during chronic viral infections; on one 
hand, the antiviral functions of the type I IFN response are extensive and well-characterised, 
but on the other hand, IFNa/b also has regulatory functions that suppress the immune 
response and can promote viral persistence (Odorizzi and Wherry, 2013; Teijaro, 2016). 
Recently, a direct causal link was found between type I IFN signalling and activated expression 
of ISGs and persistence of lymphocytic choriomeningitis virus (LCMV) infections (Teijaro et 
al., 2013), while in HCV patients an elevated IFN signature can be observed despite chronic 
presence of viral infection (Wieland et al., 2014). It has been suggested that immunoregulatory 
functions of IFNa/b could have evolved during persistent infections to limit damaging 
immunopathology that could result from prolonged IFN pathway activation (Odorizzi and 
Wherry, 2013), such as cytokine storms which are known to play a role in dengue 
pathogenesis. It may be possible that the IFN response is altered between wild-type DENV-2 
and persistent v601-4BT66A infection such that the immunosuppressive function is favoured 
during the latter, potentially to limit immunopathology which could also explain the lack of CPE 
observed in H-v601-Per1 and H-v601-Per2 cell culture.   
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Chapter 4. Anti-DENV drug treatment  
The overall aim of this section of the project was to cure the persistently-infected cells of v601-
4BT66A virus to subsequently examine host cells and any potential defects in specific pathways 
that may have enabled the establishment of a persistent infection.  
4.1. Introduction to anti-DENV drug treatment.  
When Dr. Andrew Davidson and Dr. Rosmani Ismail generated the H-v601-Per1 and H-v601-
Per2 cell lines, infection of naïve cells with the reverse-engineered v601-4BT66A virus caused 
a large percentage of the cell population to display CPE and die. A small percentage of the 
population, however, survived and expanded to confluency but were found to be persistently-
infected. By comparison, infection of the cells with the wild-type virus resulted in 100% cell 
death. It was hypothesised that the cells that became persistently-infected may have 
possessed a cellular defect that, in conjunction with the NS4BT66A viral mutation, enabled the 
establishment of a persistent infection with this strain of DENV in cell culture. As the 
bioinformatic analysis and qPCR validation in Section 3.4. showed, it may be plausible that 
defects in cholesterol biosynthesis pathways could exist which may allow persistent infection 
to occur.  
Drugs that have previously been shown to possess anti-DENV activity were selected to 
attempt to clear v601-4BT66A from the persistently-infected cell lines to ultimately allow the 
study of possible existing cellular defects. 4-hydroxyphenyl retinamide (4-HPR) is a synthetic 
retinoid compound which inhibits steady-state accumulation of DENV genomic RNA, reduces 
infectious virus titre by >100-fold and reduces intracellular viral RNA by 1000-fold in vitro 
compared to untreated, DENV-infected controls (Carocci et al., 2015; Fraser et al., 2014). 
Mycophenolic acid (MPA) is a non-nucleoside inhibitor of inosine monophosphate that 
depletes intracellular guanosine pools by blocking the synthesis of xanthosine 
monophosphate. MPA is used clinically as an immunosuppressant and was found to potently 
inhibit replication of both positive- and negative-strand DENV RNA by between 10- to 1000-
fold with an IC50 of 0.1 µg/ml (Diamond et al., 2002). Ribavirin (RBV) is a guanosine analogue 
that at a concentration of ≥ 200 µM reduced virus titre by nearly 1000-fold. Inhibition of viral 
RNA synthesis by treatment with both MPA and RBV is reversed by addition of exogenous 
guanosine to restore intracellular guanosine pools which suggests that nucleotide depletion is 
likely to be the mechanism of action for inhibition of DENV infection (Diamond et al., 2002; 
Takhampunya et al., 2006). 2’C-methylcytidine (2CMC) is another nucleoside analogue that 
inhibits DENV NS5 polymerase activity, and reduces viral RNA replication (Lee et al., 2015).  
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4.2. Cell viability assays. 
Using existing literature, dosages of each drug that are commonly used in vitro were selected 
and each compound was tested at a wide range of concentrations around this dose for their 
cellular effects using a cell viability assay. This process served to identify maximum 
concentration of each drug that could be used for potentially long-term treatment of the cell 
lines in a subsequent experiment to attempt to clear the persistent infection without causing 
significant CPE. 4-HPR has previously been used at concentrations between 5 and 7.5 µM, 
and does not affect cell viability at up to 10 µM (Carocci et al., 2015; Fraser et al., 2014). In 
vitro treatment with 10 µg/ml MPA reduced virus production by > 6 log, while 25 µg/ml RBV 
reduced virus production by 3 log, however cytostatic effects were observed under treatment 
with ≥10 µg/ml MPA and ≥50 µg/ml RBV which inhibited cell growth by 50% (Diamond et al., 
2002). Treatment of BHK-21 cells expressing a DENV replicon with RBV gave a half maximal 
effective concentration (EC50) of 6.77 ± 1.33 µM and a cytotoxic concentration causing death 
in 50% of viable cells (CC50) value of 75 µM (Hsu et al., 2012; Ng et al., 2007). 2CMC treatment 
at concentrations of 12.5, 25 and 50 µM reduced DENV RNA replication by 20%, 40% and 
80%, respectively and had an IC50 value between 11 and 20 µM and did not affect cell viability 
at concentrations ≤ 50 µM (Lee et al., 2015).  
The MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide) assay is a commonly-
used quantitative cell viability assay that indicates cellular metabolic activity. When added to 
metabolically-active cells, MTT is reduced by mitochondrial dehydrogenases to produce 
purple formazan crystals; this colourimetric change is measured spectrophotometrically at 570 
nm (van Meerloo and Cloos, 2011).  
HEK293T, H-v601-Per1 and H-v601-Per2 cells were seeded into 96 well plates and treated 
with a range of drug doses per row for each drug, in duplicate. After 2 and 4 days, the MTT 
assay was performed and cell viability was measured to determine the concentration of drugs 
that should be used in long-term treatment of all cell types. The % cell viability was calculated 
using the OD values of each cell type at each drug concentration, relative to the OD value 
obtained from HEK293T cells that remained untreated which for the purposes of analysis were 
defined as 100% viable.  
Across all experiments, the viability of H-v601-Per1 cells was significantly lower than the % 
viability of HEK293T cells when analysed after 2 days, ranging from 38.5-45.6% viability 
relative to HEK293T cells, even when left untreated (p = <0.0001). However, the reduction in 
untreated H-v601-Per1 cell viability compared to HEK293T cells was not as great when 
analysed after 4 days (20-23%). This potentially suggests that it takes longer for this cell line 
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to start propagating following seeding into a new cell culture dish compared to the other cell 
lines, particularly when compared to the uninfected, untreated HEK293T cells which were 
used as a reference for calculating % cell viability. Alternatively, there may be greater cytotoxic 
effects in the cells that were analysed after 2 days of drug treatment, following which they 
were able to recover slightly by the 4-day timepoint. As it was planned to treat the cells with 
drugs for a longer time period, the 4-day timepoint was considered more representative of the 
intended long-term treatment of the cells in subsequent experiments, therefore the results 
from the 4-day experiments were used to determine which concentrations of drugs were 
selected for subsequent experiments.  
4-HPR treatment at the lowest concentration of 0.75 µM reduced cell viability of H-v601-Per1 
and H-v601-Per2 by 17-24% after 2 days and 8-15% after 4 days, relative to the viability of 
each cell line when left untreated. Subsequent increases in 4-HPR concentration from 0.75 
µM up to 5 µM only reduced viability by 0.4-4.4% after 4 days in the H-v601-Per1 and H-v601-
Per2 cells (Figure 4.1). Thus, 4-HPR was selected for use at concentrations of 5, 2.5 and 1.25 
µM for long-term treatment of persistently-infected cells.  
MPA treatment at the lowest concentration tested of 0.75 µg/ml reduced the viability of 
HEK293T, H-v601-Per1 and H-v601-Per2 by 52.7%, 20% and 41%, respectively, after 2 days, 
and after 4 days by 40%, 47.1% and 24.7%, respectively, compared to the same cell lines that 
were left untreated at each time-point. However, subsequent increases in concentration of 
MPA from 0.75 µg/ml up to 20 µg/ml after 4 days only further reduced the % cell viability of all 
cell lines by between 2.3-11.9% (Figure 4.1). The concentrations at which % cell viability was 
greatest after 4 days ranged between 2.5-10 µg/ml, so to avoid potentially using a 
concentration of MPA that was too cytostatic to cells over longer periods of time, doses of 5, 
2.5 and 1.25 µg/ml were selected for subsequent experiments.  
With RBV treatment, there was a large difference in % cell viability between cells analysed 
after 2 and 4 days. After 4 days of treatment the largest drop in cell viability compared to 
untreated cells was in the H-v601-Per1 cell line at the lowest RBV concentration of 12.5 µM 
which fell by 22.3% from 79.2% to 56.9%, and then decreased more gradually with increasing 
concentrations of drug down to 33.9% at 300 µM. In the HEK293T cells there was a large 
reduction in % cell viability from 86% at 100 µM to 62.4% at 200 µM (Figure 4.1), therefore in 
subsequent experiments RBV was used at 50 and 100 µM to avoid high cytotoxicity over 
longer periods of time.  
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Treatment with 2CMC also showed a large difference in overall cell viability between the two 
time-points. After 4 days of treatment, the viability of HEK293T and H-v601-Per1 cells 
remained relatively constant at increasing concentrations of 2CMC; HEK293T cells were 
81.7% and 87% viable, and H-v601-Per1 cells were 68.9% and 74.3% viable at concentrations 
of 1.25 and 50 µM, respectively. H-v601-Per2 cells were 83.3% and 89.5% viable at 1.25 and 
25 µM, respectively, but the % cell viability decreased further with 50 µM treatment to 65.3%. 
Therefore, concentrations of 25 and 50 µM 2CMC were selected for subsequent experiments.  
4.3. Long-term treatment with 4-HPR and MPA.  
HEK293T, H-v601-Per1 and H-v601-Per2 cells were seeded into T25 culture flasks, incubated 
overnight, and treated with 4-HPR (5, 2.5, 1.25 µM) and MPA (5, 2.5, 1.25 µg/ml) the following 
day. Over the course of the experiment, cells were passaged when they reached ~80% 
confluency which varied in frequency between the treatments and cell lines. Additionally, 
media was changed once a week and the drugs were replenished if the cells were not 
passaged within that time to ensure that the drugs in the media remained active.  
Cells treated with 5 µM 4-HPR or 5 µg/ml MPA showed very strong CPE following addition of 
drugs and were cytostatic, thus these cell lines were terminated after 7 days of drug treatment. 
2.5 and 1.25 µg/ml MPA-treated H-v601-Per1 and H-v601-Per2 cells also showed CPE and 
were mostly cytostatic after 8 days of drug treatment. To determine if the virus was cleared by 
the drug treatment, 21 days post-drug addition, supernatant samples were taken and analysed 
for the presence of viral RNA. Within this time, MPA-treated cells were cytostatic and thus 
were not passaged, however HPR-treated cells were passaged once during this time. Only 
the cells treated with the higher concentration of 4-HPR and both concentrations of MPA were 
analysed to determine whether there had been any loss of virus. All drug-treated H-v601-Per1 
and H-v601-Per2 samples still had viral RNA present in the supernatant samples as 
determined by non-quantitative RT-PCR (Figure 4.2A). After this analysis, MPA-treated cells 
were terminated because of the unsuccessful clearance of virus and strong CPE observed 
which meant the cells were completely cytostatic. After 40 days of continued drug treatment 
which included 5 passages of each cell line at both concentrations of 4-HPR, intracellular RNA 
was extracted from untreated and 4-HPR-treated cells, and v601-4BT66A RNA was present in 
all H-v601-Per1 and H-v601-Per2 cells (Figure 4.2B). Thus, it was concluded that the doses 
of 4-HPR and MPA used, in combination with cell cytotoxicity effects were insufficient to clear 
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Figure 4.1: Cell viability of HEK293T, H-v601-Per1 and H-v601-Per2 cells when treated with 4-
HPR, MPA, RBV and 2CMC drugs. HEK293T, H-v601-Per1 and H-v601-Per2 cells were seeded into 
96 well plates at 3 x 104 cells per well and incubated for 16 h before appropriate concentrations of drugs 
were added to wells in duplicate. 2 and 4 days post-treatment, the Vybrant® MTT Cell Proliferation 
Assay Kit was used according to manufacturer’s instructions and colourimetric change was measured 
with a SpectraMax 190 Microplate Reader at 570 nm. Mean % cell viability of each sample was 
calculated as a percentage of the OD reading from untreated HEK293T cells which was defined as 





Figure 4.2: Presence of v601-NS4BT66A in 4-HPR- and MPA-treated cell lines after 21 and 40 days. 
3 x 105 HEK293T, H-v601-Per1 and H-v601-Per2 cells were seeded into T25 flasks for 1 day, then 4-
HPR and MPA drugs were added to the cell culture medium the following day. (A) 21 days post-drug 
inoculation, extracellular RNA was extracted from the supernatant of cells treated with 2.5 µM 4-HPR 
and 2.5 and 1.25 µg/ml MPA. (B) 40 days post-drug inoculation, intracellular RNA was extracted from 
the supernatant of untreated cells and cells treated with 2.5 and 1.25 4-HPR. RT-PCR was performed 
on RNA samples to detect presence of the v601-4BT66A virus using DENV NS4B gene-specific primers, 
DV2_6823 and DV2_7295r. Agarose gel electrophoresis was performed to detect the RT-PCR product 
(~500 bp) in each sample; product size was estimated using a GeneRuler 1 kb Plus DNA ladder.  
 
 
4.4. Long-term treatment with RBV and 2CMC.  
HEK293T, H-v601-Per1, H-v601-Per2, H-Rep and H-Rep-4BT66A cells were seeded into cell 
culture flasks, and the following day RBV (100, 50 µM) and 2CMC (50, 25 µM) were added to 
the medium. H-Rep and H-Rep-4BT66A cells were included to determine whether replicon 
constructs could be cleared from the cells as well as the v601-4BT66A virus. Cells were 
passaged when they reached ~80% confluency, and media changed once a week if the cells 
were not passaged in that time. H-Rep and H-Rep-4BT66A cells were also treated in separate 
flasks with puromycin added during each passage to select for cells that were still expressing 
the replicon genomes; this allowed us to investigate whether any reduction in replicon RNA 
detection was due to possible attrition over time or as a result of drug treatment. 
The cells did not immediately show CPE, but after 3 weeks of drug treatment which included 
1 round of passaging and an additional change of media to introduce fresh drugs, the cells 
treated with 50 µM of 2CMC were cytostatic and were terminated. Samples treated with 100 
µM RBV grew as well as those treated with 50 µM, so samples treated with the higher 
concentration of RBV were analysed for subsequent experiments. RNA was analysed from 
supernatant and intracellular RNA samples at various time points over a 3-month period of 
ongoing drug-treatment which included a total of 14 rounds of passaging for each cell line. 
A      B   
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After 3 months, intracellular RNA was extracted and analysed by qPCR using primers specific 
for the 3’UTR of the viral genome. In the H-v601-Per1 and H-v601-Per2 cell lines, neither of 
the drug treatments cleared the virus and viral RNA was detected in all samples. For analysis 
purposes, the amount of viral RNA detected in the H-Rep samples was used as a calibrator 
against which the other samples were compared to calculate their relative expression fold 
change. The relative fold change of DENV 3’UTR amounts in uninfected HEK293T cells 
ranged from 9.1 x 10-5 to 0.0025 (Figure 4.3).  The H-Rep-4BT66A cells treated with 100 µM 
RBV were potentially free of the replicon RNA with a relative fold change of 0.0019, while 
2CMC treatment also reduced the levels of replicon RNA in H-Rep-4BT66A cells to 0.38. 
However, in the H-Rep-4BT66A cells, replicon RNA was also significantly decreased in the 
untreated cell lines with a relative fold change of 0.049, but was still detectable in puromycin-
treated cell lines with a relative fold change of 1.60. Therefore, it was difficult to determine 
whether the loss of replicon RNA observed in RBV- or 2CMC-treated H-Rep-4BT66A cells was 
due to the effects of the drugs or to natural attrition of the replicon RNA. The level of replicon 
RNA was reduced in RBV-treated H-Rep cells with a relative fold change of 0.23, yet still 
present in both untreated and puromycin-treated H-Rep cells, which suggests that the 
reduction in replicon RNA expression in these cells was possibly due to the effects of RBV.  
While the replicon RNA was cleared from H-Rep and H-Rep-4BT66A cells treated with RBV, the 
primary aim of the experiment, to clear the persistently-infecting virus, was unsuccessful as 
the v601-4BT66A virus was still present in both cell lines despite the constant presence of either 
RBV or 2CMC. Therefore, the long-term drug treatment experiment was terminated and the 
viral and replicon RNA sequences determined to identify any mutations that have arisen as a 





Figure 4.3: Presence of v601-NS4BT66A, RepDV-GP2A, or RepDV-GP2A-NS4BT66A RNA after 3 
months of treatment with RBV and 2CMC drugs. HEK293T, H-v601-Per1, H-v601-Per2, H-Rep and 
H-Rep-4BT66A cells were cultured in T25 flasks for a total period of 3 months, either remaining untreated, 
or in the constant presence of 100 µM RBV, 25 µM 2CMC, or 3.5 µg/ml puromycin in the culture 
medium. Intracellular RNA was extracted from each sample, 200 ng was converted to cDNA using 
random hexamer primers, and qPCR was performed using 3’UTR-specific primers, DV_3’UTR_f and 
DV_3’UTR_r. Samples were analysed in triplicate on each plate. GAPDH was used as a reference gene 
for all reactions. Relative gene expression was calculated using the ΔΔCt method using Ct values from 
untreated H-Rep cells as a calibrator.  
 
4.5. Sequencing for resistance mutations in drug-treated samples.  
Previous experiments were unsuccessful in clearing v601-4BT66A virus from H-v601-Per1 or 
H-v601-Per2 cell lines using RBV or 2CMC treatments over a 3-month period. Based on these 
results, samples were selected for viral genome sequencing that still clearly had virus or 
replicon RNA present at the end of the 3-month period to identify any resistance mutations: 
H-v601-Per1 and H-v601-Per2 untreated, treated with 100 µM RBV or 25 µM 2CMC, and H-
Rep and H-Rep-4BT66A treated with 3.5 µg/ml puromycin or 25 µM 2CMC. Total intracellular 
RNA was extracted from each sample and RT-PCR performed to generate cDNA products 
corresponding to 6 fragments of the v601-4BT66A genome, or 4 fragments of the replicon RNA 
construct. The fragments were sequenced using 3-4 primers per fragment. An overview of the 
workflow for sequencing the whole viral genome is shown in Figure 4.4.   
79 mutations that potentially arose as a result of drug selection pressure are shown in Table 
4.1. Many of the mutations that were present in the drug-treated samples were also present 
in the untreated samples, indicating that these particular mutations are did not arise as a result 
of the selection pressure conferred by constant presence of the drug; 10 mutations that were 
unique to drug-treated samples are highlighted with asterisks in Table 4.1.  
Interestingly, in the virus persistently-infecting the H-v601-Per1 cells that either remained 
untreated or were treated with 100 µM RBV, the NS4BT66A mutation was lost, while the v601-
4BT66A virus treated with 25 µM in the H-v601-Per1 cells retained this mutation. However, in 
the H-v601-Per2 cells both of the A à G nucleotide mutations at positions 7020 (Leu à Leu) 






Figure 4.4: Overview of workflow for sequencing the whole viral genome of drug-treated 
samples. HEK293T, H-v601-Per1 and H-v601-Per2 cells were treated with 100 µM or 25 µM 2CMC, 
and H-Rep and H-Rep-4BT66A cells were treated with 25 µM 2CMC, or remained untreated, for 3 months. 
Total intracellular RNA was extracted from cells and cDNA was synthesised by RT-PCR using DENV-
2-specific primers to generate 6 fragments of the DENV-2 genome. cDNA of replicon RNA was 
synthesised to generate only fragments C onwards as the eGFP-PAC fusion protein-encoding 
sequence that replaced the structural genes could not be sequenced. Each of the fragments was sent 
for Sanger sequencing at the BGI with 3-4 DENV-2-specific primers. Sequence alignment to the DENV-







Table 4.1: Mutations identified in the DENV-2 genome of all drug-treated samples. H-v601-Per1, 
H-v601-Per2, H-Rep and H-Rep-4BT66A cells were cultured for 3 months in the constant presence of 
either RBV or 2CMC anti-viral drugs. Intracellular RNA was extracted, and cDNA synthesis performed 
using DENV-2-specific primers to generate 6 fragments that were sequenced using 3-4 DENV-2-
specific primers (Figure 4.4) by Sanger sequencing at Eurofins genomics. Sequence analysis was 
performed using Sequencher v.5.1. Sequences were compared to the DENV-2 New Guinea C wild-
type sequence (NCBI gene accession number: AF038403.1).  
 






















Per1  Untreated 
168 TCG à TCA/G Ser C 24 
418 CTG à A/CTG Leu à Met C 108 
483 AGT à AGA/T Ser à Arg prM 15 
485 AGA à AT/GA Arg à Ile prM 16 
1779 GGA à GGG/A Gly E 281 
3964 AAC à CAC Asn à His NS2A 163 
6437 GCA à GTA Ala à Val NS4A 21 
6443 GAC à GGC Asp à Gly NS4A 23 
6556 CTG à A/CTG Leu à Met NS4A 61 
6629 ATG à ACG Met à Thr NS4A 85 
6730 CTT à TTT Leu à Phe NS4A 119 
6818 ACC à ATC Thr à Ile NS4A 148 
7020 CTA à CTG Leu NS4B 65 





168 TCG à TCA/G Ser C 24 
1779 GGA à GGG/A Gly E 281 
3964 AAC à C/AAC Asn àHis NS2A 163 
6437 GCA à GTA Ala à Val NS4A 21 
6556 CTG à A/CTG Leu à Met NS4A 61 






7020 CTA à CTG Leu NS4B 65 
7096 GTT à TTT Val à Phe NS4B 91 





982* TCA à GCA Ser à Ala E 16 
2312* ATA à ACA Ile à Thr E 459 
6437 GCA à GTA Ala à Val NS4A 21 
6629 ATG à AC/TG Met à Thr NS4A 85 
6818 ACC à ATC Thr à Ile NS4A 148 
7020 CTA à CTG Leu NS4B 65 
7021 ACA à G/ACA Thr à Ala NS4B 66 
7510* TAC à CAC Tyr à His NS4B 229 
7562* ACG à ATG Thr à Met NS4B 246 





112 AAA à T/AAA Lys à Stop C 6 
982 TCA à G/TCA Ser à Ala E 16 
5198 GTC à GC/TC Val à Ala NS3 226 
6437 GCA à GTA Ala à Val NS4A 21 
6818 ACC à ATC Thr à Ile NS4A 148 
6915 ATA à ATG Ile à Met NS4B 30 
7020 CTA à CTG Leu NS4B 65 
7021 ACA à GCA Thr à Ala NS4B 66 





894* GCC à GCT/C Ala M 61 
6915 ATA à ATG Ile à Met NS4B 30 








4238* GGG à GC/GG Gly à Ala NS2B 36 
6437 GCA à GT/CA Ala à Val NS4A 21 
6818 ACC à AT/CC Thr à Ile NS4A 148 
7020 CTA à CTG Leu NS4B 65 




3665 ACT à ATT Thr à Ile NS2A 63 
4254 TGC à TGT Cys NS2B 41 
4258 GTG à ATG Val à Met NS2B 43 
5254 CCA à TCA Pro à Ser NS3 245 
6639 ATA à ATG Ile à Met NS4A 88 
7556 ACC à ATC Thr à Ile NS4B 244 




4258 GTG à ATG Val à Met NS2B 43 
6639 ATA à ATG/A Ile à Met NS4A 88 
7096 GTT à T/GTT Val à Phe NS4B 91 





3791 ACC à AT/CC Thr à Ile NS2A 105 
4300 GCC à A/GCC Ala à Thr NS2B 57 
4397 GAA à GC/AA Glu à Ala NS2B 89 
6733 ATT à G/ATT Ile à Val NS4A 120 
7020 CTA à CTG Leu NS4B 65 
7021 ACA à GCA Thr à Ala NS4B 66 
7178 TAT à TG/AT Tyr à Cys NS4B 118 
7556 ACC à AT/CC Thr à Ile NS4B 244 






4.6. Discussion of drug-treatment.  
The aim of this chapter was to cure persistently-infected cells of the v601-4BT66A virus using 
drugs previously shown to have anti-DENV properties which would allow further analysis of 
the cells; in particular, investigation of any cellular pathways that may be defective compared 
to control cells which may have facilitated establishment of persistent infection when the cells 
were first infected with v601-4BT66A. The drugs 4-HPR, MPA, RBV and 2CMC were chosen 
for long-term treatment of the persistently-infected cell lines, H-v601-Per1 and H-v601-Per2, 
and replicon-containing cell lines, H-Rep and H-Rep-4BT66A because they have been 
previously shown to effectively reduce DENV infection in vitro. Unfortunately, none of these 
drugs were able to clear the v601-4BT66A virus from H-v601-Per1 or H-v601-Per2, and the only 
cell line that was potentially cleared of its persistent infection was H-Rep with constant 
presence of 100 µM RBV. However, the result may be explained by the fact that the v601-
4BT66A virus had already firmly established a persistent infection, while previous studies mostly 
tested the drugs for their ability to prophylactically inhibit DENV infection (Carocci et al., 2015; 
Diamond et al., 2002; Fraser et al., 2014; Lee et al., 2015). There may also be inherent 
differences in the characteristics of the wild-type and persistently-infecting viruses which affect 
the anti-viral properties of the drugs when used against v601-4BT66A. Additionally, while the 
drugs were previously reported to effectively reduce DENV infection, complete clearance of 
DENV was not achieved; treatment with 2CMC at concentrations up to 50 µM reduced DENV 
RNA levels to 15-20% relative to RNA levels in untreated cells (Lee et al., 2015). Thus, it is 
possible that there was a reduction in DENV infection upon treatment with the drugs, but the 
remaining virus population was sufficient to allow the development of mutations that potentially 
conferred resistance to the drugs and enabled proliferation.  
To investigate whether the persistent-infecting virus or replicons had acquired new mutations 
that may have conferred resistance to the antiviral drugs, the viral or replicon RNA from cell 
lines in which virus or replicon RNA was still present after 3 months of constant passaging in 
the presence of the drugs RBV or 2CMC were sequenced.   
  
6733 ATT à GTT Ile à Val NS4A 120 
7020 CTA à CTG Leu NS4B 65 
7021 ACA à GCA Thr à Ala NS4B 66 
7178 TAT à TGT Tyr à Cys NS4B 118 




Table 4.1 shows the mutations from wild-type DENV-2 that were present in the v601-4BT66A 
virus genome or replicon RNA from all samples. Loss of the NS4BT66A mutation in the H-v601-
Per1 cells that remained untreated or were treated with RBV was unexpected as reversion 
had not been observed in previous studies. However, when sequenced, the NS4BT66A 
mutation was sometimes presented as a mixed peak of occurrence (see Table 3.2). 
Additionally, these particular cell lines were passaged for a total time of 4 months, whereas as 
a general rule the cell line would be terminated after 2.5-3 months of passaging. Thus, it is 
possible that the NS4BT66A mutation in the v601-4BT66A virus was present in a mixed population 
of cells and reverted naturally over time.  
 
 
Chapter 5. General summary  
This project focused on a mutated strain of DENV-2, v601-4BT66A, that contained two 
mutations in the NS4B gene allowing persistent infection in a variety of cell types in vitro. There 
are limited reports of persistent infection with DENV from natural infection or in vivo studies 
(Kurane et al., 1990; Nakao et al., 1989), however other members of the Flaviviridae family 
are known to cause persistent infections (Gritsun et al., 2003; Large et al., 1999; Murray et al., 
2010; Poidinger et al., 1991; Ravi et al., 1993). Thus, the discovery of a persistently-infecting 
strain of DENV by members of our research group which preceded this project is of great 
interest. The more specific purpose of this project was to investigate the mechanisms behind 
how persistent infection was established, either by the NS4BT66A mutation or by any defects in 
cellular pathways in a surviving subset of cells upon infection with v601-4BT66A that allowed 
persistent infection to occur.  
The first stage of this project was to confirm that the v601-4BT66A virus and RepDV-GP2A-
NS4BT66A replicons contained the NS4BT66A mutation, and that H-v601-Per1, H-v601-Per2, H-
Rep and H-Rep-4BT66A cell lines were persistently-infected with virus or stably expressing 
replicons (Chapter 3). This was carried out by sequencing the NS4B gene of the replicons or 
v601-4BT66A viruses, which showed that the NS4BT66A mutation was still present in all samples 
and other mutations found are shown in Table 3.1 and Table 3.2. To confirm the identity of the 
cell lines, IFAs were performed to detect the NS1 protein in H-Rep and H-Rep-4BT66A (Figure 
3.2) and the E protein in the H-v601-Per1 and H-v601-Per2 cell lines, because the E protein 
is not encoded by the replicon RNA (Figure 3.3).  
The next step was to utilise a transcriptomics dataset, which was previously generated and 
compiled by other members of the research group, to study whether any cellular pathways are 
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differentially expressed in the H-v601-Per1 and H-v601-Per2 cell lines when compared to 
Mock, uninfected HEK293T cells and to inform the design of subsequent experiments. The 
transcriptomics data was analysed using online bioinformatics tools such as DAVID and 
STRING.  
Genes involved in host cholesterol biosynthesis pathways were downregulated by at least 2-
fold in the persistently-infected cell lines relative to Mock, but also upregulated during wild-
type DENV-2 infection. This was particularly interesting because it may represent a pathway 
that was defective in the cells which allowed establishment of persistent infection, however, 
during wild-type infection it may be targeted for modulation by the virus which suggests it is 
potentially important for progression of infection. qPCR analysis validated the findings of 
transcriptomics analysis in that HMGCR, HMGCS1, IDI1 and MSMO1 were significantly 
downregulated in at least one of the persistently-infected cell lines compared to the uninfected 
cells. However, the finding from the transcriptomics analysis that these genes were 
significantly upregulated during wild-type DENV-2 infection was not confirmed by qPCR 
analysis, thus, the results were inconsistent and further validation would be required. Further 
investigation into the effect of persistent infection on host lipid metabolism pathways would be 
interesting, particularly the effect of wild-type and persistent infection on the activity of SREBP 
transcription factors which are known to regulate the expression of at least six of the identified 
genes, and on total intracellular cholesterol levels.  
Conversely, the transcriptomics data revealed that genes involved in the type I IFN response 
were upregulated by at least 2-fold during persistent infection, when compared to Mock cells 
or wild-type DENV-2-infected cells. IFA results of the localisation of STAT1 proteins in each 
cell line suggest that the NS4BT66A mutation may have an effect on the ability of NS4B to inhibit 
the translocation of STAT1 proteins to the nucleus of H-v601-Per2 and H-Rep-4BT66A, but not 
H-v601-Per1 cells. Loss of this STAT1 attenuation may explain why ISGs are upregulated 
during persistent infection compared to Mock or wild-type DENV-2-infected cells, and this must 
be via a mechanism that is STAT2-independent or still operative with low levels of STAT2 as 
this was degraded in cells expressing replicons that both encoded and did not encode the 
NS4BT66A mutation. It would be interesting to investigate further the mechanism by which ISGs 
specifically become upregulated during persistent infection, or the functional activity of STAT1 
and whether this is altered between mock, wild-type, and persistent infection.  
Long-term drug treatment to clear the persistently-infected cells of virus or replicon RNA was 
largely inconclusive, and while there was some reduction in replicon RNA observed in the 
RBV-treated cell lines, the experiment was particularly unsuccessful in clearing the 
persistently-infecting virus from H-v601-Per1 and H-v601-Per2 cells. However, this allowed 
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sequencing analysis to be performed on viruses or replicon constructs that had been treated 
for up to 3 months with RBV or 2CMC to identify potential mutations conferring resistance to 
the drugs. Of the 79 mutations identified, 10 mutations were unique to virus or replicon RNA 
isolated from cells treated with either RBV or 2CMC.  
Overall, this study has expanded understanding surrounding the discovery of a novel, 
persistently-infecting DENV-2 strain, v601-4BT66A, however the precise mechanisms enabling 
establishment of a persistent infection in vitro remain elusive. Further experiments to advance 
the current understanding of this persistently-infecting DENV-2 strain and its effect on the host 
cholesterol biosynthesis and type I IFN pathways are required, and potential investigation 
routes based on the work carried out during this study are explored in more detail in Section 
3.6. In the future, investigation into the mechanism that enabled persistent infection to initiate 
and be maintained should remain a priority, as well as studying the altered function of the 
NS4BT66A mutation compared to wild-type. This may involve considering alternative pathways 
to those focused on during this study that may be differentially affected by wild-type and 
persistent infection. Previous work using the same v601-4BT66A strain has suggested that the 
unfolded protein response (UPR) may play a role, and this could also justify further 
investigation (Ismail, 2015). Additionally, the discovery of a DENV-2 strain that causes 
persistent infection could have potential implications in the context of natural infections. Since 
flaviviruses are known to cause persistent infections it should not be unreasonable to 
anticipate that DENV could also be capable of this. In the future, in vivo experiments using 
v601-4BT66A may be warranted to determine whether the persistently-infecting phenotype can 
also be observed using animal models, and whether this could have potential ramifications in 






2CMC  2’C-methylcytidine  
4-HPR  4-hydroxyphenylretinamide  
Ab  antibody 
ACTB  actin β  
ADE  antibody-dependent enhancement  
Ala  alanine 
ANOVA  analysis of variance  
AP-1  activating protein 1 
Asp  aspartic acid 
ATPase adenosine triphosphatase  
BHK  baby hamster kidney  
BLASTn Nucleotide Basic Local Alignment Search Tool 
BME  β-Mercaptoethanol 
BSL3  biological safety level 3 
bp  base pairs  
C  capsid  
cDNA  complementary deoxyribonucleic acid  
c-GAS  cyclic GMP-AMP synthase 
CM  convoluted membrane  
CO2   carbon dioxide  
CPE  cytopathic effect 
DAPI  4',6-diamidino-2-phenylindole 
DAVID  Database for Annotation, Visualisation and Integrated Discovery  
DC  dendritic cell 
DC-SIGN dendritic cell-specific intercellular adhesion molecular-3-grabbing non-integrin 
DENV  Dengue virus  
DF  dengue fever  
DHF  dengue haemorrhagic fever  
DMEM  Dulbecco’s Modified Eagle’s Medium 
DMSO  dimethyl sulfoxide  
DNA   deoxyribonucleic acid  
DNase  deoxyribonuclease  
dsRNA  double-stranded RNA  
DSS  dengue shock syndrome 
dNTP  deoxynucleotide 
E  envelope 
EDTA  ethylenediaminetetraacetic acid 
eGFP  enhanced green fluorescent protein  
ER  endoplasmic reticulum 
FASN  fatty acid synthase 
FBS   foetal bovine serum 
g  grams 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GFP  green fluorescent protein  
h  hours 
HCV  hepatitis C virus  
His  histidine 
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase 
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 
hpi  hours post-infection 
IDI1  isopentenyl-diphosphate delta isomerase 1 
IFA  immunofluorescence assay 
IFITM  interferon-inducible transmembrane proteins  
IFN  interferon 
IFNAR  type I interferon receptor 
IFNα  interferon alpha 
IFNα-  interferon-α negative  
IFNα+  interferon-α positive  
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IgG  immunoglobulin G  
IL  interleukin 
INSIG1  insulin-induced gene 1 
IRF9  interferon regulatory factor 9  
ISG  interferon-stimulated gene 
ISGF3  interferon-stimulated gene factor 3  
ISRE  interferon-stimulated response element  
JAK1  Janus kinase 1 
JEV  Japanese encephalitis virus  
kDa  kilodaltons 
l   litres  
LD  lipid droplet  
Leu  leucine 
M  membrane 
mAb  monoclonal antibody 
MDA5  melanoma differentiation-associated gene 5  
MDCK  Madin-Darby canine kidney 
Met  methionine 
mg  milligrams  
min   minutes 
ml  millilitres  
MOI  multiplicity of infection  
MPA  mycophenolic acid  
MR  mannose receptor 
MSMO1 methylsterol monooxygenase 1 
MTase  methyltransferase domain 
MVD  mevalonate (diphospho) decarboxylase 
MVE  Murray Valley encephalitis  
NCR  non-coding region  
NFκB  nuclear factor kappa-light chain-enhancer of activated B cells 
ng  nanograms  
NGC  New Guinea strain 
NK  natural killer 
NS  non-structural  
NS1  non-structural protein 1  
NS2A  non-structural protein 2A 
NS2B  non-structural protein 2B 
NS3  non-structural protein 3 
NS4A  non-structural protein 4A 
NS4B  non-structural protein 4B 
NS5  non-structural protein 5 
NTC  no-template control 
NTPase nucleotide triphosphatase  
ORF  open reading frame  
PAC  puromycin N-acetyltransferase  
PAMP  pathogen-associated molecular patterns 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction  
PFA  paraformaldehyde  
PKR  dsRNA-dependent kinase protein 
pmol  picomoles   
prM/M  pre-membrane/membrane 
PRR  pathogen recognition receptor 
pSTAT1 phosphorylated signal transducer and activator of transcription 1 
pSTAT2  phosphorylated signal transducer and activator of transcription 2 
qPCR  quantitative real-time polymerase chain reaction 
RBV  ribavirin 
RC  replication complex  
RdRp  RNA-dependent RNA polymerase  
RIG-1  retinoic-acid-inducible gene 1  
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RNA  ribonucleic acid  
RNase  ribonuclease  
RTPase RNA triphosphatase  
RT  reverse transcription  
RT-PCR reverse-transcriptase polymerase chain reaction   
SQLE  squalene epoxidase 
sec   seconds 
ssRNA   single-stranded RNA  
STAT1  signal transducer and activator of transcription 1 
STAT2  signal transducer and activator of transcription 2 
STING  stimulator of interferon genes  
STRING Search Tool for the Retrieval of Interacting Genes/Proteins  
TBE  tris/borate/ethylenediaminetetraacetic acid 
TBEV  tick-borne encephalitis virus  
TGN  trans-Golgi network 
Thr  threonine 
TLR  toll-like receptor 
TNF  tumour necrosis factor 
Tyk2  tyrosine kinase 2 
U  units  
UBR4  ubiquitin ligase E3 recognin 4 
UTR  untranslated region  
v/v  volume per volume percent  
V  volts  
V-ATPase vacuolar ATPase 
Val  valine 
VLDL  very low-density lipoprotein  
VP  vesicle packet  
w/v  weight per volume percent  
WHO  World Health Organisation  
WNV  West Nile virus  
WT  wild-type 
x g   times gravity 
ΔΔCt  double-delta cycle threshold 
α   alpha 
β  beta  
µg  micrograms 
µl   microlitres  





HEK293  human embryonic kidney 293 
H-v601-Per1   HEK293T cells persistently-infected with v601-4BT66A; cell line 1 
H-v601-Per2   HEK293T cells persistently-infected with v601-4BT66A; cell line 2 
H-v601   HEK293T cells infected with v601  
H-Rep   HEK293T cells containing pRepDV-GP2A replicons 
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Supplementary material.  
Supplementary Table 1: Genes downregulated in H-v601-Per1 and H-v601-Per2 cells, and upregulated in H-v601 cells, relative to mock. Pairwise 
comparisons between the transcriptome of HEK293 (Mock), H-v601-Per1, H-v601-Per2, and H-v601 cells was performed. All genes that were differentially 
expressed by at least two-fold in at least one pairwise comparison were identified, and from these, 164 genes that were downregulated in H-v601-Per1 and H-
v601-Per2, and upregulated in H-v601, relative to mock, were further identified. “Expression value” indicates the value reads derived from the transcriptomics 
sequencing, indicating level of gene expression; “Log2 fold change” indicates the fold difference in gene expression from Sample A vs. Sample B.  
Gene 
Expression value Log2 fold change 
Mock H-v601-Per1  
H-v601-
Per2 H-v601 H-Rep 
H-Rep-
4BT66A  
Mock vs.  
H-v601 
Mock vs.  
H-v601-
Per1  









ALDH1A2 27.4431 22.5445 15.6866 39.0591 46.1925 29.9937 0.509216 -0.283669 -0.806913 0.792885 1.31613 
ARL17A 0.686765 0.383318 0.582039 0.922575 0.770011 0.568848 0.42585 -0.841275 -0.238699 1.26712 0.664549 
ARMCX4 0.431108 0.108809 0.373924 0.791748 0.005192 0.007628 0.87699 -1.98625 -0.205306 2.86324 1.0823 
BMPER 0.530769 0.390212 0.278734 0.811001 0.241092 0.169452 0.61162 -0.443826 -0.929193 1.05545 1.54081 
C8orf34 1.21281 0.761691 0.821389 1.80656 0.515554 0.458926 0.574889 -0.671075 -0.562215 1.24596 1.1371 
CCNG2 6.00136 4.43303 4.62964 9.33893 5.36773 4.61509 0.637968 -0.436996 -0.37439 1.07496 1.01236 
CETN3 38.8415 27.8694 35.9782 63.8936 42.5858 27.6015 0.718074 -0.478916 -0.110474 1.19699 0.828547 
COL2A1 6.9222 3.42476 3.78209 7.63417 0.023382 0.024413 0.141241 -1.01523 -0.872047 1.15647 1.01329 
CSTF3 74.147 47.9646 64.7698 104.472 65.1272 61.4391 0.494652 -0.628419 -0.195068 1.12307 0.68972 
DFNB59 1.47376 0.847432 0.843055 2.02295 0.637803 0.61347 0.45696 -0.79833 -0.805801 1.25529 1.26276 
DMC1 12.4989 10.3501 12.345 24.2723 11.7505 9.28562 0.957508 -0.272151 -0.017876 1.22966 0.975384 
EYA1 2.44403 1.64507 1.42063 3.24436 3.81804 4.44176 0.408673 -0.571113 -0.782734 0.979786 1.19141 
FABP5 7.62246 5.01068 6.14778 11.0871 13.9931 16.9905 0.540547 -0.605251 -0.31019 1.1458 0.850738 
FAM150A 4.9985 2.31651 3.67517 9.05442 0.22936 0.556731 0.857128 -1.10954 -0.443684 1.96667 1.30081 
FAM173B 6.97858 4.62885 5.11443 9.29097 5.16271 4.18649 0.412895 -0.59228 -0.448359 1.00518 0.861254 
FAM3C 5.3898 3.42242 4.22822 7.08404 7.29714 6.32945 0.394342 -0.655213 -0.350181 1.04955 0.744522 
FLVCR1-AS1 2.43812 2.28869 2.05627 4.77429 2.43523 1.71498 0.969516 -0.0912492 -0.245739 1.06077 1.21525 
FOXB1 1.73221 0.96462 0.846749 2.09142 0.820184 1.22152 0.271869 -0.844581 -1.03261 1.11645 1.30448 
GATA6-AS1 1.24874 0.780959 1.18482 1.8609 0.282028 0.428935 0.575525 -0.677155 -0.075808 1.25268 0.651334 
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GJA1 22.1063 14.6298 17.7361 33.5795 39.612 29.9324 0.603123 -0.595549 -0.317768 1.19867 0.920892 
GMFG 0.346512 0.147561 0.110066 0.607606 0.158576 0.191808 0.810229 -1.23159 -1.65454 2.04182 2.46477 
GTF2A1 10.6052 7.51198 8.7086 16.2423 13.9298 9.8482 0.614992 -0.497501 -0.284254 1.11249 0.899245 
GTF2H4 1.4484 1.13232 1.37359 2.32886 2.16322 1.81838 0.685166 -0.355175 -0.076504 1.04034 0.76167 
H2AFZ 618.555 385.015 472.095 844.442 606.288 519.284 0.449097 -0.683987 -0.389827 1.13308 0.838923 
HIST1H4I 0.592023 0.100401 0.199704 1.00721 0 0.555206 0.766645 -2.55988 -1.56779 3.32652 2.33443 
HMGB1 57.3536 32.1961 41.3367 65.2439 56.1397 54.5732 0.185958 -0.832996 -0.472461 1.01895 0.65842 
HMGCR 30.7668 19.0921 22.3969 41.4481 27.8005 26.4677 0.42993 -0.688397 -0.458078 1.11833 0.888008 
HMGCS1 24.5027 11.0513 13.0036 36.7127 14.823 14.5208 0.583339 -1.14873 -0.914031 1.73207 1.49737 
HNRNPA2B1 590.892 412.159 464.393 820.913 541.469 524.864 0.474334 -0.519694 -0.347548 0.994028 0.821883 
HNRNPCL1 5.03041 4.24043 3.97049 9.27558 6.59825 6.32511 0.88276 -0.246465 -0.34136 1.12923 1.22412 
HSP90B1 2825.7 1654.71 2471.85 7603.09 1223.86 1909.14 1.42798 -0.772029 -0.193019 2.20001 1.621 
HSPA13 27.4569 26.3277 27.1017 62.6303 22.2519 17.7736 1.18969 -0.0605838 -0.018786 1.25028 1.20848 
HSPD1 381.731 239.858 302.359 493.222 380.765 349.682 0.369682 -0.670375 -0.336295 1.04006 0.705976 
HSPE1 156.336 95.111 114.676 206.312 147.153 151.811 0.400183 -0.716963 -0.447087 1.11715 0.847269 
IDH1-AS1 2.72612 2.53265 2.31519 5.06143 1.52871 1.85464 0.892695 -0.106202 -0.235718 0.998897 1.12841 
IDI1 49.4392 23.5415 30.9303 75.2657 33.1623 30.0975 0.606337 -1.07045 -0.676635 1.67678 1.28297 
INSIG1 25.0952 12.5145 21.4595 43.1922 17.4371 14.0131 0.783357 -1.00381 -0.225798 1.78717 1.00916 
IPO9-AS1 2.3561 2.19342 1.49937 3.04056 1.35623 1.57112 0.367937 -0.103217 -0.652042 0.471154 1.01998 
ITGA8 1.46305 1.03773 1.05337 2.23719 1.29107 1.31371 0.612712 -0.495547 -0.473969 1.10826 1.08668 
KIAA0101 42.4231 30.9669 32.959 64.3964 63.5105 57.1765 0.60213 -0.454124 -0.364178 1.05625 0.966308 
LDLR 6.83483 3.57882 5.25353 7.50273 6.81145 5.04638 0.13451 -0.933421 -0.37962 1.06793 0.51413 
LHB 0.921149 0.471416 0.5728 1.1223 0.79295 2.10258 0.28495 -0.966435 -0.685404 1.25138 0.970354 
LINC00853 0.559103 0.405312 0.472307 0.810621 0.481821 0.434236 0.535914 -0.46408 -0.243389 0.999993 0.779303 
LINC01351 1.5215 0.871104 0.940887 2.35184 1.03375 0.609878 0.628294 -0.804579 -0.693403 1.43287 1.3217 
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LOC101928812 1.458 0.988651 0.839633 2.2336 1.12156 0.858216 0.615382 -0.560457 -0.796158 1.17584 1.41154 
LOC113230 2.10162 1.24044 0.924326 3.66502 0.473133 0.453538 0.802319 -0.760656 -1.18503 1.56298 1.98735 
LOC650368 0.414999 0.161971 0.391356 0.783751 17.1521 17.119 0.917289 -1.35737 -0.084623 2.27466 1.00191 
LOC731157 0.718552 0.560046 0.244996 0.969733 0.132509 0.711741 0.432495 -0.359547 -1.55234 0.792042 1.98483 
LRP2 1.85517 0.946884 1.342 2.46823 0.294904 0.340945 0.411928 -0.970291 -0.467162 1.38222 0.879091 
LUM 0.510362 0.28636 0.347368 1.32412 0.543278 0.196073 1.37544 -0.83369 -0.555056 2.20913 1.9305 
MAD2L1 96.5252 65.7332 81.6432 154.734 105.142 82.195 0.680809 -0.554283 -0.241573 1.23509 0.922382 
MANEA-AS1 0.789227 0.733018 0.763346 1.54225 0.534944 0.532869 0.966524 -0.106591 -0.048101 1.07311 1.01463 
MDH1B 0.474595 0.415011 0.455175 0.829073 0.400692 0.55979 0.804801 -0.193549 -0.060278 0.99835 0.86508 
MID1IP1-AS1 5.34565 2.67761 3.25419 5.62244 3.01085 2.87812 0.0728317 -0.997419 -0.716064 1.07025 0.788896 
MIR1304 290.109 237.786 82.2472 396.035 236.994 322.491 0.449035 -0.286929 -1.81856 0.735964 2.26759 
MIR1470 175.949 0 150.14 205.691 0 0 0.225322 #NAME? -0.228849 inf 0.45417 
MIR17 24.9535 13.8565 16.7025 28.361 11.8281 10.4282 0.184668 -0.848682 -0.57918 1.03335 0.763848 
MIR221 76.2047 60.7734 70.6965 173.262 141.814 102.131 1.185 -0.32644 -0.10824 1.51144 1.29324 
MIR3064 6110.53 4316.78 4611.04 10857.8 4375.36 5024.4 0.829364 -0.501343 -0.406207 1.33071 1.23557 
MIR320A 26.7998 22.9944 0 62.6601 0 29.8894 1.22532 -0.22094 #NAME? 1.44626 inf 
MIR3607 66.1326 0 0 166.185 0 36.3395 1.32936 #NAME? #NAME? inf inf 
MIR3614 78.2105 18.4441 20.1974 96.9441 13.7551 135.188 0.309792 -2.08421 -1.95319 2.394 2.26298 
MIR3662 39.9439 0 0 51.8246 0 38.6094 0.375661 #NAME? #NAME? inf inf 
MIR3916 138.928 84.9389 47.0895 284.689 231.435 217.732 1.03505 -0.709844 -1.56087 1.74489 2.59591 
MIR4517 590.363 335.48 139.019 689.01 368.363 359.084 0.222922 -0.815376 -2.08632 1.0383 2.30924 
MIR5001 238.806 225.343 186.679 374.16 124.121 165.773 0.647813 -0.0837194 -0.355285 0.731533 1.0031 
MIR5008 13.8109 0 0 19.0745 0 0 0.465836 #NAME? #NAME? inf inf 
MIR5047 2285.43 1140.05 1478.01 3532.48 2136.4 1916.04 0.628218 -1.00337 -0.628807 1.63159 1.25702 
MIR564 289.12 137.126 251.426 444.423 94.788 240.711 0.620266 -1.07617 -0.201533 1.69643 0.821799 
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MIR6727 322.833 285.111 91.8261 1178.05 612.899 990.645 1.86754 -0.179263 -1.81381 2.0468 3.68135 
MIR6764 175.949 150.966 0 205.691 0 0 0.225322 -0.22094 #NAME? 0.446261 inf 
MIR6875 223.548 0 46.9927 257.519 101.556 161.356 0.204092 #NAME? -2.25008 inf 2.45417 
MIR7107 30.5086 26.1884 0 35.6583 0 0 0.225021 -0.220289 #NAME? 0.445309 inf 
MIRLET7D 39.8537 0 0 101.633 75.0928 58.3851 1.35059 #NAME? #NAME? inf inf 
MSMO1 20.8557 10.7809 15.0143 30.3344 21.1019 17.5169 0.540515 -0.951965 -0.4741 1.49248 1.01461 
MST1 1.38095 1.28696 0.749804 1.78692 0.669021 0.899452 0.371817 -0.101687 -0.881074 0.473504 1.25289 
MZT1 53.2331 37.7417 39.434 99.8712 36.8131 28.1183 0.907745 -0.496163 -0.432885 1.40391 1.34063 
N4BP2 4.3699 3.38795 3.49763 8.00689 2.92165 2.84634 0.873642 -0.367187 -0.321224 1.24083 1.19487 
NUDCD2 40.5315 32.0306 40.1945 76.5897 38.3446 38.3195 0.918105 -0.339593 -0.012046 1.2577 0.930152 
NUDT12 10.7347 8.22739 9.32255 16.4008 10.659 7.26533 0.611489 -0.38377 -0.20348 0.995259 0.814969 
OR7E12P 0.252558 0.134445 0.115566 0.609711 10.6133 8.87469 1.27151 -0.909604 -1.12789 2.18111 2.3994 
OSTN 3.26416 3.18425 2.34603 8.60667 1.45803 2.61806 1.39874 -0.0357595 -0.476491 1.4345 1.87523 
PCYT1B 0.97227 0.628306 0.618774 1.31804 0.617351 0.362699 0.438961 -0.62989 -0.651945 1.06885 1.09091 
PDHA1 41.3083 24.7734 39.5157 51.052 63.944 62.2375 0.305535 -0.73764 -0.064005 1.04317 0.36954 
PGK1 210.976 142.552 180.242 310.859 114.77 104.379 0.559182 -0.565589 -0.227145 1.12477 0.786327 
PIGA 9.21179 6.02201 7.6554 11.9709 6.91295 5.896 0.377973 -0.613237 -0.267003 0.99121 0.644976 
PSAT1 165.464 143.782 161.241 315.385 96.963 81.1707 0.930599 -0.202632 -0.037297 1.13323 0.967896 
PTPRCAP 0.446622 0.192189 0.330711 0.580051 0.573185 0.533204 0.377125 -1.21653 -0.433484 1.59366 0.810609 
PUF60 2.9728 1.8277 1.93865 3.81279 2.29507 2.63868 0.359026 -0.701797 -0.61677 1.06082 0.975796 
RAB40A 0.688402 0.561089 0.465167 1.04227 1.77531 0.923188 0.598404 -0.295022 -0.565501 0.893426 1.1639 
RASL10B 0.701822 0.005591 0.01112 0.726967 0.037093 0.083631 0.0507839 -6.97197 -5.97988 7.02275 6.03066 
RGS4 0.725831 0.386541 0.557353 0.791211 1.72379 1.56354 0.12443 -0.909013 -0.381042 1.03344 0.505472 
RIPPLY2 7.06164 6.68791 5.63934 11.4222 0.934267 0.873719 0.693768 -0.0784475 -0.324477 0.772215 1.01824 
RND2 3.92679 1.99985 3.31935 5.20836 2.10177 2.33269 0.407481 -0.973459 -0.242447 1.38094 0.649928 
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RNF175 0.39961 0 0 1.03575 0.027464 0 1.37401 #NAME? #NAME? inf inf 
RNU4ATAC 17.5103 12.2151 8.91219 17.771 6.42007 16.5181 0.0213177 -0.519542 -0.974356 0.54086 0.995674 
RNVU1-15 23.7721 15.6894 18.9443 39.989 7.79398 14.9101 0.750334 -0.599477 -0.32751 1.34981 1.07784 
RPS18 0.579594 0.444927 0.442495 1.33463 0.748395 0.401897 1.20332 -0.381472 -0.389381 1.58479 1.5927 
RPS29 448.813 175.023 256.459 521.998 417.543 445.172 0.217929 -1.35857 -0.807384 1.5765 1.02531 
RSL24D1 58.9394 49.319 57.303 99.5207 64.5141 57.3207 0.755763 -0.257091 -0.040623 1.01285 0.796387 
SCARNA20 3.4814 2.98706 2.97073 8.13977 0 7.76548 1.22532 -0.22094 -0.228849 1.44626 1.45417 
SCARNA23 24.5762 24.398 8.91219 28.111 19.5395 15.531 0.193871 -0.0104967 -1.46341 0.204368 1.65728 
SCARNA27 221.71 88.8814 141.327 228.95 212.654 127.128 0.0463645 -1.31872 -0.64963 1.36508 0.695994 
SCD 148.447 91.0446 124.855 182.58 121.066 102.575 0.298576 -0.705304 -0.249691 1.00388 0.548267 
SCML1 49.818 30.4456 44.7481 68.9251 30.5107 26.6447 0.468362 -0.710434 -0.154842 1.1788 0.623204 
SCOC 55.0798 37.9976 45.6366 84.2861 58.4098 39.7 0.613771 -0.535615 -0.271332 1.14939 0.885103 
SEC61G 222.502 199.751 217.184 514.023 225.485 214.82 1.20802 -0.155616 -0.034897 1.36363 1.24291 
SEMA3C 4.26482 3.77488 2.28938 4.8151 2.99782 2.75164 0.175082 -0.176052 -0.897526 0.351134 1.07261 
SHISA2 5.09843 3.13003 4.09327 7.10392 4.1841 3.45748 0.478562 -0.703877 -0.3168 1.18244 0.795362 
SMIM14 3.01285 2.99224 2.84355 5.6819 1.45993 1.46921 0.915245 -0.0099013 -0.083433 0.925146 0.998678 
SMS 26.2116 14.8745 23.9956 32.7871 39.6827 34.3452 0.322928 -0.817358 -0.127432 1.14029 0.450359 
SNORA14B 174.57 111.673 99.6689 215.327 83.6392 93.2114 0.30272 -0.644528 -0.808594 0.947248 1.11131 
SNORA15 6.35935 5.45636 5.48761 16.4188 5.86367 14.1849 1.3684 -0.22094 -0.2127 1.58934 1.5811 
SNORA18 269.915 215.999 257.033 464.759 403.486 325.325 0.783976 -0.321479 -0.070552 1.10546 0.854528 
SNORA29 65.5205 27.327 48.7197 75.4078 63.7769 38.0815 0.202769 -1.26162 -0.42744 1.46439 0.630209 
SNORA58 3.99138 2.04267 2.37008 7.08306 3.6904 2.21264 0.827483 -0.966435 -0.751951 1.79392 1.57943 
SNORA76C 239.136 47.0662 113.899 396.996 224.35 220.828 0.731295 -2.34506 -1.07008 3.07636 1.80137 
SNORD105 22.3591 0 0 30.8773 0 0 0.465682 #NAME? #NAME? inf inf 
SNORD110 1001.67 635.914 518.271 1170.96 813.948 1282.59 0.225293 -0.6555 -0.950624 0.880792 1.17592 
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SNORD126 21.8465 9.37946 0 27.8522 20.14 12.1921 0.350389 -1.21983 #NAME? 1.57021 inf 
SNORD12B 92.494 32.1207 78.1571 138.319 154.353 135.504 0.580573 -1.52585 -0.242982 2.10643 0.823555 
SNORD14C 265.06 66.0717 225.014 454.713 492.757 278.685 0.778635 -2.00422 -0.236305 2.78285 1.01494 
SNORD16 335.351 188.88 311.755 450.431 467.967 358.222 0.425636 -0.828203 -0.105259 1.25384 0.530895 
SNORD19B 524.163 404.784 482.763 1059.5 622.472 750.783 1.0153 -0.372864 -0.118702 1.38817 1.134 
SNORD22 578.31 391.041 498.057 905.209 878.876 757.589 0.646408 -0.564524 -0.215534 1.21093 0.861941 
SNORD28 1610.31 1014.39 1442.96 2360.33 2184.44 1881.24 0.551644 -0.666726 -0.158316 1.21837 0.70996 
SNORD31 712.362 473.826 673.193 1240.58 1176.53 703.89 0.800327 -0.588254 -0.081590 1.38858 0.881917 
SNORD42A 411.436 233.033 347.882 1038.93 762.177 302.908 1.33635 -0.820133 -0.242069 2.15649 1.57842 
SNORD45C 455.723 149.707 238.093 704.53 263.009 593.686 0.628504 -1.60602 -0.936633 2.23452 1.56514 
SNORD49A 964.667 677.814 869.776 1478.12 1226.72 527.051 0.61566 -0.509143 -0.149387 1.1248 0.765048 
SNORD50B 361.505 51.4414 102.32 471.395 451.868 443.13 0.382923 -2.81301 -1.82092 3.19594 2.20385 
SNORD53 40.2613 0 34.3556 149.74 74.2462 280.832 1.89499 #NAME? -0.228849 inf 2.12384 
SNORD65 966.92 874.549 562.812 2409.49 2083.3 997.348 1.31726 -0.144858 -0.780744 1.46211 2.098 
SNORD67 67.3058 34.9167 45.5595 82.5355 49.7835 29.9135 0.294285 -0.946811 -0.562978 1.2411 0.857263 
SNORD69 603.657 361.728 446.778 867.726 282.218 924.429 0.523509 -0.738823 -0.43417 1.26233 0.95768 
SNORD72 30.478 0 0 42.0937 56.2047 0 0.465836 #NAME? #NAME? inf inf 
SNORD80 7284.71 4270.02 6288.28 11964.1 8484.51 5978.29 0.715772 -0.77063 -0.212208 1.4864 0.92798 
SNORD96A 4635.73 2295.82 3240.26 5980.47 3179.16 2649.36 0.367462 -1.01379 -0.516687 1.38125 0.884149 
SNORD98 525.351 224.283 519.631 1434.69 496.068 97.5646 1.44938 -1.22796 -0.015792 2.67734 1.46518 
SNRPE 54.467 40.7081 41.5217 85.1558 61.2189 54.7783 0.644723 -0.420066 -0.391515 1.06479 1.03624 
SNRPG 57.5128 39.6245 51.8299 83.4139 50.9643 61.2796 0.536403 -0.537493 -0.150099 1.0739 0.686503 
SPAG8 0.556813 0.230565 0.384067 0.625074 0.429475 0.470186 0.166835 -1.27202 -0.535835 1.43885 0.70267 
SPARC 4.45521 0.950907 1.96659 8.36797 12.7683 3.40761 0.909386 -2.22812 -1.1798 3.1375 2.08918 
SPC25 0.307792 0.21935 0.290679 0.608486 0.188579 0.404005 0.98327 -0.488719 -0.082525 1.47199 1.0658 
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ST3GAL6-AS1 0.460003 0.327822 0.316097 0.846371 0.428436 0.647632 0.879648 -0.488731 -0.541276 1.36838 1.42092 
STARD4 8.11822 6.60576 6.6147 15.6302 6.80337 5.97456 0.9451 -0.297439 -0.295489 1.24254 1.24059 
SULF1 3.2881 2.67036 2.80594 6.33437 6.94355 4.58935 0.945948 -0.300217 -0.228769 1.24617 1.17472 
SULT1C4 2.02076 1.87774 1.94568 4.09329 0.178666 0.175046 1.01836 -0.105904 -0.054628 1.12426 1.07299 
SYTL5 1.2429 1.23732 0.749094 1.90221 1.66049 1.63246 0.613973 -0.0064890 -0.730487 0.620462 1.34446 
TFAM 23.3559 13.0286 18.8172 36.2233 44.572 45.0728 0.633129 -0.84211 -0.311741 1.47524 0.944869 
TIMM17A 107.348 79.7757 77.0385 153.268 109.736 99.2525 0.513763 -0.428276 -0.478646 0.942039 0.992409 
TMEM100 2.26495 1.39666 1.49263 4.77166 4.04012 1.92958 1.07501 -0.6975 -0.601618 1.77251 1.67663 
TMSB4X 12.1564 9.25037 7.97571 23.1644 1.97314 3.67559 0.930193 -0.394132 -0.608029 1.32432 1.53822 
TNFRSF10D 4.79517 2.43374 4.24356 5.43668 13.8757 13.5736 0.181143 -0.978408 -0.176309 1.15955 0.357452 
TXNDC17 23.5686 16.7314 21.165 33.7328 22.8833 19.9296 0.517285 -0.494307 -0.155183 1.01159 0.672468 
UBAC2-AS1 2.16774 1.41739 1.96355 2.82924 0.860653 0.707231 0.384222 -0.612959 -0.142726 0.997181 0.526947 
ULBP1 1.24548 1.11871 0.774033 2.51809 0.992301 0.992666 1.01562 -0.15487 -0.686241 1.17049 1.70186 




Supplementary Table 2: Genes upregulated by at least 2-fold in H-v601-Per1 and H-v601-Per2 cells and downregulated in H-v601 cells, relative to 
mock. Pairwise comparisons between the gene expression levels of HEK293 (Mock), H-v601-Per1, H-v601-Per2 and H-v601 cells are shown. 673 genes that 
were both upregulated by at least 2-fold in H-v601-Per1 or H-v601-Per2 and downregulated by at least 2-fold in H-v601 cells were identified. “Expression value” 
indicates the value reads derived from the transcriptomics sequencing, indicating level of gene expression; “Log2 fold change” indicates the fold difference in 
gene expression from Sample A vs. Sample B.  
Gene 
Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















ABCA1 0.388976 0.667666 0.778933 0.594448 0.501492 0.327372 0.611869 0.779445 1.00182 -0.16758 -0.38995 
ABHD12B 1.59302 1.7189 1.87688 0.887118 1.77792 1.17446 -0.84457 0.109719 0.236568 -0.95429 -1.08114 
ABLIM3 0.61981 1.23979 1.18146 0.462535 0.934001 1.2406 -0.42226 1.0002 0.93067 -1.42246 -1.35293 
ACE 0.896309 1.36371 1.44573 0.667904 0.373676 0.683436 -0.42436 0.605465 0.689727 -1.02982 -1.11408 
ACHE 2.18938 4.11218 2.49927 1.27835 0.577382 0.793506 -0.77624 0.909382 0.190986 -1.68562 -0.96723 
ACTA2 2.21046 11.2412 4.8437 2.30426 4.78405 6.20859 0.059958 2.34638 1.13177 -2.28642 -1.07181 
ACTL6B 0.193022 0.731714 0.588122 0.132588 0.196571 0.268348 -0.54182 1.92252 1.60735 -2.46433 -2.14917 
ACVRL1 0.226039 0.581854 0.397841 0.139345 0.283179 0.219066 -0.69791 1.36409 0.815622 -2.06199 -1.51353 
ADAMTS10 1.0478 2.11185 1.54659 0.912266 1.46528 1.68267 -0.19984 1.01114 0.561722 -1.21098 -0.76157 
ADAMTS7 0.839739 1.1444 0.845135 0.542801 0.752679 0.55646 -0.62952 0.44658 0.009241 -1.0761 -0.63876 
ADAMTSL5 0.636974 1.00036 0.744841 0.436186 0.723032 0.696839 -0.54629 0.651214 0.225699 -1.19751 -0.77199 
ADPRHL1 2.11476 2.98354 2.92563 1.33347 1.40944 2.01782 -0.66531 0.496531 0.468252 -1.16184 -1.13356 
AGPAT1 2.15119 2.43551 2.72746 1.28618 1.74898 1.89158 -0.74204 0.179086 0.34242 -0.92113 -1.08446 
ALG1L9P 0.249564 0.520788 0.563749 0.204869 0.726413 0.430592 -0.28471 1.06129 1.17565 -1.34599 -1.46035 
ALOXE3 0.470368 0.706565 0.855301 0.370851 0.524974 0.834387 -0.34295 0.587033 0.862643 -0.92998 -1.20559 
AMDHD1 0.395953 1.08524 0.868128 0.502509 0.170593 0.27715 0.343821 1.45461 1.13258 -1.11079 -0.78876 
ANKRD1 0.166076 3.41484 0.900942 0.257283 0.434185 0.778339 0.631509 4.3619 2.43959 -3.73039 -1.80808 
ANKRD24 0.400621 0.889076 0.608301 0.388895 0.231328 0.408264 -0.04286 1.15007 0.602547 -1.19293 -0.64541 
ANKRD31 0.263243 0.73079 0.629234 0.406084 0.176513 0.131475 0.625382 1.47306 1.2572 -0.84768 -0.63182 
ANO9 0.007294 0.895018 0.397932 0.008527 0.014036 0.079417 0.225322 6.93908 5.76969 -6.71376 -5.54437 
AP2A2 0.574906 0.662475 0.648914 0.333056 0.513891 0.536454 -0.78756 0.20454 0.174701 -0.9921 -0.96226 
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AQP1 0.761035 0.787806 0.893197 0.44873 0.590085 0.544674 -0.76212 0.049877 0.231015 -0.81199 -0.99313 
AR 0.156334 0.655635 1.05688 0.217105 4.6602 5.06171 0.473758 2.06826 2.75711 -1.5945 -2.28335 
ARC 0.47948 1.27131 0.974281 0.323663 0.562431 1.47389 -0.56698 1.40677 1.02287 -1.97375 -1.58984 
ARL14 0.054446 0.557679 0.168485 0.066837 0 0.163059 0.295839 3.35655 1.62973 -3.06071 -1.33389 
ARL17A 0.587828 1.09864 1.34858 0.819286 0.943519 1.01659 0.478972 0.902254 1.19797 -0.42328 -0.719 
ASGR1 0.66853 1.51198 0.702262 0.659871 0.909705 0.48374 -0.01881 1.17738 0.071018 -1.19618 -0.08983 
ATAD3C 0.172624 0.893212 3.39836 0.094021 0.148728 0.121213 -0.87658 2.37137 4.29913 -3.24794 -5.17571 
ATG9B 0.249037 0.578239 0.462332 0.238655 0.389946 0.692092 -0.06143 1.21531 0.892569 -1.27674 -0.954 
ATOH8 0.274938 0.588412 0.492871 0.177782 0.424547 0.676818 -0.629 1.09772 0.842104 -1.72672 -1.4711 
ATP1A1-AS1 1.54992 3.87146 3.21313 3.08516 3.6273 3.90461 0.993147 1.32068 1.05178 -0.32754 -0.05864 
ATP1B2 4.02038 5.10192 5.3004 2.05292 3.79682 3.89194 -0.96965 0.343708 0.398769 -1.31336 -1.36842 
ATP2A3 1.4457 1.48388 1.80854 0.849379 1.73405 2.41334 -0.76729 0.037603 0.323056 -0.80489 -1.09035 
AURKC 0.346425 0.90963 0.825475 0.468403 0.608267 0.666768 0.435204 1.39274 1.25268 -0.95753 -0.81748 
B3GAT1 1.24708 1.34809 1.43026 0.551378 0.821883 1.05061 -1.17744 0.112369 0.197722 -1.28981 -1.37516 
BATF2 0.477129 0.861415 0.925849 0.383833 0.853625 0.807475 -0.3139 0.852329 0.956397 -1.16623 -1.2703 
BCL3 1.38805 2.7427 2.26996 0.778128 1.79161 2.08487 -0.83498 0.982541 0.709612 -1.81752 -1.54459 
BCYRN1 0 1.78237 1.77007 0.809493 1.33248 1.25658 inf inf inf -1.1387 -1.12872 
BDNF 0.190216 0.577617 0.453518 0.166341 0.107321 0.097082 -0.1935 1.60248 1.25352 -1.79597 -1.44702 
BIK 0.393191 0.660228 0.798251 0.541608 1.52848 1.62921 0.462021 0.747734 1.02161 -0.28571 -0.55959 
BOK 0.642932 0.7516 0.91076 0.349968 0.364457 0.438364 -0.87744 0.2253 0.502406 -1.10274 -1.37985 
BRD4 37.4638 45.5346 42.4898 20.4867 42.9675 46.7056 -0.87081 0.281465 0.181619 -1.15228 -1.05243 
BRSK1 3.33569 8.24774 5.89823 3.47611 6.91499 9.43808 0.059487 1.30601 0.822296 -1.24653 -0.76281 
BSPRY 0.770282 1.4387 1.60315 0.810044 0.225126 0.542778 0.072615 0.901304 1.05745 -0.82869 -0.98484 
BST2 0.771222 6.80426 9.21115 0.553639 1.17092 1.61115 -0.4782 3.14122 3.57816 -3.61942 -4.05636 
C10orf10 0.771225 1.8976 1.58358 0.804173 1.15047 1.56432 0.060354 1.29895 1.03797 -1.23859 -0.97761 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















C14orf23 0.760342 1.56206 1.1891 1.12386 3.98595 3.80171 0.563745 1.03873 0.645154 -0.47499 -0.08141 
C19orf38 0.443487 0.9365 0.694059 0.591719 0.291199 0.442292 0.416023 1.07839 0.646169 -0.66237 -0.23015 
C19orf66 0.550679 0.582955 0.629879 0.289461 0.180657 0.12941 -0.92784 0.082173 0.193864 -1.01002 -1.12171 
C1QL1 5.05988 5.97589 5.18665 2.68166 3.52166 3.49268 -0.91598 0.240051 0.035701 -1.15603 -0.95168 
C1QTNF1 1.27064 1.80233 1.64407 0.796523 1.13406 1.42608 -0.67377 0.504309 0.371715 -1.17808 -1.04548 
C1RL 0.200078 0.340657 0.560659 0.133625 0.210788 0.238245 -0.58237 0.767755 1.48656 -1.35012 -2.06893 
C2CD4A 0.084869 2.30631 1.17817 0.125185 0.044823 0.098971 0.560748 4.7642 3.79516 -4.20345 -3.23442 
C6orf163 1.18038 1.28043 1.47848 0.647385 1.52076 1.92255 -0.86656 0.117371 0.324861 -0.98393 -1.19142 
C7orf13 0.801421 1.43326 1.03503 0.584777 1.22191 1.26587 -0.45467 0.83867 0.369041 -1.29334 -0.82372 
C7orf61 0.4419 0.626916 0.581149 0.209586 0.324086 0.383873 -1.07618 0.504552 0.39519 -1.58073 -1.47137 
C8orf37-AS1 0.294131 1.39709 1.39605 0.483207 0 0.266883 0.716181 2.24789 2.24682 -1.53171 -1.53063 
C8orf49 0.580177 0.682395 0.752857 0.212399 0.440977 0.57932 -1.44972 0.234114 0.375882 -1.68383 -1.8256 
C9orf172 0.45368 0.548677 0.541876 0.274794 0.272086 0.777324 -0.72332 0.274281 0.256287 -0.9976 -0.97961 
C9orf9 10.5851 11.4383 11.7949 5.88336 8.04507 7.78912 -0.84732 0.111843 0.156129 -0.95916 -1.00345 
CABP1 1.57468 2.35464 1.99074 1.0749 0.663421 1.35958 -0.55085 0.580449 0.33825 -1.1313 -0.8891 
CACNG6 0.528269 0.883671 0.888744 0.364485 0.115218 0.111157 -0.53541 0.742237 0.750494 -1.27765 -1.28591 
CACNG8 2.02659 18.2891 2.15667 1.75242 2.61796 2.96622 -0.2097 3.17386 0.089752 -3.38357 -0.29945 
CARD6 0.322362 0.938679 0.597225 0.537097 1.1841 0.84326 0.7365 1.54195 0.889594 -0.80545 -0.15309 
CASP10 0.318222 0.808676 0.857354 0.677702 2.94915 3.84385 1.09062 1.34553 1.42986 -0.25491 -0.33924 
CATSPER3 0.642969 1.06966 0.75662 0.34528 0.380078 0.532893 -0.89698 0.734333 0.23482 -1.63131 -1.1318 
CCDC101 16.7026 19.3916 17.4238 9.51024 13.9994 18.3981 -0.81252 0.215357 0.060985 -1.02788 -0.8735 
CCDC11 0.32703 0.789061 0.533309 0.363126 0.181381 0.525431 0.15105 1.27071 0.705551 -1.11966 -0.5545 
CCDC159 0.933131 2.07732 1.99114 1.76143 1.03641 0.759176 0.916595 1.15457 1.09344 -0.23798 -0.17685 
CCDC160 0.466243 1.05591 1.10695 0.869544 0.73746 0.662834 0.899177 1.17934 1.24744 -0.28016 -0.34827 
CCDC62 0.584437 0.599027 0.666947 0.317817 0.561837 0.265153 -0.87885 0.035575 0.190525 -0.91443 -1.06937 
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CCDC88B 0.454703 0.719027 0.542419 0.314299 0.766803 0.915932 -0.53279 0.661119 0.254481 -1.19391 -0.78727 
CCKBR 0.435771 0.565324 0.880968 0.354616 0.659069 0.430043 -0.29731 0.375508 1.01552 -0.67282 -1.31283 
CCL20 0.030603 1.27104 0.104579 0.035777 0 0.089667 0.225322 5.37618 1.77283 -5.15085 -1.54751 
CCL27 0.080461 0.903263 0.823309 0.675496 0.909632 0.358946 3.06959 3.48879 3.35507 -0.4192 -0.28549 
CCT6P3 1.03874 2.44344 1.69352 1.45919 0.95253 1.01904 0.490327 1.23407 0.705184 -0.74375 -0.21486 
CD160 0.863877 0.998249 1.24676 0.448025 0.659422 0.612669 -0.94725 0.208573 0.52929 -1.15582 -1.47654 
CD70 1.90711 4.84683 2.43555 2.00852 1.10143 1.56426 0.074745 1.34565 0.352855 -1.27091 -0.27811 
CDA 0.625331 1.49078 1.14359 0.581213 2.41207 1.7933 -0.10555 1.25337 0.870882 -1.35892 -0.97643 
CDH24 4.38285 5.53448 5.08597 2.78514 4.61271 5.29558 -0.65412 0.336578 0.214653 -0.9907 -0.86877 
CDH3 0.550394 0.829009 0.734033 0.370093 0.736928 0.864708 -0.57258 0.590923 0.415379 -1.1635 -0.98796 
CDHR1 2.72267 3.22871 3.61979 1.4827 1.62288 1.49827 -0.8768 0.245933 0.410883 -1.12273 -1.28768 
CDIPT-AS1 1.95948 3.25084 2.24859 1.12276 1.36059 1.01906 -0.80342 0.730344 0.198555 -1.53376 -1.00197 
CDKN1A 8.30769 26.3493 13.9835 9.9376 21.8498 23.5571 0.25845 1.66525 0.751208 -1.4068 -0.49276 
CDKN2B 2.32284 4.65837 3.42033 2.35045 3.47982 3.23589 0.017046 1.00393 0.558242 -0.98689 -0.5412 
CDR1 10.0709 10.759 10.9552 3.84499 22.482 31.0257 -1.38914 0.095358 0.121425 -1.4845 -1.51057 
CDYL2 0.388237 1.55983 0.891225 0.267042 0.400698 0.317312 -0.53987 2.00638 1.19885 -2.54625 -1.73872 
CEACAM19 1.60108 2.61088 3.32497 0.994781 1.62008 1.8459 -0.6866 0.705486 1.05429 -1.39208 -1.74089 
CEL 0.441197 0.696588 0.494692 0.257107 0.401604 0.518137 -0.77905 0.658881 0.165105 -1.43793 -0.94416 
CELF3 0.215114 0.614293 0.443046 0.186658 0.291708 0.318441 -0.2047 1.51383 1.04235 -1.71853 -1.24706 
CERS6-AS1 0.891588 1.73218 2.78708 0 1.46166 0.817902 #NAME? 0.958141 1.6443 #NAME? #NAME? 
CGA 0.106823 0.585622 0.151659 0.049177 0.06852 0.129235 -1.11917 2.45475 0.505607 -3.57392 -1.62478 
CGB7 0.028815 0.67376 0.319435 0.033686 0.164036 0.53053 0.225322 4.54734 3.47063 -4.32202 -3.24531 
CHD5 0.620143 1.09422 0.776022 0.376874 0.441601 0.987424 -0.71852 0.819224 0.323497 -1.53774 -1.04201 
CHRM3 0.586787 1.2879 0.836495 0.577601 0.161062 0.136959 -0.02276 1.13411 0.511521 -1.15688 -0.53428 
CHRNB4 0.509023 0.590274 0.537809 0.279881 0.755763 0.696365 -0.86292 0.213652 0.079361 -1.07657 -0.94228 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















CLCF1 0.49885 0.81813 0.916536 0.376176 0.550764 0.582934 -0.4072 0.713724 0.877585 -1.12092 -1.28478 
CLIC2 0.441859 0.795064 0.693451 0.367484 0.279788 0.288255 -0.26591 0.847484 0.650208 -1.11339 -0.91611 
CLSTN2 0.398733 0.854161 0.610486 0.264632 0.212041 0.106909 -0.59143 1.09908 0.614535 -1.69052 -1.20597 
CLU 2.78729 6.07669 3.64296 1.96644 6.67783 8.14954 -0.50328 1.12442 0.386244 -1.6277 -0.88952 
CNN2 25.2867 30.9207 30.107 13.2573 26.6713 26.1587 -0.93159 0.290195 0.251724 -1.22178 -1.18331 
CNTFR 8.03669 10.5708 8.42722 2.95249 4.56912 6.25931 -1.44467 0.395412 0.068455 -1.84008 -1.51313 
COL12A1 0.23182 1.31233 1.32183 0.267944 0.038734 0.246957 0.208929 2.50106 2.51146 -2.29213 -2.30254 
COL23A1 0.667856 0.943415 1.01625 0.38086 0.195053 0.619066 -0.81028 0.498356 0.605646 -1.30863 -1.41592 
COL9A2 0.417938 0.658158 0.562502 0.319127 0.519099 0.348783 -0.38916 0.655146 0.428571 -1.0443 -0.81773 
COMP 1.13895 1.59152 1.52845 0.774454 1.1222 0.881676 -0.55645 0.482704 0.424364 -1.03916 -0.98082 
COPZ2 0.301225 0.402973 0.554134 0.195775 0.206362 0.158758 -0.62164 0.419843 0.879393 -1.04149 -1.50104 
CPNE4 0.011812 0.548816 0.247763 0.02288 0.14386 0.133179 0.953771 5.53796 4.39061 -4.58419 -3.43683 
CRABP2 30.5169 50.5193 64.2499 40.7327 8.29283 14.4832 0.416576 0.727224 1.07408 -0.31065 -0.65751 
CREB3L1 1.83257 3.60319 3.03972 1.29443 2.75947 3.09045 -0.50156 0.975403 0.730065 -1.47696 -1.23162 
CREBRF 1.56738 3.78393 2.47089 1.95773 1.95457 2.51846 0.320825 1.27153 0.656678 -0.9507 -0.33585 
CRIP2 3.09235 6.44789 5.13269 2.33646 1.6701 2.93698 -0.40438 1.06012 0.731011 -1.4645 -1.13539 
CRTAC1 0.411463 0.560106 0.587669 0.284914 0.273642 0.335881 -0.53024 0.444937 0.514242 -0.97517 -1.04448 
CRTC1 3.34143 3.91859 3.8303 1.66855 3.43685 4.69864 -1.00187 0.229868 0.196991 -1.23174 -1.19886 
CSAG3 0.832028 3.44518 2.14203 0.979938 0 0.12489 0.236057 2.04987 1.36427 -1.81382 -1.12821 
CSF1 2.96186 5.14342 3.87909 2.16858 4.71816 5.68245 -0.44976 0.796221 0.389211 -1.24598 -0.83897 
CSRNP1 2.73807 5.85895 4.27383 3.07744 2.45146 3.36974 0.168571 1.09748 0.642368 -0.92891 -0.4738 
CTB-178M22.2 0.377634 0.744985 0.79292 0.500785 0.81552 0.821826 0.407203 0.980223 1.07019 -0.57302 -0.66298 
CTSZ 4.11099 7.23539 7.29028 1.83842 0.202478 0.176168 -1.16102 0.815585 0.82649 -1.9766 -1.98751 
CUZD1 1.57304 4.25248 2.48424 1.51606 1.77833 2.8649 -0.05324 1.43475 0.659244 -1.48798 -0.71248 
CXCL1 0.183452 1.34395 0.498924 0.253091 0.077679 0.242286 0.464255 2.87301 1.44342 -2.40875 -0.97916 




Expression value Log2 fold change 
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H-v601-

















CXCL11 0 4.33757 1.5576 0.071123 0.025716 0.305514 inf inf inf -5.93042 -4.45286 
CXCL16 3.52964 5.9659 4.18858 2.72581 1.21604 0.038589 -0.37284 0.757219 0.246941 -1.13006 -0.61978 
CXCL8 0.012979 0.964232 0.221309 0.030345 0.023934 0.06158 1.22532 6.21515 4.09183 -4.98983 -2.86651 
CYP1A1 0.630972 1.87063 1.29165 1.17027 0.478881 0.932771 0.891191 1.56788 1.03357 -0.67669 -0.14238 
CYP4X1 0.236606 0.694947 0.41642 0.25383 0.445467 0.36741 0.101375 1.55441 0.815549 -1.45304 -0.71417 
DDB2 8.76418 27.1183 19.4065 12.9478 16.6062 24.0843 0.563018 1.62957 1.14685 -1.06656 -0.58383 
DDN 1.6837 2.11105 1.70718 0.831007 1.84669 0.764117 -1.0187 0.326326 0.019979 -1.34503 -1.03868 
DDR2 3.25166 7.0399 6.72676 4.20976 14.538 17.0635 0.37256 1.11438 1.04873 -0.74182 -0.67617 
DDX11-AS1 0.612856 0.830394 0.963473 0.470217 0.159877 0.38967 -0.38222 0.438247 0.652695 -0.82047 -1.03492 
DDX58 1.25651 18.7631 9.06119 1.85958 1.51919 3.29363 0.56555 3.9004 2.85028 -3.33485 -2.28473 
DDX60 0.508905 3.36884 1.44019 0.547093 0.474032 0.564124 0.104389 2.72678 1.50079 -2.62239 -1.3964 
DENND1C 0.667248 0.838965 0.847886 0.349409 1.67861 1.34639 -0.93331 0.330386 0.345646 -1.26369 -1.27895 
DENND6B 0.960026 2.07738 1.42832 0.778834 0.496692 1.01977 -0.30176 1.11362 0.573171 -1.41538 -0.87493 
DHRS2 1.08018 10.3003 9.00445 1.77044 9.12038 24.202 0.712837 3.25334 3.05936 -2.5405 -2.34653 
DHRS4L1 0.761742 1.48177 1.00691 0.737144 0.53195 0.704347 -0.04736 0.959943 0.402559 -1.0073 -0.44992 
DHX58 0.105525 1.9657 1.04001 0.109051 0.198252 0.480382 0.047418 4.21939 3.30094 -4.17198 -3.25352 
DISP2 0.74564 1.29918 0.976569 0.539393 0.519296 0.733048 -0.46714 0.801055 0.389244 -1.2682 -0.85639 
DLG4 2.38077 4.97692 4.45634 2.29151 4.62529 4.62967 -0.05513 1.06382 0.904427 -1.11895 -0.95956 
DLGAP1-AS1 0.274505 0.845708 0.378758 0.222979 0.188057 0.296352 -0.29992 1.62332 0.464441 -1.92325 -0.76437 
DMRTA1 0.093684 0.788215 0.467057 0.142082 0.176455 0.206073 0.600844 3.07271 2.31772 -2.47186 -1.71687 
DNAH17 0.189399 0.708397 0.32657 0.20893 0.153695 0.226961 0.141592 1.90313 0.785965 -1.76154 -0.64437 
DNM1 14.2315 17.9134 20.1997 9.86789 17.2313 24.587 -0.52828 0.33195 0.50524 -0.86023 -1.03352 
DPYD 0.10388 0.330584 0.919373 0.159057 0.311158 0.479177 0.614626 1.67009 3.14573 -1.05547 -2.5311 
DPYSL3 1.1568 1.24006 3.81711 0.560754 1.48117 9.32358 -1.04469 0.100278 1.72235 -1.14497 -2.76704 
DRAM1 0.758737 1.38401 0.860507 0.661549 1.97983 1.75655 -0.19775 0.867186 0.181588 -1.06494 -0.37934 
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0.454143 0.699685 0.735679 0.307103 0.331059 0.462625 -0.56442 0.623558 0.69593 -1.18798 -1.26035 
DTX3 1.69327 4.92188 1.86662 1.23833 0.993943 0.410409 -0.45141 1.5394 0.140618 -1.99081 -0.59203 
DUSP2 2.81752 4.37406 3.8237 1.38514 0.15082 0.115623 -1.0244 0.634547 0.440542 -1.65894 -1.46494 
DUSP23 0.655095 0.816601 1.17303 0.223704 0 0.045161 -1.55012 0.317927 0.840461 -1.86804 -2.39058 
EEF1A2 77.9157 135.718 84.278 54.753 22.142 38.3176 -0.50898 0.80063 0.113242 -1.30961 -0.62222 
EFCAB14-AS1 0.54739 0.859257 0.892339 0.434534 0.948321 0.797014 -0.3331 0.650521 0.705024 -0.98362 -1.03812 
EFNA2 2.3782 2.9144 2.57806 1.32986 1.66439 2.01442 -0.83859 0.293329 0.116415 -1.13192 -0.95501 
EGFL7 24.2793 25.3655 29.3049 14.1993 26.0892 31.1986 -0.77391 0.063139 0.271414 -0.83705 -1.04532 
EGR1 0.925038 2.70073 1.6876 0.802768 1.67927 2.13979 -0.20453 1.54576 0.867385 -1.75029 -1.07192 
EGR2 0.285205 0.506634 0.603606 0.130608 0.381157 0.303296 -1.12675 0.828944 1.08161 -1.9557 -2.20836 
EHD2 1.48639 1.74818 1.54213 0.772936 0.957582 0.263893 -0.94339 0.234041 0.053114 -1.17743 -0.99651 
ELFN1 1.01913 1.18373 1.08853 0.395529 0.30597 0.420424 -1.36549 0.215995 0.09504 -1.58148 -1.46052 
ELFN2 1.35726 1.63249 1.62424 0.663173 0.981422 1.19966 -1.03324 0.266376 0.259071 -1.29961 -1.29231 
EMID1 3.96233 4.91335 4.38215 2.41931 2.79956 2.90553 -0.71176 0.310356 0.145288 -1.02211 -0.85705 
EMP3 10.5101 22.1732 16.0955 11.8259 16.7023 10.4488 0.170173 1.07705 0.614887 -0.90687 -0.44471 
EPB41L4A-AS2 0.491955 0.772917 0.680839 0.341264 0.560736 0.661917 -0.52764 0.651787 0.468787 -1.17943 -0.99643 
ERBB4 0.447991 1.02844 1.02153 0.463482 0.034581 0.099199 0.049043 1.19892 1.18919 -1.14988 -1.14014 
ETV4 0.475753 0.886341 1.09212 0.675113 0.286846 0.547152 0.504918 0.89765 1.19884 -0.39273 -0.69393 
ETV7 0 0.965892 0.66149 0.07901 0.325127 0.805574 inf inf inf -3.61175 -3.06561 
EVA1C 0.421043 0.765186 0.482315 0.257514 0.498948 0.428096 -0.70932 0.861843 0.196007 -1.57116 -0.90533 
FAAH 0.994515 1.88009 1.72134 0.7433 0.969756 1.02474 -0.42005 0.918736 0.791469 -1.33878 -1.21152 
FAM131C 2.36105 2.9103 2.58286 0.763287 1.76859 2.70619 -1.62913 0.301738 0.129543 -1.93087 -1.75867 
FAM133A 0.308383 0.354932 0.585806 0.276865 0.200308 0.323066 -0.15554 0.202819 0.925699 -0.35836 -1.08124 
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FAM49A 0.438179 0.619591 0.613164 0.15889 0.22415 0.493058 -1.4635 0.499796 0.484754 -1.96329 -1.94825 
FAM86HP 1.05975 1.33425 1.31057 0.639845 0.837384 1.49423 -0.72793 0.332309 0.306473 -1.06024 -1.0344 
FAXDC2 0.633775 2.43368 1.93157 0.73303 2.8154 2.74654 0.2099 1.9411 1.60773 -1.7312 -1.39783 
FBLL1 0.344856 1.13692 0.855162 0.402347 0.170086 0.175059 0.222446 1.72106 1.3102 -1.49862 -1.08776 
FBXO2 1.01561 1.75055 1.70358 0.76225 1.31806 1.13696 -0.41401 0.785466 0.746224 -1.19948 -1.16023 
FCHO1 2.03712 2.73932 2.59836 1.2852 2.99043 3.04273 -0.66454 0.427287 0.351071 -1.09183 -1.01561 
FGF13 0.538425 3.08473 1.00353 0.346291 0.273277 2.52139 -0.63676 2.51833 0.898271 -3.15509 -1.53503 
FGF17 0.693997 1.13577 0.766754 0.469682 0.501715 0.512567 -0.56325 0.710668 0.143835 -1.27391 -0.70708 
FGF21 0 0.719958 0.487523 0.224896 0 0.239527 inf inf inf -1.67866 -1.11621 
FGFBP1 0.272097 0.624135 0.446113 0.394602 1.11664 1.05719 0.536275 1.19774 0.713286 -0.66146 -0.17701 
FHL3 11.998 14.6358 13.4706 7.275 11.6585 12.3973 -0.72177 0.286709 0.167019 -1.00848 -0.88879 
FIBCD1 0.364464 0.407617 0.563761 0.24784 0.140384 0.224749 -0.55637 0.161436 0.629305 -0.7178 -1.18567 
FILIP1L 0.24178 0.648118 0.567015 0.302042 0.835091 0.68198 0.321052 1.42256 1.22969 -1.10151 -0.90864 
FLJ22184 1.23671 1.62423 1.39654 0.701901 0.456238 0.406616 -0.81717 0.393242 0.175349 -1.21041 -0.99252 
FOSL1 0.444647 0.976308 0.578217 0.172494 0.70951 0.479182 -1.36612 1.13467 0.378948 -2.50079 -1.74506 
FOXA3 0.374312 1.14809 1.0323 0.58448 0.457667 0.721872 0.642914 1.61692 1.46356 -0.974 -0.82064 
FRMD3 0.710377 1.22484 1.06438 0.533923 0.633057 0.996429 -0.41195 0.785934 0.583363 -1.19789 -0.99532 
FUT1 0.034026 0.961976 0.414823 0.338034 0.082317 0.121088 3.31247 4.82131 3.6078 -1.50883 -0.29533 
FXYD1 0.222291 0.742803 0.375798 0.064486 0.73871 0.461978 -1.7854 1.74053 0.757507 -3.52593 -2.54291 
FXYD5 40.4384 46.544 40.5019 18.3795 85.3227 83.0206 -1.13763 0.20287 0.002266 -1.3405 -1.13989 
GAB3 0.263213 0.640586 0.398237 0.226255 0.446689 0.232361 -0.21828 1.28316 0.597398 -1.50144 -0.81568 
GABRA3 2.99314 4.10035 3.61476 1.35228 0.02784 0.027395 -1.14627 0.454086 0.272238 -1.60035 -1.4185 
GABRE 0.180587 1.0766 0.585552 0.08006 0.493843 0.68445 -1.17354 2.57572 1.6971 -3.74926 -2.87064 
GADD45B 5.29408 8.85917 6.83349 3.19068 4.46576 6.74098 -0.73052 0.742792 0.368244 -1.47331 -1.09876 
GAL3ST1 0.521396 0.531125 0.627409 0.313045 0.471456 0.61492 -0.73601 0.026671 0.267026 -0.76268 -1.00303 
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GALNT5 0.241392 0.564504 0.533201 0.406683 0.470168 0.281331 0.752528 1.22561 1.1433 -0.47308 -0.39078 
GBP1P1 0.360467 0.81013 0.580436 0.452177 0.570176 0.949912 0.32702 1.16829 0.687268 -0.84127 -0.36025 
GDF15 0.256 5.58996 1.75125 0.527909 1.36903 1.99498 1.04415 4.44862 2.77417 -3.40448 -1.73002 
GFY 0.175342 0.293474 0.57645 0.13004 0.302467 0.633075 -0.43121 0.743064 1.71703 -1.17428 -2.14824 
GHRL 0.467661 1.2915 0.793108 0.529308 2.10923 1.02102 0.178645 1.46551 0.762055 -1.28687 -0.58341 
GIPC3 4.22597 6.18436 7.53451 2.91673 2.60615 1.55172 -0.53493 0.549341 0.834232 -1.08427 -1.36916 
GNGT1 1.29299 2.76881 1.80188 1.76687 0.858146 0.23705 0.45048 1.09855 0.478792 -0.64807 -0.02831 
GPNMB 0.210511 0.601713 0.348422 0.264688 0.191067 0.220567 0.330401 1.51518 0.726941 -1.18478 -0.39654 
GPR146 0.518407 0.968837 0.887202 0.449227 0.801615 1.09386 -0.20664 0.90217 0.775179 -1.10881 -0.98182 
GPR153 3.84692 4.51711 4.41739 2.15449 3.73926 4.38303 -0.83636 0.231697 0.19949 -1.06806 -1.03585 
GPR3 0.772544 0.954042 0.773721 0.472525 0.868517 0.99315 -0.70923 0.304436 0.002197 -1.01366 -0.71142 
GPR50 0.844394 2.63759 2.42264 0.447983 0.897989 1.3175 -0.91447 1.64323 1.52059 -2.5577 -2.43506 
GPSM1 29.8243 35.4746 31.6895 16.6912 28.3144 33.8298 -0.8374 0.250301 0.087518 -1.0877 -0.92492 
GRHL3 0.235648 0.784348 0.376881 0.154088 0.319009 0.505154 -0.61288 1.73486 0.677477 -2.34774 -1.29036 
GRIK4 0.487219 1.07926 0.936658 0.4019 0.533146 0.682738 -0.27773 1.14739 0.942952 -1.42513 -1.22069 
GRIK5 0.672017 0.985971 0.997559 0.417878 0.597801 0.678579 -0.68542 0.553047 0.569904 -1.23846 -1.25532 
GRINA 80.68 89.4839 85.6119 37.0204 80.2789 92.0943 -1.12389 0.149416 0.0856 -1.27331 -1.20949 
GSTO2 2.61929 4.15307 3.52459 2.0875 4.09462 6.92842 -0.3274 0.665003 0.42828 -0.9924 -0.75568 
GTF2H2 0.417151 0.658691 0.475033 0.211956 0.548716 0.363933 -0.97681 0.659032 0.187457 -1.63584 -1.16426 
GUCA1B 0.839316 1.43637 1.55078 0.582155 1.34958 0.939554 -0.52781 0.775145 0.885709 -1.30296 -1.41352 
HCFC1-AS1 0.336662 0.555239 0.884082 0.241848 0.322013 0.602277 -0.4772 0.721807 1.39288 -1.19901 -1.87008 
HERC5 9.78521 37.775 20.9894 9.42677 12.3198 11.3586 -0.05384 1.94876 1.10098 -2.0026 -1.15482 
HES7 1.10221 1.98223 2.2803 1.84182 0.178261 0.605831 0.74073 0.846724 1.04882 -0.10599 -0.30809 
HIC1 0.916235 1.18228 1.39149 0.481594 0.564947 0.675813 -0.9279 0.367779 0.602841 -1.29568 -1.53074 
HIGD1B 0.683002 1.56296 0.842984 0.381026 1.25527 2.06931 -0.842 1.19432 0.303616 -2.03632 -1.14562 
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HIST1H2AC 2.63969 6.41723 3.39992 1.94231 0.977072 2.62969 -0.4426 1.28158 0.365134 -1.72418 -0.80773 
HIST1H2AD 0.251558 1.14707 0.648199 0.137918 0.361973 0.583118 -0.86708 2.189 1.36554 -3.05608 -2.23263 
HIST1H2AI 0.81265 1.02993 1.37783 0.288875 0.559711 0.830634 -1.49219 0.34184 0.761695 -1.83403 -2.25389 
HIST1H2AK 1.22603 1.98527 1.62096 0.953732 0.713545 0.944652 -0.36234 0.695344 0.402857 -1.05768 -0.7652 
HIST1H2BD 5.28137 9.39957 7.04179 3.48782 2.44717 3.11551 -0.59859 0.831683 0.415031 -1.43027 -1.01362 
HIST1H2BJ 4.53044 7.11791 5.57523 3.21204 2.76755 3.69694 -0.49616 0.651805 0.299381 -1.14797 -0.79554 
HIST1H2BN 1.04497 2.50068 2.50664 1.01338 0.305875 1.1538 -0.04428 1.25886 1.26229 -1.30314 -1.30657 
HIST1H3B 0.65824 1.2002 1.17668 0.440116 0.279638 1.1757 -0.58073 0.866588 0.838039 -1.44732 -1.41877 
HIST1H3E 0.99011 1.89426 1.28695 0.457165 0.992434 1.76909 -1.11487 0.935976 0.378291 -2.05085 -1.49317 
HIST1H4C 12.0847 22.8754 17.0104 1.76698 17.896 20.0735 -2.77382 0.920617 0.49324 -3.69444 -3.26706 
HIST1H4H 0.692639 2.26405 1.65738 1.05664 1.48477 1.21222 0.609315 1.70873 1.25873 -1.09941 -0.64942 
HIST2H2BE 1.1211 2.64543 1.52978 0.786422 0.44099 0.943914 -0.51154 1.23859 0.448409 -1.75013 -0.95995 
HMOX1 57.5826 65.8089 59.2149 32.7096 29.5322 33.9519 -0.81592 0.192649 0.040327 -1.00857 -0.85624 
HPCA 0.278401 0.814804 0.372979 0.127443 0.24707 0.242025 -1.12731 1.54929 0.421933 -2.6766 -1.54924 
HPX 0.207559 0.563519 0.479756 0.261122 0.208044 0.216436 0.331203 1.44094 1.20878 -1.10974 -0.87758 
HSD17B14 2.65746 5.57738 5.62679 2.87151 2.06845 2.23652 0.111761 1.06954 1.08227 -0.95778 -0.97051 
HSPA6 0.047986 4.39407 0.997828 0.054957 0.014676 0.126517 0.195691 6.51681 4.37811 -6.32112 -4.18242 
HSPB1 54.5839 82.5207 54.7107 35.6973 44.7406 10.8955 -0.61266 0.596282 0.00335 -1.20894 -0.61601 
HSPB8 0.371605 3.75786 1.95774 0.998141 0.723672 0.833193 1.42547 3.33807 2.39735 -1.9126 -0.97188 
HSPG2 1.81237 1.84596 1.99975 0.918625 2.37807 2.34621 -0.98033 0.026491 0.141945 -1.00682 -1.12227 
HTR1D 0.732913 1.23599 0.990576 0.582243 0.253515 0.242853 -0.33202 0.75395 0.434625 -1.08597 -0.76665 
HTR2C 0.17196 0.473776 0.682643 0.152518 0.205606 0.189262 -0.17309 1.46214 1.98906 -1.63522 -2.16215 
HVCN1 0.359006 0.754928 0.727428 0.589402 0.099323 0.148371 0.715244 1.07233 1.0188 -0.35709 -0.30355 
ICAM1 0.278806 1.22383 0.676758 0.0592 0.256751 0.388852 -2.23559 2.13407 1.27938 -4.36966 -3.51497 
IDUA 1.29454 1.67045 1.51292 0.743641 1.15253 1.31701 -0.79976 0.367803 0.224906 -1.16756 -1.02466 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















IFI44L 0.273997 0.759502 0.81717 0.239876 0.644125 0.686612 -0.19187 1.47089 1.57648 -1.66276 -1.76834 
IFI6 7.61894 19.5333 18.062 6.92534 12.5982 15.6811 -0.13771 1.35827 1.24529 -1.49598 -1.383 
IFIH1 0.814504 21.0274 9.41731 1.23807 0.632006 1.60279 0.6041 4.6902 3.53132 -4.0861 -2.92722 
IFIT1 1.00993 70.7712 32.0998 2.55953 2.64825 12.0786 1.34163 6.13084 4.99024 -4.78921 -3.64862 
IFIT2 0.101339 81.6938 34.9401 1.4184 1.03569 14.1405 3.807 9.65489 8.42955 -5.84789 -4.62255 
IFIT3 0.264017 80.337 31.1563 0.80443 0.883057 9.12587 1.60734 8.24929 6.88275 -6.64195 -5.27542 
IFITM1 10.0568 14.7331 19.3776 6.34603 10.8528 10.0989 -0.66425 0.550889 0.946215 -1.21514 -1.61046 
IFITM2 22.3026 34.1612 34.1453 10.7379 13.3013 10.8413 -1.0545 0.615149 0.614477 -1.66965 -1.66898 
IFITM3 7.37645 19.4612 17.6457 4.10294 3.72201 3.61185 -0.84627 1.3996 1.25832 -2.24587 -2.10459 
IFNB1 0.061254 19.935 4.20515 0.973042 0.115415 0.389048 3.98963 8.34629 6.10122 -4.35666 -2.11158 
IGF2 1.50479 2.29717 2.1009 0.448355 0.58823 1.36703 -1.74685 0.61029 0.481439 -2.35714 -2.22829 
IGFBP3 0.751658 1.33238 0.841011 0.421892 0.077128 0.071053 -0.8332 0.825854 0.162049 -1.65906 -0.99525 
IGFBP4 4.06197 4.20684 4.49456 2.22292 1.84799 2.3571 -0.86973 0.050559 0.145999 -0.92028 -1.01572 
IGFBP6 0.514302 1.5665 1.39448 0.85568 1.60899 1.18053 0.734457 1.60685 1.43904 -0.8724 -0.70458 
IGFBP7 3.04212 4.10313 3.47171 1.45538 0.522328 0.818017 -1.06368 0.431649 0.190572 -1.49533 -1.25425 
IGLL3P 0.502363 0.798452 0.91624 0.421823 1.33289 1.33279 -0.25209 0.668477 0.866997 -0.92057 -1.11909 
IGSF1 0.180705 1.25047 1.26148 0.21735 1.12492 1.54727 0.266383 2.79076 2.80341 -2.52438 -2.53702 
IGSF21 0.56645 1.25873 1.25914 0.373552 0.27829 0.631331 -0.60064 1.15195 1.15241 -1.75259 -1.75305 
IKZF1 1.11321 1.36764 1.21654 0.451449 0.325898 0.389071 -1.30209 0.296957 0.128052 -1.59905 -1.43015 
IL32 0.189866 9.85416 4.22578 0.060644 0.509106 1.95309 -1.64654 5.69768 4.47617 -7.34422 -6.12271 
INHBE 0.246096 4.66225 2.46905 1.14214 0.261621 0.340889 2.21444 4.24373 3.32666 -2.02929 -1.11222 
INPP5D 0.042257 1.32558 0.484673 0.093475 0.93821 1.36785 1.14538 4.97128 3.51974 -3.8259 -2.37436 
INSC 0.245033 1.18081 0.80922 0.761841 0.123971 0.116932 1.63651 2.26873 1.72356 -0.63222 -0.08704 
IQSEC2 5.77452 6.71848 6.29106 2.95208 5.83291 6.5306 -0.96797 0.218434 0.123601 -1.1864 -1.09157 
ISG15 4.11058 203.473 72.8468 5.55473 5.31367 22.0228 0.434376 5.62935 4.14745 -5.19498 -3.71308 
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H-v601-

















JAM2 1.56402 3.36518 2.82712 1.53584 0.970892 1.27886 -0.02623 1.10542 0.854074 -1.13166 -0.88031 
JUNB 8.68312 14.7472 10.999 5.67203 6.91467 9.54178 -0.61435 0.764156 0.34109 -1.3785 -0.95544 
JUP 18.3302 28.7571 22.3234 13.8683 17.5967 18.8256 -0.40243 0.649699 0.284334 -1.05212 -0.68676 
KCNB1 0.309917 0.692326 0.392662 0.344433 0.113461 0.257958 0.152341 1.15957 0.341405 -1.00723 -0.18907 
KCND3 0.660028 0.929257 0.664756 0.264731 0.122026 0.188975 -1.318 0.49355 0.010297 -1.81155 -1.3283 
KCNH2 2.36829 3.70535 2.44232 1.54552 0.511454 1.02804 -0.61575 0.645764 0.044407 -1.26151 -0.66016 
KCNH3 0.345034 0.765149 0.618906 0.396014 0.693504 0.859886 0.198813 1.149 0.842981 -0.95019 -0.64417 
KCNJ4 4.29918 4.97448 4.34141 2.49638 1.75136 2.00787 -0.78422 0.210485 0.014102 -0.99471 -0.79833 
KCNN1 1.36405 1.85839 1.56308 0.928293 4.75874 6.55931 -0.55524 0.446159 0.196499 -1.0014 -0.75174 
KCNN2 0.297813 0.623746 0.525709 0.15681 0.554612 0.471964 -0.92539 1.06655 0.819859 -1.99194 -1.74525 
KCNN4 0.038558 0.818986 0.301789 0.011186 0.307649 0.336429 -1.78533 4.40873 2.96843 -6.19406 -4.75377 
KCNS3 0.685919 0.750132 1.05954 0.364455 0.634406 0.638234 -0.9123 0.129105 0.627323 -1.0414 -1.53962 
KCNV1 0 0.392635 0.609487 0.02659 0 0.046895 inf inf inf -3.88424 -4.51865 
KCTD8 0.049413 0.202962 0.716079 0.071922 0.045769 0.044396 0.541547 2.03826 3.85717 -1.49672 -3.31562 
KLF2 1.04809 1.66023 1.20595 0.446947 1.89817 1.28493 -1.22958 0.663623 0.202413 -1.89321 -1.432 
KLF4 1.66115 3.65211 2.73793 1.51636 1.53916 1.9323 -0.13157 1.13655 0.720908 -1.26812 -0.85248 
KRBA2 0.334696 0.715557 0.396256 0.274032 0.661189 0.444841 -0.28851 1.09622 0.243584 -1.38472 -0.53209 
KRT17 0.028861 1.36144 0.315167 0.04987 0.213203 0.62307 0.789054 5.55986 3.44892 -4.77081 -2.65987 
KRT75 0.030725 1.58305 0.302546 0.014006 0.077248 0.372288 -1.13331 5.68716 3.29968 -6.82047 -4.43299 
KRTAP21-2 0 3.3216 1.37524 0.754282 0.594925 0.945234 inf inf inf -2.1387 -0.86651 
L1CAM 0.246139 0.639772 0.446173 0.196344 0.315635 0.524373 -0.32609 1.37808 0.858128 -1.70417 -1.18422 
L3MBTL4 0.295921 0.65766 0.412341 0.383057 0.022164 0 0.372345 1.15213 0.478623 -0.77978 -0.10628 
LAMB2P1 0.454898 1.19446 1.00426 0.417378 0.612426 0.51786 -0.12419 1.39274 1.14252 -1.51693 -1.2667 
LAMB3 0.056671 0.642536 0.242769 0.018887 0.097022 0.129869 -1.58521 3.5031 2.0989 -5.08831 -3.68411 
LAMC3 1.07057 1.84614 1.59171 0.778337 1.51731 0.606594 -0.45991 0.786137 0.572195 -1.24605 -1.03211 
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LCN15 0.777266 1.67493 1.48701 0.459896 0.193116 0.482348 -0.7571 1.10762 0.935938 -1.86472 -1.69304 
LGALS1 5.59735 21.6096 9.80216 5.65326 11.2356 13.7016 0.014337 1.94886 0.808355 -1.93452 -0.79402 
LGALS3BP 8.69439 19.9932 17.8915 1.89494 81.1998 69.7693 -2.19793 1.20135 1.04111 -3.39928 -3.23904 
LIF 0.488434 3.16906 1.30207 0.583777 0.485112 0.886772 0.257254 2.69782 1.41457 -2.44056 -1.15732 
LIMS2 1.15491 1.52216 1.1639 0.484967 0.23937 0.455535 -1.25182 0.398346 0.011193 -1.65016 -1.26301 
LINC00515 0.23746 0.560418 0.539758 0.513026 1.19948 0.718195 1.11135 1.23882 1.18463 -0.12747 -0.07328 
LINC00599 0.282306 0.39928 0.580237 0.303883 0.135631 0.076012 0.106256 0.50014 1.03938 -0.39388 -0.93313 
LINC00652 0.418665 0.588811 0.527556 0.226805 1.09045 1.31628 -0.88434 0.492009 0.333527 -1.37635 -1.21787 
LINC00663 0.326579 0.685335 0.429172 0.413652 0.697762 0.424006 0.340985 1.06938 0.394123 -0.72839 -0.05314 
LINC00950 0.210648 0.58982 0.523711 0.300614 0.346135 0.376388 0.51308 1.48544 1.31394 -0.97237 -0.80086 
LINC01234 2.28986 2.8805 2.59166 1.44777 13.3152 13.6095 -0.66143 0.33106 0.178615 -0.99249 -0.84004 
LINC01252 0.345778 0.693215 0.536343 0.391101 0.053166 0.09645 0.177692 1.00346 0.633309 -0.82576 -0.45562 
LINC01341 0.298643 0.46384 0.56025 0.270278 0.394295 0.434746 -0.14398 0.635205 0.907649 -0.77918 -1.05163 
LINGO3 0.378156 0.622816 0.534322 0.164449 0.038929 0.036712 -1.20134 0.719826 0.49873 -1.92116 -1.70007 
LIPE 1.04655 1.1859 1.47212 0.476657 2.27971 2.3071 -1.13461 0.180341 0.492261 -1.31495 -1.62687 
LMCD1 1.01437 2.10472 1.2027 1.14103 0.811906 1.03672 0.169752 1.05304 0.245695 -0.88329 -0.07594 
LMO3 0.765738 0.95778 1.24152 0.367268 0.043043 0.171931 -1.06002 0.322843 0.697187 -1.38286 -1.75721 
LMOD1 2.44644 6.07747 4.20947 2.94264 2.7049 2.90569 0.266428 1.31279 0.782956 -1.04636 -0.51653 
LMTK3 0.941077 1.01106 1.23956 0.553156 1.0723 1.56294 -0.76663 0.103479 0.397438 -0.87011 -1.16406 
LOC100129148 0.401655 5.88846 2.97272 2.01341 1.98097 4.62243 2.32561 3.87386 2.88776 -1.54825 -0.56215 
LOC100130691 0.282976 0.624471 0.414949 0.315368 0.244214 0.241862 0.156357 1.14195 0.552254 -0.9856 -0.3959 
LOC100132057 0.567639 1.75203 1.19224 0.656062 0.290202 0.872182 0.208859 1.62599 1.07063 -1.41713 -0.86177 
LOC100134368 0.792251 1.3198 1.11688 0.486084 1.19519 0.8949 -0.70475 0.736295 0.495442 -1.44105 -1.20019 
LOC100240734 0.205566 0.422181 0.693532 0.396604 0.25025 0.492517 0.948099 1.03826 1.75436 -0.09016 -0.80627 
LOC100268168 0.472845 1.11662 0.776622 0.580022 0.494456 0.382646 0.294741 1.2397 0.715845 -0.94496 -0.4211 
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LOC100506082 3.14776 4.29741 3.3998 1.17027 1.51644 1.0469 -1.42749 0.449144 0.111127 -1.87663 -1.53861 
LOC100506119 0.130543 0.610169 0.32874 0.261005 0.068397 0.048055 0.999547 2.22468 1.33242 -1.22513 -0.33287 
LOC100507250 0.812373 1.37853 1.86167 1.07775 0.841938 0.664791 0.407815 0.762915 1.19639 -0.3551 -0.78857 
LOC100652999 0.439931 0.661056 0.50022 0.117789 0.100086 0.233595 -1.90108 0.587495 0.185287 -2.48857 -2.08636 
LOC101927217 0.19719 0.934275 0.625811 0.488787 0.090241 0.27288 1.30962 2.24426 1.66614 -0.93464 -0.35652 
LOC101927571 0.135278 0.84172 0.921983 0 0.260318 0.150873 #NAME? 2.63741 2.76881 #NAME? #NAME? 
LOC101928470 1.90578 2.25035 2.69134 1.33 3.10811 1.94954 -0.51896 0.239763 0.497943 -0.75872 -1.0169 
LOC101928837 0.69948 1.01275 2.86859 0.920614 0 0.427818 0.396314 0.53392 2.03599 -0.13761 -1.63968 
LOC101928943 0.089309 0.684771 0.279512 0.227816 0.336557 0.238012 1.351 2.93875 1.64604 -1.58775 -0.29504 
LOC101929221 0.291502 0.453227 0.636718 0.179442 0.327999 0 -0.69999 0.636726 1.12715 -1.33671 -1.82714 
LOC101929715 0.753794 1.4444 1.68915 1.12039 0.983619 0.429037 0.571758 0.938229 1.16406 -0.36647 -0.5923 
LOC102723439 0.189778 0.55536 0.800866 0.392805 0.472019 1.005 1.0495 1.54911 2.07725 -0.49961 -1.02775 
LOC102724467 0.24423 1.21728 0.737416 0.433801 0.066576 0.125566 0.828791 2.31735 1.59424 -1.48856 -0.76545 
LOC283070 2.6831 3.03938 2.99834 1.34478 2.18856 2.47633 -0.99653 0.179874 0.16026 -1.17641 -1.15679 
LOC283352 0.479208 2.40437 0.673851 0 4.67657 4.29388 #NAME? 2.32693 0.491777 #NAME? #NAME? 
LOC283693 0.258813 0.710052 0.435608 0.347408 0.257815 0.435647 0.424718 1.45601 0.751119 -1.03129 -0.3264 
LOC284837 0.366338 0.797736 0.736914 0.301529 0.791355 1.0677 -0.28088 1.12274 1.00832 -1.40362 -1.2892 
LOC285074 1.02151 2.06144 1.97082 1.43157 2.15336 2.60901 0.486892 1.01295 0.948092 -0.52606 -0.4612 
LOC441204 0.592693 0.657017 0.628256 0.329287 0.025175 0.095224 -0.84794 0.148645 0.084067 -0.99659 -0.93201 
LOC441454 0.534543 0.820292 1.17022 0.513516 0.60116 0.551898 -0.0579 0.617831 1.13041 -0.67573 -1.1883 
LOC642236 0.611967 0.920621 0.804328 0.374814 0.043236 0.065831 -0.70728 0.589153 0.39433 -1.29643 -1.10161 
LOC643201 0.086773 0.665232 0.540324 0.198497 0.359569 0.983212 1.19381 2.93855 2.63852 -1.74474 -1.44471 
LOC653160 0.631249 0.838586 0.848352 0.388657 0.7462 0.604136 -0.69971 0.40975 0.426455 -1.10946 -1.12616 
LOC90246 1.86082 2.16088 2.24788 1.11307 1.03483 1.64304 -0.74139 0.215687 0.272633 -0.95708 -1.01402 
LPPR3 4.35429 6.12316 6.26336 2.97535 1.27591 2.06097 -0.54938 0.49184 0.524499 -1.04122 -1.07388 
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LRP4-AS1 0.246442 0.597578 0.81211 0.31418 0.555932 0.76571 0.350342 1.27788 1.72043 -0.92754 -1.37008 
LRRC23 1.68895 3.40676 3.15044 2.67743 3.02868 2.23419 0.664719 1.01227 0.899423 -0.34755 -0.2347 
LRRC4B 3.94702 4.95657 4.78783 2.04076 4.92506 5.41409 -0.95165 0.328581 0.278609 -1.28023 -1.23026 
LRRC75A 2.28295 2.45531 2.74321 1.26735 1.92999 2.18023 -0.84909 0.105002 0.264963 -0.95409 -1.11405 
LTBP2 0.51987 0.714114 0.723815 0.357505 0.457223 0.513126 -0.54019 0.458004 0.477469 -0.99819 -1.01766 
LTBP3 7.81477 11.6228 9.03715 5.42754 5.63404 7.55806 -0.52591 0.572682 0.209665 -1.09859 -0.73557 
LTC4S 0.295716 0.583561 0.681412 0.321832 0.161901 0.275933 0.122095 0.980669 1.20431 -0.85857 -1.08222 
LXN 3.19036 4.17008 6.15521 2.54652 4.28149 4.0134 -0.32519 0.386357 0.94809 -0.71155 -1.27328 
MAFA 1.55242 2.12935 2.15049 0.892376 1.21492 1.87885 -0.79879 0.455896 0.470147 -1.25469 -1.26894 
MAGEB2 3.50442 8.25718 8.44491 2.73311 0 0.175757 -0.35863 1.23647 1.26891 -1.59511 -1.62754 
MAGEC2 0.28523 0.782904 0.40827 0.247484 0.041014 0.158002 -0.20479 1.45671 0.517398 -1.6615 -0.72219 
MAL2 0.279073 1.48604 3.13766 0.067312 0.112343 0.23612 -2.05171 2.41276 3.49097 -4.46447 -5.54268 
MALAT1 46.4638 61.1971 61.7245 13.1531 61.4474 49.0718 -1.82071 0.397355 0.409736 -2.21807 -2.23045 
MAMLD1 4.49642 5.19384 5.23767 2.37782 4.043 4.4656 -0.91914 0.208026 0.220151 -1.12716 -1.13929 
MAMSTR 2.33385 2.55989 2.81196 1.36909 2.14474 2.08302 -0.7695 0.133369 0.268863 -0.90287 -1.03836 
MATN1-AS1 0.618157 1.38926 1.06914 0.948549 0.651577 0.962595 0.617749 1.16827 0.790409 -0.55052 -0.17266 
MBD6 15.9762 17.2934 16.5162 8.27748 21.7385 23.5946 -0.94866 0.114302 0.047961 -1.06296 -0.99662 
MCF2L-AS1 0.703738 1.02835 1.03006 0.498423 0.270993 0.50879 -0.49767 0.547221 0.549622 -1.04489 -1.04729 
MEIS3 4.25249 5.08834 5.78512 2.42473 2.05818 3.19596 -0.81048 0.258887 0.444038 -1.06937 -1.25452 
MGAT5B 1.87838 2.14794 1.98622 1.0668 0.662635 1.31007 -0.8162 0.193461 0.080538 -1.00966 -0.89673 
MGLL 1.70695 1.79381 1.82752 0.802469 1.44683 1.31641 -1.08891 0.071599 0.098466 -1.16051 -1.18737 
MIR1256 4.99166 8.91033 8.47719 0 0 0 #NAME? 0.835959 0.764066 #NAME? #NAME? 
MIR1287 0.285128 21.6727 0.571235 0.404878 0.513678 0.273079 0.505879 6.24813 1.00248 -5.74225 -0.4966 
MIR1302-8 0 6.35603 12.6153 5.11559 0 0 inf inf inf -0.31323 -1.3022 
MIR3665 0 27.0801 7.71208 4.5862 14.2848 0 inf inf inf -2.56186 -0.74982 
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MIR3936 0 42.9893 47.114 28.6267 0 12.5379 inf inf inf -0.58661 -0.71879 
MIR5193 0.271312 0.605378 0.491503 0.425469 0.484346 0.630292 0.649103 1.15788 0.857248 -0.50878 -0.20815 
MIR548AN 75.5667 90.0779 257.557 34.7888 189.845 73.8029 -1.11913 0.253423 1.76907 -1.37255 -2.8882 
MIR568 0.243943 10.8751 0.334766 0.244912 0.098893 0.08891 0.005721 5.47835 0.456611 -5.47262 -0.45089 
MIR590 47.8669 116.893 193.728 86.4751 272.686 183.681 0.853258 1.2881 2.01694 -0.43484 -1.16368 
MIR593 0 36.5859 26.6899 12.2059 0 0 inf inf inf -1.58371 -1.12871 
MIR6073 4.62067 27.4786 37.2945 1.30552 1.23726 1.08238 -1.82348 2.57213 3.01279 -4.39561 -4.83627 
MIR612 21.1916 37.338 53.3414 0 20.0918 0 #NAME? 0.817155 1.33176 #NAME? #NAME? 
MIR6126 36.2359 61.273 45.6377 20.8712 34.3554 32.3983 -0.79591 0.757831 0.332805 -1.55374 -1.12871 
MIR6132 7.18274 25.1688 24.4889 18.3169 27.0654 8.01186 1.35057 1.80903 1.76952 -0.45846 -0.41895 
MIR621 77.2644 233.494 152.828 18.4981 148.867 159.422 -2.06243 1.59551 0.984038 -3.65793 -3.04646 
MIR6513 0.991132 1.83736 1.18427 0.900387 234.162 1.93146 -0.13853 0.890486 0.256846 -1.02902 -0.39538 
MIR6516 76.7335 92.8544 303.033 78.5102 46.9105 244.901 0.033023 0.275113 1.98155 -0.24209 -1.94853 
MIR659 72.8647 95.9575 81.5146 0 138.195 21.7864 #NAME? 0.397177 0.16184 #NAME? #NAME? 
MIR6716 5.97363 6.35341 32.6852 4.52306 6.88478 6.3156 -0.40131 0.088922 2.45196 -0.49023 -2.85327 
MIR6717 16.0656 16.2969 102.756 12.2194 111.303 16.0606 -0.3948 0.020622 2.67717 -0.41543 -3.07197 
MIR6821 0 120.605 399.473 109.55 262.973 156.769 inf inf inf -0.1387 -1.86651 
MIR6835 241.064 318.934 410.963 0 0 134.427 #NAME? 0.403843 0.769592 #NAME? #NAME? 
MIR6872 0.980954 1.65868 113.525 0.986441 203.735 1.31074 0.008047 0.757778 6.85461 -0.74973 -6.84656 
MIR7109 17.6281 109.523 200.36 16.1099 12.2572 132.672 -0.12993 2.63528 3.50665 -2.76521 -3.63658 
MIR7113 0 623.889 803.913 601.278 907.434 0 inf inf inf -0.05326 -0.41901 
MIR7-3HG 0 0.545811 0.147349 0.047698 0.456893 0.16386 inf inf inf -3.51641 -1.62724 
MR1 0.846335 1.71822 1.22994 0.9888 1.38399 1.06003 0.224449 1.02162 0.53929 -0.79717 -0.31484 
MRVI1-AS1 0 0.700087 0.416057 0.375334 0.175168 0.294451 inf inf inf -0.89936 -0.14861 
MTNR1A 0.522094 1.06686 0.663048 0.466357 0.821684 0.316736 -0.16287 1.03099 0.344805 -1.19386 -0.50768 
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MYRIP 0.433538 0.972519 0.880981 0.317534 0.08452 0.0239 -0.44925 1.16557 1.02295 -1.61482 -1.4722 
NACAD 0.461511 0.504475 0.590277 0.293464 0.357187 0.428324 -0.65318 0.12842 0.355028 -0.7816 -1.00821 
NDUFA4L2 0.400713 1.00231 0.641498 0.551381 0.225402 0.375953 0.46048 1.32268 0.678878 -0.8622 -0.2184 
NELL1 0.305085 0.916783 1.02994 0.362704 0.672508 0.50899 0.249583 1.58737 1.75528 -1.33779 -1.5057 
NEURL1 0.603447 0.749009 0.819643 0.340916 0.875089 0.972246 -0.82381 0.311755 0.441769 -1.13557 -1.26558 
NFIC 9.89553 10.9148 10.0485 3.2709 13.0206 14.7832 -1.59709 0.141432 0.022137 -1.73852 -1.61922 
NFIX 11.4692 11.7567 11.7552 5.30169 15.2177 16.7362 -1.11324 0.035728 0.03554 -1.14897 -1.14878 
NFKB2 7.79734 17.8928 12.6907 8.12523 8.5826 8.90137 0.059427 1.19833 0.702713 -1.1389 -0.64329 
NFKBIA 12.4153 42.7488 21.8306 12.8923 11.9847 17.7671 0.054392 1.78377 0.814237 -1.72938 -0.75985 
NGFR 0.360648 1.21557 0.862155 0.186617 0.252574 0.40068 -0.95051 1.75297 1.25735 -2.70348 -2.20787 
NHLH1 0.467923 0.557861 0.486437 0.230305 0.55053 0.522923 -1.02273 0.253634 0.055983 -1.27636 -1.07871 
NLRC5 0.313689 0.726757 0.662116 0.235592 0.742 0.790054 -0.41304 1.21214 1.07775 -1.62518 -1.49079 
NMNAT2 1.58457 4.11432 2.60742 1.64158 0.558667 0.745857 0.051001 1.37657 0.718534 -1.32556 -0.66753 
NOTCH3 10.591 11.5532 11.7238 5.90239 6.22225 6.21539 -0.84347 0.12545 0.146603 -0.96892 -0.99008 
NOTUM 0.292346 0.524591 0.602251 0.421616 0.164506 0.201237 0.528252 0.843514 1.04269 -0.31526 -0.51444 
NOV 0.115232 1.25656 0.761787 0.111411 0.18377 0.629603 -0.04865 3.44687 2.72484 -3.49552 -2.77349 
NOVA2 3.3214 4.15385 3.65101 1.65801 2.0998 3.42284 -1.00234 0.322656 0.136503 -1.325 -1.13884 
NOXA1 3.51956 7.02591 5.21088 3.23736 2.50932 2.83964 -0.12058 0.997291 0.566133 -1.11787 -0.68671 
NPAS1 9.73561 11.5986 14.3904 6.68174 19.3651 19.8238 -0.54305 0.252612 0.56376 -0.79566 -1.10681 
NPIPA1 0.635516 0.881171 0.665103 0.412596 0.533965 0.914016 -0.6232 0.471493 0.065648 -1.09469 -0.68885 
NPM2 1.06717 1.09616 1.16768 0.517546 0.691717 0.792744 -1.04403 0.038666 0.129857 -1.0827 -1.17389 
NR1D1 2.04873 2.69349 2.48402 1.30911 3.21752 4.0497 -0.64615 0.394747 0.277949 -1.04089 -0.9241 
NRG2 1.8421 2.37828 2.13654 1.15788 1.98131 2.51207 -0.66987 0.368563 0.213921 -1.03844 -0.8838 
NRXN2 0.988128 1.68496 1.28251 0.589651 0.806027 1.4821 -0.74484 0.769942 0.376204 -1.51478 -1.12104 
NT5C1A 1.10787 1.92525 2.40797 1.27222 2.16901 2.29991 0.19956 0.797253 1.12002 -0.59769 -0.92047 
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H-v601-

















NUAK2 0.682384 1.40497 0.737593 0.536789 0.521342 0.80186 -0.34623 1.04188 0.112241 -1.38811 -0.45847 
NUCB1-AS1 0.367382 0.790213 0.913215 0.312953 0.515862 0.263752 -0.23134 1.10496 1.31367 -1.3363 -1.54501 
NUPR1 2.38119 25.1262 14.1212 2.8981 1.52597 2.39785 0.283426 3.39944 2.5681 -3.11601 -2.28468 
NWD2 0.126617 0.461082 0.657441 0.208929 0.045963 0.08188 0.722543 1.86455 2.37639 -1.14201 -1.65385 
NXPH4 10.3131 10.4368 12.0646 4.514 8.43872 9.57697 -1.192 0.01721 0.22631 -1.20921 -1.41831 
NYAP1 0.285082 0.631664 0.422711 0.381691 0.732728 0.579276 0.421028 1.14778 0.568294 -0.72675 -0.14727 
NYNRIN 5.24593 7.04532 5.9901 3.29343 5.1256 4.21963 -0.67161 0.425466 0.191381 -1.09707 -0.86299 
OASL 0.039196 57.6914 25.7607 0.555126 0.592468 6.96536 3.82404 10.5234 9.36025 -6.6994 -5.53621 
ODF3L2 0.647105 0.813046 0.723129 0.119773 0.343636 0.533965 -2.4337 0.329336 0.160253 -2.76304 -2.59396 
OLFM2 8.93817 11.0271 11.1903 4.45488 7.0559 9.19644 -1.00459 0.302998 0.3242 -1.30759 -1.32879 
OLFML2A 0.546393 0.989687 1.04696 0.33219 0.871199 0.912615 -0.71793 0.857032 0.938202 -1.57496 -1.65613 
ONECUT1 0.738273 0.923932 0.786655 0.316909 0.40274 0.52361 -1.22009 0.323633 0.091577 -1.54372 -1.31166 
OPRD1 0.738721 1.02133 0.846105 0.425871 0.071633 0.067553 -0.79461 0.467352 0.195809 -1.26196 -0.99042 
OPTN 4.98782 12.2371 8.10134 6.78972 9.06259 6.87395 0.444942 1.29479 0.699752 -0.84984 -0.25481 
OR2B6 0.559766 0.853142 0.629865 0.417926 0.198933 0.239491 -0.42158 0.607962 0.170219 -1.02954 -0.5918 
ORAI3 2.38081 4.14931 3.26409 2.07215 2.45563 2.70332 -0.20033 0.801416 0.455227 -1.00174 -0.65555 
OSBP2 4.65743 6.0044 4.79054 2.85052 3.36619 4.79215 -0.70831 0.366485 0.040653 -1.07479 -0.74896 
OSBPL7 1.38264 3.20568 3.05954 1.45367 2.9006 2.84335 0.072268 1.2132 1.14589 -1.14093 -1.07362 
OSGIN1 0.566757 1.03606 0.640843 0.389912 0.511973 0.585693 -0.53958 0.870304 0.177239 -1.40989 -0.71682 
OSR1 0.47741 1.03376 0.559791 0.436062 0 0.020919 -0.1307 1.11459 0.229659 -1.24529 -0.36035 
OVGP1 3.55463 7.17723 5.35996 2.06501 7.71818 9.77217 -0.78355 1.01373 0.592521 -1.79728 -1.37607 
P4HA2-AS1 0.738056 1.81925 1.68245 1.27234 1.34862 1.57008 0.78568 1.30154 1.18876 -0.51586 -0.40308 
PACS1 10.6753 13.1348 11.4982 5.65922 13.7904 13.1336 -0.9156 0.299121 0.107131 -1.21472 -1.02273 
PALM 8.79135 9.56743 10.3509 4.97422 10.9645 11.4409 -0.82161 0.122047 0.235606 -0.94366 -1.05722 
PARD6G-AS1 0.505945 0.605688 0.548376 0.225168 0.923998 0.685944 -1.16798 0.259594 0.116185 -1.42757 -1.28416 
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PCOLCE-AS1 0.185611 0.537474 0.582191 0.430682 0.177779 0.358357 1.21434 1.53391 1.64921 -0.31957 -0.43487 
PDGFB 0.351329 0.860811 0.617758 0.419478 0.188846 0.224995 0.255771 1.29287 0.814216 -1.0371 -0.55845 
PDGFD 0.094032 0.280785 0.548922 0.038388 0.028954 0.134999 -1.29248 1.57824 2.54538 -2.87072 -3.83786 
PHLDA3 10.3332 20.913 12.2995 8.74107 19.1311 23.8652 -0.24141 1.01711 0.25131 -1.25851 -0.49272 
PIANP 2.86477 3.55994 2.98849 1.78858 2.70622 3.74878 -0.67961 0.313432 0.060997 -0.99304 -0.74061 
PIGZ 0.480355 0.765045 0.543681 0.373205 0.498502 0.580223 -0.36413 0.671443 0.178661 -1.03558 -0.54279 
PILRA 0.869572 1.03073 1.24657 0.546626 0.557911 0.730485 -0.66975 0.245293 0.519585 -0.91504 -1.18934 
PIP5KL1 0.369367 0.762441 0.976886 0.566741 0.754533 0.596515 0.617635 1.04557 1.40314 -0.42794 -0.7855 
PITX3 1.16393 1.58142 1.57004 0.736017 1.50523 1.77498 -0.66119 0.442225 0.4318 -1.10341 -1.09299 
PLA2G4C 0.249328 2.41811 1.05294 0.316544 0.16035 0.56646 0.344362 3.27777 2.07831 -2.93341 -1.73394 
PLEKHA4 0.783856 2.17601 1.60742 0.619387 2.21701 1.90578 -0.33975 1.47303 1.03609 -1.81278 -1.37584 
PLK3 1.65072 2.92464 2.28197 1.34149 2.31319 2.7719 -0.29926 0.825162 0.467184 -1.12442 -0.76644 
PML 9.58754 12.8318 10.733 5.8715 9.55294 11.3267 -0.70743 0.420491 0.162825 -1.12792 -0.87026 
PNCK 0.648564 1.77836 1.70829 0.628018 0.14156 0.323647 -0.04644 1.45523 1.39724 -1.50167 -1.44368 
POLR2J4 1.39837 1.91541 1.58407 0.833973 1.37216 1.34672 -0.74567 0.453909 0.17989 -1.19958 -0.92556 
PPAPDC1A 1.77953 1.99818 1.87857 0.826739 0.979641 1.2261 -1.10599 0.167192 0.078141 -1.27319 -1.18413 
PPP1R15A 10.8062 48.955 24.6706 19.9789 14.525 18.8929 0.886614 2.17959 1.19093 -1.29298 -0.30432 
PPP1R1A 1.88254 2.74104 2.98414 1.21662 1.05412 0.93239 -0.62981 0.54204 0.664632 -1.17185 -1.29444 
PPP1R1C 0.519624 0.95646 1.15909 0.470533 0.601583 0.676894 -0.14317 0.880237 1.15745 -1.02341 -1.30063 
PRC1-AS1 0.531662 0.881807 0.600932 0.160211 0.612063 0.402894 -1.73054 0.729955 0.176693 -2.46049 -1.90723 
PRKCB 1.21652 4.54628 2.96462 1.30584 5.02642 8.25666 0.102221 1.90193 1.28509 -1.79971 -1.18287 
PRKCG 0.510918 0.817665 0.579134 0.30019 0.472788 0.682511 -0.76722 0.678419 0.180806 -1.44563 -0.94802 
PRPH 0.905419 1.35805 1.37611 0.331321 0.760505 0.594955 -1.45036 0.584883 0.603938 -2.03524 -2.05429 
PRR24 5.60269 7.84665 5.95677 3.56934 5.6944 6.96194 -0.65046 0.485958 0.088412 -1.13642 -0.73887 
PRR35 0.91095 1.38836 1.03051 0.300267 0.773644 0.671399 -1.60112 0.607941 0.17791 -2.20907 -1.77903 
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PSPN 0.072931 0.380706 0.745723 0.271245 0.549671 0.295025 1.89499 2.38407 3.35403 -0.48908 -1.45905 
PTCH2 0.701453 0.813541 0.789918 0.353557 0.609249 0.797817 -0.9884 0.21387 0.171358 -1.20227 -1.15976 
PTGES 0.932843 1.90805 2.01359 0.6264 0.81208 1.12501 -0.57455 1.03239 1.11006 -1.60694 -1.68461 
PTN 0.058583 0.422105 0.694227 0.016996 0.027976 0.042596 -1.78533 2.84905 3.56685 -4.63438 -5.35218 
PVT1 3.07975 11.0299 7.06362 3.13623 4.56267 7.35351 0.02622 1.84054 1.19759 -1.81432 -1.17138 
RAB38 1.89375 2.62875 3.83355 1.35469 0.087052 0.045445 -0.48329 0.473131 1.01743 -0.95642 -1.50072 
RAB3IL1 4.87606 5.89743 4.89103 2.889 4.21968 5.11469 -0.75514 0.274371 0.004421 -1.02952 -0.75957 
RAB6C-AS1 0.654489 0.847174 0.735684 0.416004 0.34412 0.371373 -0.65377 0.372289 0.168717 -1.02606 -0.82249 
RAET1G 0.32639 0.651522 0.404511 0.205613 0.915436 0.686539 -0.66667 0.997217 0.309582 -1.66389 -0.97625 
RAI2 1.18453 1.23669 1.33937 0.626962 0.760591 1.0617 -0.91786 0.06218 0.17724 -0.98004 -1.0951 
RAP1GAP 4.12242 4.90912 4.24905 2.25237 3.32992 5.31611 -0.87205 0.251971 0.043647 -1.12402 -0.91569 
RASD2 0.958727 1.34898 1.09141 0.625987 0.604397 0.924268 -0.61499 0.492673 0.187005 -1.10766 -0.80199 
RASGEF1C 1.87861 2.80303 2.37697 0.971221 1.21422 1.27812 -0.95179 0.577325 0.339463 -1.52912 -1.29125 
RBFOX3 2.02006 2.25192 2.75877 1.10343 2.24665 3.83617 -0.87241 0.156757 0.449626 -1.02916 -1.32203 
RCAN3AS 0.146032 0.612879 0.678417 0.243114 0 0.193022 0.735342 2.06931 2.21588 -1.33397 -1.48054 
RELB 0.975605 4.21438 2.50122 0.664736 1.33123 1.78122 -0.55352 2.11095 1.35826 -2.66447 -1.91178 
RENBP 1.94963 5.62144 4.18161 2.38203 0.352583 0.572862 0.288993 1.52774 1.10086 -1.23875 -0.81186 
RGS9 0.418809 0.799461 0.515832 0.31017 0.379349 0.598173 -0.43323 0.932736 0.300611 -1.36597 -0.73384 
RHEBL1 0.624798 3.78373 1.80928 1.04877 0.90536 0.793238 0.747238 2.59835 1.53396 -1.85111 -0.78672 
RIMS2 0.419479 0.927816 0.785977 0.724361 0.175288 0.2146 0.78811 1.14524 0.905887 -0.35713 -0.11778 
RIN3 3.8432 4.36414 4.23838 1.94228 1.05525 1.09886 -0.98456 0.18339 0.141206 -1.16795 -1.12576 
RND1 2.09238 4.6197 3.47834 2.52058 1.85813 2.35319 0.268611 1.14266 0.733256 -0.87404 -0.46465 
RNF208 13.188 16.5325 13.1922 4.76799 1.3633 2.43166 -1.46777 0.326084 0.000464 -1.79385 -1.46823 
RNU11 9.0816 21.0074 20.4299 0 11.5366 12.126 #NAME? 1.20988 1.16966 #NAME? #NAME? 
RNU12 4.14543 9.05637 5.22853 0 3.9303 0 #NAME? 1.12741 0.334884 #NAME? #NAME? 
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RNU86 7400.23 10139.1 12597.3 5860.48 3631.98 6934.03 -0.33655 0.454284 0.767471 -0.79084 -1.10402 
ROCK1P1 0.286893 0.822292 0.405084 0.372708 0.277773 0.218183 0.377534 1.51914 0.497712 -1.14161 -0.12018 
ROPN1L 0.397448 0.96626 0.578765 0.198433 0.673002 1.10367 -1.00212 1.28164 0.542211 -2.28376 -1.54433 
RPA4 0.26384 0.614447 0.37163 0.364576 0.331045 0.535337 0.466558 1.21963 0.494205 -0.75307 -0.02765 
RSAD2 0 1.43093 0.522221 0.015019 0.022194 0.304928 inf inf inf -6.57403 -5.11981 
RTDR1 0.581744 0.70722 0.601917 0.211341 0.318944 0.391781 -1.46081 0.281776 0.049181 -1.74259 -1.50999 
RTN4RL1 2.02096 2.08226 2.42333 1.12736 1.27868 1.24528 -0.8421 0.04311 0.261945 -0.88521 -1.10404 
RTN4RL2 6.79515 9.14033 7.58316 4.22223 4.25452 5.89769 -0.6865 0.427742 0.158295 -1.11424 -0.84479 
RUNDC3A 0.613086 1.15246 1.20582 0.531863 0.513194 0.94772 -0.20504 0.91056 0.97585 -1.1156 -1.18089 
RUNX1T1 1.6191 1.66921 2.67017 0.970463 1.63618 2.25799 -0.73845 0.043971 0.721739 -0.78242 -1.46019 
RXRG 1.04811 1.63044 1.28395 0.741759 1.97441 1.9028 -0.49877 0.637471 0.292799 -1.13624 -0.79156 
RYR2 0.234351 0.869736 0.480971 0.287192 0.615531 1.26552 0.293344 1.89191 1.03728 -1.59856 -0.74394 
S100P 0.321975 0.555206 0.596654 0.162293 0 0.301952 -0.98835 0.786075 0.889945 -1.77443 -1.8783 
SAMD9 0.738929 1.8174 1.45121 0.518334 2.03987 1.90229 -0.51155 1.29837 0.973752 -1.80992 -1.48531 
SCARNA14 2.82907 10.117 7.23183 7.21456 5.44402 0 1.35059 1.83839 1.35403 -0.4878 -0.00345 
SCARNA2 1.45283 1.48885 2.07365 0.526849 3.10034 4.08743 -1.4634 0.035333 0.513306 -1.49874 -1.97671 
SCARNA4 14.5744 28.2424 24.4834 4.1973 6.90904 17.0352 -1.79591 0.954424 0.748363 -2.75033 -2.54427 
SCARNA9 8.93381 11.7347 10.8551 4.22767 17.3991 19.3794 -1.07941 0.393438 0.281025 -1.47285 -1.36044 
SCG3 0.354178 0.661553 0.761081 0.263258 0.267071 0.864759 -0.428 0.901383 1.10358 -1.32938 -1.53157 
SCN3B 0.790131 1.70367 1.31259 0.578594 0.344272 0.666239 -0.44954 1.10848 0.732257 -1.55802 -1.1818 
SDSL 1.68965 4.57491 2.4785 1.84618 2.53996 2.67464 0.12782 1.43702 0.552739 -1.3092 -0.42492 
SECTM1 0.833914 2.02211 1.34193 0.706288 0.143575 0.215854 -0.23964 1.27789 0.686339 -1.51753 -0.92598 
SELENBP1 9.95076 20.0553 13.059 12.2395 26.9279 27.756 0.298669 1.0111 0.39217 -0.71244 -0.0935 
SEPSECS-AS1 0.322148 0.730004 0.362311 0.296024 0.284757 0.148338 -0.12201 1.18018 0.169506 -1.30219 -0.29152 
SEZ6L2 7.42721 8.42927 7.99355 2.99922 10.926 12.5308 -1.30824 0.182587 0.106016 -1.49082 -1.41425 
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SHANK1 0.22312 0.568006 0.495077 0.266212 0.40005 0.394419 0.254753 1.34808 1.14983 -1.09333 -0.89508 
SHC2 3.82076 10.5221 5.91119 4.79734 0.680069 1.74774 0.328374 1.4615 0.629587 -1.13312 -0.30121 
SHD 0.206793 0.554455 0.350032 0.318553 0.313464 0.176526 0.623346 1.42288 0.759301 -0.79954 -0.13596 
SHISA4 0.569565 2.0162 1.5029 0.691177 1.93631 2.38337 0.279193 1.8237 1.39982 -1.54451 -1.12063 
SHISA8 3.54256 3.59721 3.98033 1.76836 1.45011 1.83816 -1.00238 0.022086 0.168093 -1.02447 -1.17048 
SLC17A7 0.909397 1.2696 1.44318 0.565316 0.844145 1.10547 -0.68585 0.481397 0.666272 -1.16725 -1.35212 
SLC22A4 0.786464 0.953144 0.853862 0.428235 0.552342 0.875017 -0.87698 0.277312 0.118622 -1.15429 -0.9956 
SLC38A3 3.87354 5.02718 5.24248 2.47646 3.93165 5.46892 -0.64537 0.376099 0.4366 -1.02147 -1.08197 
SLC6A16 0.619871 0.792346 0.918456 0.362591 1.12761 1.35082 -0.77362 0.354164 0.567243 -1.12779 -1.34087 
SLC7A5P1 5.1319 9.86393 10.6259 7.98095 6.14758 11.2634 0.637068 0.942669 1.05002 -0.3056 -0.41295 
SLC7A7 0.381218 0.670646 0.495125 0.267062 0.451581 0.46159 -0.51345 0.814934 0.377175 -1.32838 -0.89062 
SLC8A2 0.453946 0.664982 0.656224 0.221066 0.327255 0.601764 -1.03804 0.550796 0.531669 -1.58884 -1.56971 
SLC9A9 0.756686 2.3277 1.64449 1.35467 1.15957 1.03618 0.840169 1.62114 1.11987 -0.78097 -0.27971 
SLCO3A1 1.15704 1.57582 1.51307 0.408828 0.462418 1.10901 -1.50087 0.445661 0.387042 -1.94653 -1.88791 
SLFN5 1.13191 2.63615 1.99213 1.6196 0.870874 0.790516 0.516879 1.21967 0.815548 -0.70279 -0.29867 
SMARCD3 28.8204 32.598 29.4986 16.2223 25.2075 33.8897 -0.82911 0.177689 0.033556 -1.0068 -0.86267 
SNAP25 0.052965 1.05423 1.02338 0.026855 0.261745 0.323273 -0.97987 4.31501 4.27216 -5.29488 -5.25203 
SNCG 0.665064 1.9192 1.01453 0.559025 0.954144 1.21472 -0.25058 1.52894 0.609246 -1.77952 -0.85983 
SND1-IT1 0.367338 0.550267 0.561217 0.061274 0.348738 0.36562 -2.58375 0.583025 0.61145 -3.16678 -3.1952 
SNORA68 38.6275 61.8524 40.6521 4.39151 72.4043 81.6235 -3.13684 0.679202 0.073704 -3.81604 -3.21054 
SNORA74A 2.78519 7.28283 4.73797 0.817406 9.05249 7.64458 -1.76865 1.38673 0.766496 -3.15538 -2.53515 
SNORA75 14.2292 22.05 14.4741 9.92185 15.8782 30.3755 -0.52017 0.631924 0.024617 -1.1521 -0.54479 
SNORD14E 122.861 265.921 155.852 42.1018 112.418 101.987 -1.54507 1.11397 0.343152 -2.65904 -1.88823 
SNORD15A 6.28778 12.5882 10.8077 8.68417 30.9209 15.4984 0.465836 1.00145 0.781439 -0.53562 -0.3156 
SNORD3A 3.17065 16.6152 7.57918 2.77982 3.02082 9.93098 -0.18979 2.38965 1.25726 -2.57944 -1.44705 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















SNORD6 119.909 205.765 357.679 140.178 0 66.8662 0.225322 0.77906 1.57672 -0.55374 -1.3514 
SNORD95 954.619 1777.09 2317.09 1414.03 1023.5 3183.1 0.56682 0.896522 1.27932 -0.3297 -0.7125 
SORCS2 0.292358 0.573116 0.437166 0.180863 0.285233 0.323512 -0.69284 0.971091 0.580446 -1.66393 -1.27328 
SP110 0.419241 1.24456 0.862391 0.260142 0.446017 0.502349 -0.68848 1.56979 1.04056 -2.25827 -1.72905 
SPATA18 1.29478 2.58221 1.93024 1.57535 1.92094 1.60824 0.282973 0.995904 0.57608 -0.71293 -0.29311 
SPTBN4 1.00363 1.70618 1.36723 0.676372 1.09577 1.24298 -0.56934 0.765538 0.446026 -1.33488 -1.01537 
SQRDL 0.268853 0.846041 0.713575 0.466755 0.301796 0.517987 0.795847 1.65391 1.40825 -0.85806 -0.6124 
SRRM3 1.51332 2.72701 2.33557 1.19025 2.11935 2.6156 -0.34645 0.849606 0.626064 -1.19606 -0.97251 
SRRM5 0.776296 1.12566 0.862118 0.539765 0.703512 0.896603 -0.52428 0.536091 0.151278 -1.06037 -0.67556 
ST6GALNAC2 0.321336 0.620737 0.63758 0.238494 0.624481 0.300266 -0.43013 0.949898 0.988523 -1.38003 -1.41865 
STAC 0.10245 0.371922 0.763313 0.009979 0.124568 0.052452 -3.3599 1.86008 2.89735 -5.21998 -6.25725 
STAP2 0.570336 1.01562 1.2081 0.536978 0.95446 1.23479 -0.08695 0.832479 1.08286 -0.91943 -1.16981 
STC1 0.134177 0.433214 0.944537 0.255879 0.67068 0.701056 0.931319 1.69094 2.81547 -0.75962 -1.88415 
STRA6 0.374028 0.828662 0.400347 0.384276 0.325153 0.276569 0.038996 1.14764 0.098106 -1.10864 -0.05911 
STX1A 4.25688 7.96447 6.83033 3.3525 4.86283 6.54592 -0.34456 0.903781 0.682158 -1.24834 -1.02672 
STXBP6 1.79445 3.41744 2.92926 1.03915 2.43059 4.66706 -0.78813 0.929377 0.706997 -1.71751 -1.49513 
SULT2B1 0.591963 1.21824 1.10006 0.716987 0.51906 0.85699 0.276439 1.04121 0.894001 -0.76478 -0.61756 
SUSD4 2.14346 3.74443 2.18142 1.77071 0.705185 0.716542 -0.27561 0.804804 0.025326 -1.08042 -0.30094 
SYN1 0.738564 0.994125 0.774922 0.083718 0.628394 1.39991 -3.14111 0.428705 0.06933 -3.56981 -3.21044 
SYNC 0.543529 0.652876 0.621461 0.304271 0.821024 0.462867 -0.837 0.264452 0.193308 -1.10145 -1.03031 
SYNDIG1 0.957778 1.85093 2.11241 0.543634 0.206117 0.52056 -0.81706 0.950489 1.14112 -1.76754 -1.95818 
SYNGR4 0.170271 0.661361 0.368308 0.094426 1.05537 0.817721 -0.85057 1.95761 1.11308 -2.80818 -1.96365 
SYNM 2.18628 3.38045 2.37853 1.65654 0.202855 0.126803 -0.40031 0.628736 0.121591 -1.02904 -0.5219 
SYNPO 0.597193 1.50873 0.997257 0.396025 0.665365 0.945023 -0.59261 1.33706 0.739767 -1.92967 -1.33237 
SYT12 0.273435 0.669163 0.607507 0.118292 0.402909 0.434862 -1.20884 1.29116 1.15171 -2.5 -2.36054 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















SYT9 1.11115 1.5573 1.45038 0.495185 0.197653 0.560653 -1.16601 0.486989 0.38438 -1.653 -1.55039 
SYTL2 0.608713 0.873426 0.630461 0.414832 0.402878 0.470909 -0.55324 0.520923 0.050644 -1.07416 -0.60388 
TAPBPL 0.317929 0.892016 0.735201 0.141423 0.369345 0.339087 -1.16868 1.48837 1.20944 -2.65705 -2.37812 
TBX19 0.659868 1.77286 1.2737 0.696886 0.986121 0.884971 0.078745 1.42583 0.948778 -1.34709 -0.87003 
TBXA2R 0.863292 1.18736 1.06026 0.246914 2.1394 2.60853 -1.80584 0.459836 0.296495 -2.26568 -2.10234 
TCEAL7 0.199956 0.756158 0.305096 0.28091 0.038251 0.249499 0.490426 1.919 0.60958 -1.42858 -0.11915 
TEKT3 0.386249 0.749502 0.430874 0.351105 0.351944 0.256381 -0.13763 0.956401 0.157736 -1.09403 -0.29536 
TENC1 0.67373 1.01706 0.891514 0.331751 0.505735 0.661063 -1.02207 0.594169 0.404087 -1.61624 -1.42616 
TFAP2E 0.684869 0.782639 0.736893 0.341348 0.4679 0.434561 -1.00458 0.192518 0.105627 -1.1971 -1.11021 
TFEB 3.35918 4.70039 3.95566 2.19484 2.0411 2.25954 -0.61399 0.48467 0.235809 -1.09866 -0.8498 
TGFA 0.681193 0.891027 0.699816 0.436279 0.765374 0.786835 -0.64281 0.387405 0.038913 -1.03022 -0.68173 
TGFB1 19.7849 20.1392 20.6872 9.72128 16.1904 18.7152 -1.02518 0.02561 0.064337 -1.05079 -1.08952 
TGM2 1.1296 1.21362 1.20588 0.554168 1.0308 1.50388 -1.02741 0.103511 0.094276 -1.13092 -1.12169 
TINCR 1.16088 1.47709 1.51805 0.69778 1.36284 1.77466 -0.73437 0.347542 0.386998 -1.08192 -1.12137 
TJP3 0.250025 0.686983 0.519969 0.294894 0.254767 0.376099 0.238128 1.45821 1.05636 -1.22008 -0.81823 
TLDC2 0.6036 0.814629 0.76393 0.378721 0.715271 0.817237 -0.67246 0.43255 0.339847 -1.10501 -1.0123 
TLX3 1.05311 1.31315 1.10763 0.598987 0 0.115988 -0.81407 0.318366 0.072819 -1.13243 -0.88688 
TMEM108 2.46512 2.98793 2.74532 1.49335 2.96753 3.43136 -0.7231 0.277492 0.155319 -1.0006 -0.87842 
TMEM132E 1.8701 3.57358 3.80269 1.57362 0.696846 1.30953 -0.24902 0.934256 1.02391 -1.18328 -1.27293 
TMEM173 2.17555 3.48386 2.46804 1.34334 1.38292 1.09339 -0.69556 0.679306 0.181987 -1.37486 -0.87755 
TMEM178A 0.355795 0.851185 0.771323 0.547766 0.227811 0.114447 0.622513 1.25843 1.11629 -0.63591 -0.49378 
TMEM200A 0.321893 0.67154 0.424363 0.325195 0.069436 0.112813 0.014724 1.06089 0.398718 -1.04617 -0.38399 
TMEM91 2.32755 3.27487 2.3777 1.45745 2.11029 3.133 -0.67536 0.492622 0.030753 -1.16799 -0.70612 
TMPRSS9 0.344911 0.567595 0.381685 0.176922 0.698148 0.565145 -0.96312 0.718635 0.146155 -1.68175 -1.10927 
TNC 0.207923 1.36339 0.866368 0.243394 1.57812 1.34578 0.227242 2.71307 2.05893 -2.48583 -1.83169 




Expression value Log2 fold change 
Mock H-v601-Per1 
H-v601-

















TNFRSF9 0.030688 0.961427 0.258151 0.035043 0.006476 0.052611 0.191461 4.96943 3.07246 -4.77796 -2.881 
TOX3 0.135114 0.639577 1.08693 0.069521 0.256955 0.388591 -0.95866 2.24294 3.00801 -3.20161 -3.96668 
TP53INP1 1.26724 3.17256 2.05626 1.87447 3.6578 2.70494 0.564794 1.32396 0.698334 -0.75916 -0.13354 
TP53TG5 0.240229 0.559274 0.642909 0.354233 0.423878 0.667749 0.560287 1.21915 1.4202 -0.65886 -0.85992 
TPTEP1 0.417843 1.68399 0.920718 0.3208 0.091731 0.05767 -0.38129 2.01085 1.1398 -2.39214 -1.52109 
TRIM58 1.53726 2.55974 1.73011 0.948982 1.81413 2.28761 -0.69591 0.735641 0.170505 -1.43155 -0.86641 
TSPAN11 0.619793 0.917112 0.685033 0.430422 0.131195 0.121798 -0.52604 0.565313 0.144387 -1.09135 -0.67042 
TTC21A 0.609635 1.06315 1.17653 0.586688 0.918097 0.757455 -0.05535 0.802329 0.948522 -0.85768 -1.00388 
UAP1L1 11.1263 16.6617 13.5961 7.89349 6.36341 8.45268 -0.49524 0.582562 0.289213 -1.0778 -0.78445 
UBE2L6 5.54932 13.6653 7.84131 4.17926 8.06634 7.2096 -0.40906 1.30014 0.498785 -1.7092 -0.90785 
UBE2QL1 0.78759 1.13625 0.849185 0.468189 0.181389 0.422108 -0.75035 0.528758 0.108635 -1.27911 -0.85899 
UCN 3.11531 3.72786 3.63317 1.70189 4.22505 4.27192 -0.87224 0.258973 0.221853 -1.13121 -1.09409 
UNC5A 1.60761 1.91175 1.67006 0.855272 0.567908 0.701067 -0.91047 0.249969 0.054983 -1.16044 -0.96545 
UNC5B-AS1 0.265097 0.726233 0.674649 0.275635 0.419492 0.64409 0.056242 1.45391 1.34762 -1.39767 -1.29138 
UTF1 1.18028 2.03497 1.91491 0.493042 0.354012 0.333845 -1.25935 0.785884 0.698146 -2.04523 -1.95749 
VLDLR-AS1 0.09298 0.67718 0.39382 0.184219 0.05968 0.060837 0.986436 2.86455 2.08255 -1.87812 -1.09611 
VPREB3 1.03447 2.52975 1.08935 0.439989 0.872995 0.970141 -1.23336 1.2901 0.074574 -2.52346 -1.30793 
VSNL1 0.065544 0.221257 0.682049 0.067816 0.310496 0.357832 0.049165 1.7552 3.37935 -1.70603 -3.33018 
VSTM2B 0.208464 0.309703 0.575201 0.121521 0.036079 0.034024 -0.77859 0.571085 1.46427 -1.34968 -2.24286 
VSTM2L 2.42129 3.26696 2.47503 1.30069 1.01704 1.72392 -0.8965 0.432176 0.03167 -1.32867 -0.92817 
VWA5A 0.153463 0.536321 0.633557 0.32042 0.539304 0.6427 1.06207 1.80521 2.04559 -0.74314 -0.98351 
WDR31 0.596396 2.00721 1.67381 0.986228 0.671168 0.788182 0.725651 1.75085 1.48879 -1.0252 -0.76314 
WDR63 1.24833 2.29766 1.67086 0.874447 1.32414 1.36233 -0.51355 0.880172 0.4206 -1.39372 -0.93415 
WIPF3 2.85652 3.24097 3.29039 1.3815 2.67321 2.1657 -1.04802 0.182165 0.203999 -1.23019 -1.25202 
YPEL3 4.30294 11.137 9.68341 4.31799 11.9679 10.8623 0.005035 1.37196 1.17019 -1.36693 -1.16516 




Expression value Log2 fold change 
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H-v601-

















ZFHX2 1.51916 2.10114 1.69743 0.97399 1.25102 1.72984 -0.64129 0.467898 0.160075 -1.10919 -0.80137 
ZFP2 0.536066 0.876031 0.633863 0.394076 0.730983 0.572895 -0.44394 0.708572 0.24176 -1.15251 -0.6857 
ZFP36 1.78164 4.89857 4.47172 1.10054 1.46311 1.89861 -0.695 1.45915 1.32762 -2.15415 -2.02262 
ZNF205-AS1 0.475826 0.643664 0.761039 0.340234 0.468543 0.303906 -0.48391 0.435873 0.677537 -0.91978 -1.16144 
ZNF233 0.50026 0.758265 0.635561 0.162584 0.984583 0.915689 -1.62149 0.600025 0.345354 -2.22152 -1.96685 
ZNF296 7.12544 7.85218 7.99829 3.01654 6.55648 9.02722 -1.24009 0.140113 0.166711 -1.3802 -1.4068 
ZNF385A 8.93348 12.1163 10.3131 3.48818 9.61181 12.8125 -1.35675 0.439655 0.207185 -1.7964 -1.56393 
ZNF385C 0.361664 1.1169 1.02354 0.264854 0.588524 0.753147 -0.44946 1.62677 1.50085 -2.07623 -1.95031 
ZNF423 1.85471 2.09609 2.24289 1.06038 0.830492 1.17006 -0.80662 0.176505 0.274161 -0.98313 -1.08078 
ZNF426 1.1529 2.18995 2.55379 0.885176 7.05667 7.92575 -0.38123 0.925633 1.14737 -1.30686 -1.5286 
ZNF429 1.65906 2.94861 2.46272 1.29941 2.9778 3.60804 -0.35252 0.829663 0.569885 -1.18218 -0.9224 
ZNF433 0.724617 1.51557 1.18453 0.392099 2.40761 2.23029 -0.886 1.06457 0.709023 -1.95057 -1.59503 
ZNF441 0.676212 1.40405 1.38144 0.678512 2.96443 3.9004 0.004899 1.05405 1.03062 -1.04915 -1.02572 
ZNF442 0.261478 0.686198 0.57653 0.456506 0.676434 0.958259 0.803941 1.39193 1.1407 -0.58799 -0.33676 
ZNF462 2.14899 3.29356 4.11779 0.973547 5.82719 6.26891 -1.14234 0.615988 0.938211 -1.75833 -2.08055 
ZNF467 1.84751 4.90592 3.51259 1.48747 1.82777 2.947 -0.31273 1.40894 0.92695 -1.72167 -1.23968 
ZNF502 0.073155 0.249917 0.553845 0 1.78022 2.49183 #NAME? 1.77241 2.92045 #NAME? #NAME? 
ZNF582-AS1 1.52429 3.76176 2.98343 1.96655 2.16762 2.7681 0.367532 1.30327 0.968832 -0.93574 -0.6013 
ZNF585A 5.90977 12.0408 9.32334 7.9956 11.8907 11.8103 0.436105 1.02676 0.657745 -0.59065 -0.22164 
ZNF628 2.34507 2.68328 2.46951 1.27289 2.48312 3.11118 -0.88153 0.194365 0.07459 -1.07589 -0.95612 
ZNF785 0.91208 1.19481 1.1985 0.58365 0.606253 0.861547 -0.64406 0.389543 0.393997 -1.0336 -1.03805 
ZNF793 0.227752 0.354717 0.62425 0.152341 2.0533 3.13245 -0.58017 0.639202 1.45466 -1.21937 -2.03482 
ZNF91 1.8502 2.86759 3.75439 1.16228 4.45974 5.04043 -0.67072 0.632156 1.0209 -1.30288 -1.69162 
ZNFX1 4.90971 8.26963 5.80172 4.07475 4.97952 6.09443 -0.26893 0.752184 0.240842 -1.02111 -0.50977 
ZP3 1.15503 1.74722 1.72578 0.683949 0.504347 0.489152 -0.75597 0.597133 0.579325 -1.3531 -1.33529 




Expression value Log2 fold change 
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ZSWIM4 1.56366 2.40235 2.04788 1.05534 1.13634 1.45048 -0.56721 0.619523 0.389207 -1.18674 -0.95642 
ZYX 55.5033 63.9702 56.665 31.4093 62.06 67.5325 -0.82138 0.204826 0.029883 -1.02621 -0.85127 
 
 
